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Folate-mediated one-carbon metabolism is a network of interdependent 
pathways in which single carbon units derived from serine or glycine are activated and 
used for the biosynthesis of purines, thymidylate, and methionine.  Folate-mediated 
one-carbon metabolism plays essential roles in development, DNA replication, the 
maintenance of genome stability, and gene expression.  Consequently, impairments in 
this network are associated with an increased incidence of neural tube defects, 
cardiovascular disease, and cancer. 
 Cytoplasmic serine hydroxymethyltransferase (cSHMT) serves as a source of 
folate-activated one-carbon units by catalyzing the conversion of serine and 
tetrahydrofolate (THF) to glycine and 5,10-methyleneTHF, the one-carbon donor in 
the thymidylate biosynthesis reaction.  cSHMT is regulated by several factors at both 
the transcriptional and translational levels.  At the translational level, cSHMT 
expression is enhanced through an internal ribosome entry site (IRES) located in the 
5’untranslated region (UTR) of the transcript.   
IRESes are cis-acting regulatory elements that permit 5’-cap-independent 
translation by interacting with IRES trans-acting factors (ITAFs) and recruiting the 
40S ribosomal subunit.  IRESes permit protein synthesis when cap-mediated ribosome 
scanning is impaired.  Although it had previously been reported that the 3’UTR of the 
 cSHMT transcript and the proteins CUG-Binding Protein 1 (CUGBP1) and heavy 
chain ferritin (H ferritin) influence the IRES-mediated translation of cSHMT, the 
mechanism by which they act and the physiological conditions that stimulate cSHMT 
IRES activity had not been determined.  The results of the current studies reveal that 
by interacting with both the 3’UTR and a novel ITAF heterogeneous nuclear 
ribonucleoprotein H2 (hnRNP H2), CUGBP1 circularizes the cSHMT transcript, 
thereby enhancing translation rates.  Although H ferritin does not play a direct role in 
the IRES-mediated translation of cSHMT, it may stimulate IRES activity by 
facilitating the interaction between CUGBP1 and hnRNP H2.  The results of the 
current studies also reveal that the cSHMT IRES functions to enhance rates of cSHMT 
protein expression in response to UV-induced cellular stress.  Following exposure to 
UV radiation, CUGBP1, hnRNP H2, and H ferritin protein levels increase in the 
cytoplasm.  This stimulates cSHMT IRES activity, increases cSHMT protein levels, 
and allows for the production of thymidylate necessary for DNA repair.    
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CHAPTER 11 
 
INTRODUCTION TO FOLATE-MEDIATED ONE-CARBON METABOLISM 
 
Part I: Abstract 
 Tetrahydrofolate polyglutamates are a family of cofactors that carry and 
chemically activate one-carbon units for biosynthesis.  Tetrahydrofolate-mediated one-
carbon metabolism is a metabolic network of interdependent biosynthetic pathways 
that is compartmentalized in the cytoplasm, mitochondria and nucleus.   One-carbon 
metabolism in the cytoplasm is required for the synthesis of purines and thymidylate 
and the remethylation of homocysteine to methionine.  One-carbon metabolism in the 
mitochondria is required for the synthesis of formylated methionyl-tRNA, the 
catabolism of choline, purines, and histidine, and the interconversion of serine and 
glycine.  Mitochondria are also the primary source of one-carbon units for cytoplasmic 
metabolism.  Increasing evidence indicates that folate-dependent de novo thymidylate 
biosynthesis occurs in the nucleus of certain cell types.  Disruption of folate-mediated 
one-carbon metabolism is associated with many pathologies and developmental 
anomalies, yet the biochemical mechanisms and causal metabolic pathways 
responsible for the initiation and/or progression of folate-associated pathologies have 
yet to be established.  This review focuses on our current understanding of mammalian 
folate-mediated one-carbon metabolism, its cellular compartmentation, and knowledge 
gaps that limit our understanding of one-carbon metabolism and its regulation.   
 
 
                                                 
1 Reprinted from Vitamins and Hormones, Volume 79, Jennifer T. Fox and Patrick J. Stover, Chapter 1: 
Folate-Mediated One-Carbon Metabolism, p. 1-44, Copyright (2008), with permission from Elsevier. 
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Part II: Overview 
The reduced tetrahydrofolates (THF) serve as a family of enzyme cofactors 
that chemically activate and carry one-carbon units on the N-5 and/or N-10 of THF at 
the oxidation level of formate (e.g. 10-formylTHF), formaldehyde (e.g. 5,10-
methyleneTHF) or methanol (e.g. 5-methylTHF) (1-4).  Folate derivatives also contain 
a covalently-bound polyglutamate peptide of varying length.  Serum folates contain a 
single glutamate residue, whereas intracellular folates contain a polyglutamate peptide 
usually consisting of 5 to 8 glutamate residues that are polymerized through unusual γ-
linked peptide bonds (5,6). The polyglutamate peptide increases the affinity of THF 
cofactors for folate-dependent enzymes and binding proteins, and prevents their efflux 
from the cell and intracellular organelles (3).  Tetrahydrofolate polyglutamates are 
coenzymes that donate or accept one-carbon units in a network of reactions known as 
one-carbon metabolism, which occurs in three specific and isolated cellular 
compartments: the mitochondria, nucleus and cytoplasm (Figure 1.1) (7-9).   The one-
carbon forms of THF can be interconverted enzymatically (Figure 1.1), although each 
cofactor form is specific to a particular biosynthetic pathway.  The formyl group of 
10-formylTHF is incorporated into the C2 and C8 of the purine ring in the cytoplasm 
and is used to synthesize formylated methionyl-tRNA in mitochondria (Figure 1.1).  
The one-carbon moiety of 5,10-methyleneTHF is required to convert uridylate to 
thymidylate, and the one carbon carried by 5-methylTHF is required to remethylate 
homocysteine to methionine.  The cellular concentration of folate-binding proteins (50 
µM) exceeds that of folate derivatives (20-35 µM).  Given that the dissociation 
constant (Kd) of polyglutamated folates for many folate-binding proteins is typically in 
the 100 nM range, the concentration of free folate in the cell is negligible (3,10,11).  
This implies that each folate-dependent biosynthetic pathway competes for a limiting 
pool of folate cofactors (11,12).   
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Figure 1.1.  Compartmentation of folate-mediated one-carbon metabolism in 
the cytoplasm, mitochondria and nucleus.  One-carbon metabolism in the 
cytoplasm is required for the de novo synthesis of purines and thymidylate, and for 
the remethylation of homocysteine to methionine.  One-carbon metabolism in 
mitochondria generates one-carbon units for cytoplasmic one-carbon metabolism 
by generating formate from serine, glycine, sarcosine and dimethylglycine.  One-
carbon metabolism in the nucleus synthesizes dTMP from dUMP and serine.  1, 
Mitochondrial serine hydroxymethyltransferase; 2, Aminomethyltransferase; 3, 
Sarcosine dehydrogenase; 4, Dimethylglycine dehydrogenase; 5, 5,10-
Methylenetetrahydrofolate dehydrogenase (NAD dependent); 6, 5,10-
Methenyltetrahydrofolate cyclohydrolase; 7, Methionyl-tRNA formyltransferase; 
8, 10-Formyltetrahydrofolate synthetase; 9, 10-Formyltetrahydrofolate synthetase; 
10, 10-Formyltetrahydofolate dehydrogenase; 11-12, Phosphoribosylglycinamide 
formyltransferase & Phosphoribosylaminoimidazolecarboxamide 
formyltransferase; 13, 5,10-Methenyltetrahydrofolate cyclohydrolase; 14-15, 
Glycine formiminotransferase/ formimidoyltetrahydrofolate cyclodeaminase & 
Glutamate formiminotransferase/ formimidoyltetrahydrofolate cyclodeaminase; 
16, Cytoplasmic serine hydroxymethyltransferase; 17, Methenyltetrahydrofolate 
synthetase; 18, 5,10-Methylenetetrahydrofolate dehydrogenase (NADP 
dependent); 19, Thymidylate synthase; 20, Methylenetetrahydrofolate reductase; 
21, Methionine synthase; 22, Glycine N-methyltransferase; 23, Dihydrofolate 
reductase. 
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            Epidemiological studies implicate impaired folate metabolism in several 
pathologies and developmental anomalies including neural tube defects (NTDs) 
(13,14), cardiovascular disease (15-17) and cancer (18-22).  One-carbon metabolism 
can be impaired by folate and other B-vitamin deficiencies and/or common, penetrant 
genetic mutations and polymorphisms (13,23-25).  However, the biochemical 
mechanisms and causal metabolic pathways responsible for the initiation and/or 
progression of folate-associated pathologies have yet to be established.  In fact, there 
are still major gaps in our fundamental understanding of one-carbon metabolism and 
its regulation.  There is also the potential for identifying putative “missing” enzymes 
and their associated genes whose discovery may be necessary to complete the 
assembly of the folate-dependent metabolic network.  This review focuses on our 
current understanding of mammalian folate-mediated one-carbon metabolism, its 
cellular compartmentation, and knowledge gaps that limit our understanding of folate 
metabolism and its regulation.   
 
Part III: Introduction to Cytoplasmic One-Carbon Metabolism 
Folate-mediated one-carbon metabolism in the cytoplasm is a metabolic 
network of interdependent biosynthetic pathways that are required for the biosynthesis 
of purines and thymidylate, and the remethylation of homocysteine to methionine 
(Figure 1.1).  Methionine can be adenosylated to S-adenosylmethionine (AdoMet), a 
cofactor and methyl group donor for numerous methylation reactions including the 
methylation of neurotransmitters and other small molecules, phospholipids, proteins 
including histones, RNA and cytosine bases within CpG islands in DNA.  Many 
AdoMet-dependent methylation reactions, including those involved in chromatin 
methylation, serve regulatory functions by affecting gene transcription (26), protein 
localization (27), and the catabolism of small molecules (28).  The sources of one-
 5
carbon moieties for cytoplasmic one-carbon metabolism include formate, serine, 
histidine and purines.   
Proteins involved in folate metabolism can be classified into four functional 
categories, although many folate-dependent enzymes exhibit two or more of these 
activities: 1) One-carbon generating enzymes, 2) THF one-carbon interconverting 
enzymes, 3) THF-dependent biosynthetic enzymes and 4) non-catalytic THF binding 
proteins.  This section details the mechanisms, regulation, and physiological functions 
of the enzymes involved in cytoplasmic one-carbon metabolism, as well as common 
genetic variants that affect enzyme function and the one-carbon network. 
 
A. Enzymes that Generate One-Carbon Units 
 
1. Cytoplasmic Serine Hydroxymethyltransferase (cSHMT) 
Reaction – Serine hydroxymethyltransferase (SHMT) catalyzes the reversible 
and PLP-dependent interconversion of serine and glycine.  Mammals express 
cytoplasmic (SHMT1 or cSHMT) and mitochondrial (SHMT2) SHMT isozymes; the 
human isozymes share 63% amino acid sequence identity and are encoded on separate 
genes (29).  When catalyzing serine cleavage, cSHMT transfers the C3 of serine to 
THF generating glycine and 5,10-methyleneTHF, the cofactor required for 
thymidylate biosynthesis.  The one-carbon moiety of 5,10-methyleneTHF can also 
support homocysteine remethylation when converted to 5-methylTHF by 
methylenetetrahydrofolate reductase (MTHFR) (Figure 1.1).  cSHMT-derived one-
carbons are not believed to make significant contributions to purine biosynthesis, 
because the reductive environment (NADPH/NADP+ ratio) in the cytoplasm does not 
support the conversion of 5,10-methyleneTHF to 10-formylTHF (30).   When 
catalyzing serine synthesis, cSHMT depletes methyleneTHF pools for AdoMet 
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synthesis and regenerates unsubstituted THF for purine biosynthesis (31,32).  cSHMT 
may also play a role in gluconeogenesis; glycine is a glucogenic amino acid through 
its conversion to serine, although it is not known which SHMT isozyme functions in 
this capacity (33).   
Mechanism - The cSHMT protein is a homotetramer consisting of two obligate 
dimers.  Residues from each subunit of the obligate dimer contribute to the formation 
of a single active site on each subunit, where Lys257 is covalently bound to the 
pyridoxal phosphate (PLP) cofactor (34-36).  The definitive mechanism for the 
reaction is still subject to debate (35).  The proposed retroaldol cleavage mechanism 
involves a base-catalyzed proton abstraction from the C3-hydroxyl group of serine to 
form glycine and a formaldehyde intermediate.  The SHMT-bound formaldehyde then 
condenses with THF to form 5,10-methyleneTHF through an N-5 iminium cation 
intermediate.  However, this mechanism is not consistent with the structure of the 
Bacillus stearothermophilus SHMT (bsSHMT)-serine complex (37) and metabolic 
labeling experiments (38), both of which indicate that the C3-hydroxyl group of serine 
is oriented in the synperiplanar configuration rather than the antiperiplanar 
configuration required for a retroaldol mechanism.  In addition, the catalytic base has 
never been identified.  A second putative “direct displacement” mechanism was 
revealed from the structures of bsSHMT complexed with serine and with 5-
formylTHF and glycine (37).  This proposed mechanism proceeds with the N5 of THF 
displacing the C3 hydroxyl of serine to form a covalent intermediate.   However, 
Szebenyi et al (39) provide evidence that the reverse reaction could not proceed by 
direct displacement and that the position of N5 of THF is unfavorable for nucleophilic 
attack.  Rather, they propose a third mechanism whereby the N5 of THF attacks the 
C3-hydroxy group of serine to form N5-hydroxymethyleneTHF, glycine, and possibly 
a transient formaldehyde intermediate (35,39).   
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Regulation – In addition to their primary catalytic function, both SHMT 
isozymes catalyze the irreversible conversion of 5,10-methenylTHF to 5-formylTHF 
(Figure 1.1).  5-formylTHF is not a cofactor for folate-dependent one-carbon transfer 
reactions, but rather is an inhibitor of several folate-dependent reactions including 
SHMT (40,41).  The SHMT isozymes may also play roles as a folate binding proteins 
(42).  Both 5-formylTHF and 5-methylTHF polyglutamates are tight-binding SHMT 
inhibitors.   
Unlike many enzymes involved in cytoplasmic folate-mediated one-carbon 
metabolism, cSHMT is not ubiquitously expressed in tissues; but it is abundant in the 
liver, kidney, and colon and is also found in the brain (43).  Its expression and/or 
activity are regulated by several nutrients and metabolic factors including pyridoxal 
phosphate (vitamin B6), retinoic acid, zinc, and ferritin.  Vitamin B6 deficiency was 
shown to decrease cSHMT activity in rat liver (44) and protein levels in cultured cells 
(45).   Retinoic acid, which inhibits proliferation and induces differentiation during 
vertebrate development, greatly reduces cSHMT mRNA levels (46).  In contrast, zinc 
induces cSHMT transcription by acting through a metal regulatory element present 
within the promoter (47).  The heavy chain subunit of the iron-storage protein ferritin 
was also shown to increase cSHMT protein levels (48)  by stimulating the cap-
independent translation of the transcript (49). 
Physiological Function/Gene Variants – Although the cSHMT and SHMT2 
isozymes exhibit similar catalytic and physical properties, they have distinct 
physiological functions.  Loss of the mitochondrial SHMT2 isozyme creates a glycine 
auxotrophy in Chinese hamster ovary cells (50), indicating that cSHMT is not a 
primary source of glycine and that cSHMT cannot substitute for SHMT2 function.  
Stable isotope tracer studies using cultured cells indicate that cSHMT-derived 5,10-
methyleneTHF is preferentially directed to thymidylate biosynthesis relative to 
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homocysteine remethylation (31,48).  This preferential partitioning of cSHMT-derived 
one-carbons to thymidylate synthesis may be achieved through the cell cycle-
dependent partitioning of the thymidylate synthesis pathway in the nucleus (51) 
(Figure 1.1) (see Nuclear Folate Metabolism below).  The cSHMT protein has also 
been demonstrated to be a 5-methylTHF tight-binding protein in cultured cells; 
increased expression of cSHMT increased cellular levels of 5-methylTHF at the 
expense of other one-carbon forms of folate while depleting AdoMet levels (31).  This 
latter observation is consistent with cSHMT serving as a 5-methylTHF-binding 
protein in the cytoplasm and thereby limiting the availability of 5-methylTHF for 
homocysteine remethylation (Figure 1.1) (31). 
A common cSHMT single nucleotide polymorphism (SNP), C1420T, has been 
shown to be protective against adult acute lymphocytic leukemia (ALL) (52) and 
malignant lymphoma (53). This SNP results in an amino acid substitution of leucine to 
phenylalanine at position 474 of the protein (L474F) and prevents cSHMT 
SUMOylation (9).  The cSHMT C1420T gene variant has also been shown to be 
associated with elevated plasma and red cell folate levels (54), and some studies report 
that it protects against neural tube defects (55,56).  When present in combination with 
the MTHFR C677T polymorphism (see below), cSHMT C1420T is a risk factor for 
cardiovascular disease (57).  
 
2. 10-FormylTHF Synthetase (FTHFS) 
Reaction – 10-formylTHF synthetase is a formate-activating enzyme found in 
a wide variety of organisms, including bacteria, plants, insects, nematodoes, yeast, and 
mammals.  In eukaryotes, 10-formylTHF synthetase activity is found on the C-
terminal domain of the trifunctional enzyme, C1-THF synthase, which also contains 
5,10-methenylTHF cyclohydrolase and 5,10-methyleneTHF dehydrogenase activities 
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(see Section III.B.1) (58).  C1-THF synthase is encoded by the Mthfd1 gene.  10-
formylTHF synthetase catalyzes the ATP-dependent conversion of THF and formate 
to 10-formylTHF, ADP, and inorganic phosphate.  The reaction is reversible (1).  The 
enzyme requires monovalent cations (NH4+, K+, or Rb+) to achieve maximal activity; 
in Clostridium cylindrosporum and Clostridium acidiurici, these cations serve to 
maintain the quaternary structure of the enzyme (59) and decrease the Km of formate 
by stabilizing its negative charge (60).  The enzyme also requires a divalent metal ion, 
usually Mg2+, which is coordinated between the β- and γ-phosphates of the ATP 
substrate (61). 
Mechanism – The 10-formylTHF synthetase reaction proceeds by a random 
sequential mechanism, based on results from steady-state kinetic measurements (62) 
and partial exchange reactions (63).  The reaction initiates with the formation of a 
formylphosphate intermediate generated through a nucleophilic attack by formate on 
the γ-phosphate of MgATP.  The activated formyl group is then transferred directly to 
N-10 of THF with the loss of phosphate to form 10-formylTHF (64,65).   Involvement 
of the formylphosphate intermediate is supported by the transfer of 18O from formate 
to inorganic phosphate (66) and the synthesis of ATP from ADP and carbamoyl 
phosphate, a structural analogue of formylphosphate (67).  However, the most 
conclusive proof comes from experiments that successfully used synthetic formyl 
phosphate as a substrate for the enzyme (64).   
Regulation – To date, there have been few reports regarding the regulation of 
10-formylTHF synthetase expression and activity.  The enzyme is inhibited by THF 
and purine nucleotides (68,69).  Perry et al demonstrated that nitrous oxide-induced 
vitamin B12 deficiency stimulates 10-formylTHF synthetase activity in rats (70).  
However, these results were not confirmed by an independent group who showed that 
nitrous oxide exposure decreased hepatic C1-THF synthase expression (71).  
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Mammalian Mthfd1, which encodes all three activities of cytoplasmic C1-THF 
synthase, is expressed ubiquitously and is transcriptionally upregulated in response to 
conditions that require increased DNA synthesis (30).  The promoter region of the rat 
C1-THF synthase gene contains several transcription factor binding sites through 
which this regulation could occur, including NF-κB, HNF-4α1, RARα1, C/EBP, and 
PPAR.  However, the rat promoter region does not share significant homology with 
the human Mthfd1 promoter region (58).  In mice, the upregulation of C1-THF 
synthase expression is thought to occur through insulin-like growth factor-1 (IGF1), 
which increases the stability of the mRNA transcript (72).  In yeast, C1-THF synthase 
mRNA levels are decreased in the presence of adenine, histidine, methionine, and 
pantothenic acid (73).   
Physiological Function/Gene Variants –Cytoplasmic 10-formylTHF 
synthetase activity is believed to be the primary entry point of one-carbons for 
cytoplasmic folate-dependent biosynthetic reactions.  Once formed, 10-formylTHF 
can be used as cofactor for purine biosynthesis (74), or the one-carbon can be 
sequentially dehydrated and reduced for use in the biosynthesis of thymidylate and 
methionine (Figure 1.1).  However, studies using Saccharomyces cervisiae have raised 
the possibility that 10-formylTHF synthetase may play other roles in purine 
biosynthesis in addition to its catalytic activity.  Barlowe et al (75) observed that yeast 
lacking the ADE3 gene that encodes C1-THF synthase are auxotrophic for purines; 
yeast carrying point mutations in ADE3 that inactivated all three of its enzymatic 
activities did not require purines for growth, suggesting that adequate cytoplasmic 10-
formylTHF was produced in the absence of 10-formylTHF synthetase activity.  In 
addition, the heterologous expression of Clostridium acidiurici 10-formylTHF 
synthetase in an ade3 deletion strain did not restore the wildtype phenotype (75).  
Collectively, these studies indicate that C1-THF synthase possesses other potentially 
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noncatalytic activities required for pure biosynthesis.  However, Song et al reported 
that a monofunctional 10-formylTHF synthetase activity can restore the wildtype 
phenotype in the ade3 deletion strain (76), a result consistent with the hypothesis that 
the catalytic activity of cytoplasmic 10-formylTHF synthetase is involved in purine 
biosynthesis. 
A common SNP in human Mthfd1, G1958A, results in the substitution of 
glutamine for arginine at position 653 which encodes the 10-formyl-THF synthetase 
domain of C1-THF synthase.  The effect of this substitution on the physical or 
catalytic properties is not known.  Although R653Q does not affect homocysteine 
levels, plasma folate levels or red blood cell folate levels (77), it was found to increase 
a mother’s risk of having a child with a neural tube defect (NTD) in several different 
populations (77-79).  This polymorphism has also been identified as a maternal risk 
factor for severe placenta abruption and unexplained second trimester loss (80,81).  
 
3. Glutamate Formiminotransferase & Glycine Formiminotransferase 
  Reaction – The catabolism of histidine and purines generates one-carbon units 
that enter the cytoplasmic folate-activated one-carbon pool as 5,10-methenylTHF 
(Figure 1.1).  During their catabolism, the imidazole ring of histidine, adenine, and 
guanine is converted to a formimino group, which can be transferred to THF to form 
5-formiminoTHF.   
Mechanism –  In mammalian liver cells, formiminoglutamic acid, an 
intermediate in histidine catabolism, reacts with THF to form 5-formiminoTHF in a 
reaction catalyzed by glutamate formiminotransferase (82).  Formiminotransferase 
activity exists as part of a bifunctional enzyme complex with 
formimidoyltetrahydrofolate cyclodeaminase activity on the C-terminal domain of the 
protein, which allows for the rapid conversion of 5-formiminoTHF to 5,10-
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methenylTHF (83,84).  The bifunctional enzyme is assembled as a circular tetramer of 
dimers and channels folate polyglutamates between catalytic sites (85). Similarly, 
formiminoglycine, which is a product of purine ring degradation, is also a source of 5-
formiminoTHF through the activity of glycine formiminotransferase.  As in histidine 
catabolism, 5-formiminoTHF is converted to 5,10-methenylTHF and is available for 
one-carbon transfer reactions in the cytoplasm (86). 
Regulation – Histidine and purine catabolism occurs in the liver in mammalian 
cells and can be influenced by vitamin B12 levels, metals, and THF.  Vitamin B12 
deficiency has been shown to increase the urinary excretion of formiminoglutamate, 
presumably because unsubstituted THF is not available during severe vitamin B12 
deficiency for the formiminotransferase reaction (see Methionine Synthase below).  
Both glutamate formiminotransferase (87) and glycine formiminotransferase (88) are 
inhibited by various cations, including Mn2+ and Zn2+, and the cyclodeaminase activity 
of the bifunctional enzyme is inhibited by THF. 
  Physiological Function/Gene Variants – The quantitative contribution of 
purine and histidine catabolism to the cytoplasmic folate-activated one-carbon pool is 
not known.  However, severe inborn errors of metabolism are associated with 
impairments in histidine and purine catabolism.  Histidinemia and glutamate 
formiminotransferase deficiency are autosomal recessive disorders resulting from 
mutations in the histidase (HAL) and formiminotransferase/cyclodeaminase (FTCD) 
genes, respectively.  Both have been characterized by mental retardation, speech 
impairment, and developmental delay; severe glutamate formiminotransferase 
deficiency is also associated with elevated serum folate (89).  Three disease-causing 
mutations that significantly reduce glutamate formiminotransferase activity have also 
been found (89).  The R135C mutation is located within an extended loop of the 
formiminotransferase domain that is involved in folate-binding; R229P is thought to 
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disrupt the formiminotransferase dimerization interface.  The 1033insG mutation 
results in the production of a monofunctional enzyme that allows the transfer of the 
forminimo group to THF, but cannot catalyze the second reaction, the production of 
5,10-methenylTHF. 
 
B. Folate Interconverting Enzymes 
 
1. 5,10-MethenylTHF Cyclohydrolase and 5,10-methyleneTHF Dehydrogenase 
(MTHFC/MTHFD) 
Reaction – As mentioned above, mammalian C1-THF synthase is a homodimer 
and trifunctional enzyme consisting of two functionally independent domains encoded 
by Mthfd1.  The C-terminal domain contains 10-formylTHF synthetase activity 
whereas the N-terminal domain contains 5,10-methenylTHF cyclohydrolase 
(MTHFC) and 5,10-methyleneTHF dehydrogenase (MTHFD) activities (90,91).  
MTHFC catalyzes the reversible  interconversion of 10-formylTHF and 5,10-
methenylTHF, whereas MTHFD catalyzes the  NADP+-dependent and reversible 
interconversion of 5,10-methenylTHF and 5,10-methyleneTHF. 
Mechanism –MTHFC and NADP+-dependent MTHFD share an overlapping 
active site on C1-THF synthase, which allows for the interconversion of folate-
activated one-carbon units between the formate and formaldehyde levels of oxidation 
(92,93).  There is evidence that the folate substrates are channeled between the 
MTHFD and MTHFC active sites without dissociating from the complex and 
equilibrating with the cytoplasmic milieu.  Exogenous methenylTHF does not 
compete as a substrate for the cyclohydrolase reaction with the methenylTHF 
produced in the dehydrogenase reaction (68,94).  Substrate channeling permits 
increased metabolic rates in the presence of low substrate concentrations, and protects 
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reaction intermediates from competing reactions or degradation (Reviewed in (95)).  
Within the bifunctional complex, the reaction catalyzed by 10-methenylTHF 
cyclohydrolase is rate-limiting in the overall conversion of 10-formylTHF to 5,10-
methyleneTHF (96).     
Regulation – The regulation of C1-THF synthase is described above for 10-
formylTHF synthetase; no specific regulation of the cyclohydrolase or dehydrogenase 
activities apart from regulation of Mthfd1 is known.     
Physiological Function/Gene Variants – The reversible reactions catalyzed by 
MTHFC and MTHFD are essential for the provision of folate-activated one-carbons 
for thymidylate biosynthesis and homocysteine remethylation when the 
dehydrogenase reaction proceeds in the reductive direction (Figure 1.1).   A SNP in 
Mthfd1 has been identified that affects the MTHFD/MTHFC domain and has an 
association with disease.  Although its functional significance is currently unknown, 
R134K was shown to be associated with a significant increase in risk for 
postmenopausal breast cancer (97).  
 
2. 10-FormyTHF Dehydrogenase (FDH) 
Reaction – 10-formylTHF dehydrogenase (FDH) catalyzes the irreversible and 
NADP+-dependent oxidation of 10-formylTHF to THF and CO2.  FDH consists of two 
functionally distinct domains connected by an intermediate linker.  The C-terminal 
domain catalyzes an NADP+-dependent aldehyde-dehydrogenase reaction, and the N-
terminal domain catalyzes the hydrolysis of 10-formylTHF to THF and formate 
(hydrolase reaction) (98,99).  Although the two domains can function independently, 
the two active sites work in concert through a 4’-phosphopantetheine swinging arm 
that is bound through a phosphoester bond to Ser354; the swinging arm transfers 
formate between the two active sites (98).   
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Mechanism – The 10-formylTHF dehydrogenase reaction initiates with a 
hydrolase reaction where a water molecule, activated by aspartate 142, acts as a 
nucleophile by attacking the formyl carbon atom of 10-formylTHF to produce a 
hydrated aldehyde intermediate (98,100).  In the absence of NADP+, this intermediate 
can be further cleaved to release formate.  In the presence of NADP+, the reaction 
continues through an aldehyde-dehydrogenase-like mechanism where the formyl 
group of the intermediate is cleaved with oxidation to CO2. 
Regulation – FDH is one of the most abundant folate enzymes, but is 
expressed primarily in the liver, kidney and the central nervous system (84).   FDH 
displays product inhibition by THF and also contains a second THF-tight-binding site 
that is separate from its active site (101).  The product inhibition by THF can be 
suppressed by both cSHMT and C1-THF synthase (102), presumably by channeling 
the THF polyglutamate cofactor to these acceptor proteins. 
Physiological Function/Gene Variants – It is not known if the individual 
reactions catalyzed by the N-terminal and C-terminal domains of FDH have any 
physiological significance.  The dehydrogenase reaction, on the other hand, has been 
proposed to have several important metabolic roles.  These include: 1) recycling THF 
cofactors by removing excess 10-formylTHF, 2) protecting the cell from formate 
toxicity through its conversion to CO2, 3) regulation of de novo purine biosynthesis, 4) 
removal of excess one-carbon units from folate metabolism in the form of CO2  and 5) 
sequestering and storing cellular folate in the form of THF.  These proposed 
physiological functions were investigated in human neuroblastoma (103) and no 
evidence was found that FDH sequestered THF, nor that it regulated de novo purine 
biosynthesis.  FDH was shown, however, to regulate cellular concentrations of 10-
formylTHF and the homocysteine remethylation cycle, presumably by regulating the 
supply folate-activated one-carbon units. 
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Two SNPS within the FDH gene have been shown to alter the risk of 
developing postmenopausal breast cancer.  One gene variant [rs2276731 (T/C)] is 
associated with an increased risk, while the other [rs2002287 (T/C)] is associated with 
a decreased risk.  Both SNPs are located within introns, and therefore they may exist 
in linkage-disequilibrium with a coding SNP such as V812I, G481S, or F330V (97). 
 
3. 5,10-MethenylTHF Synthetase (MTHFS) 
Reaction - 5,10-methenylTHF synthetase (MTHFS, also referred to as 5-
formylTHF cyclo-ligase) catalyzes the ATP-dependent and irreversible conversion of 
5-formylTHF to 5,10-methenylTHF.  It is the only enzyme identified to date that 
utilizes 5-formylTHF as a substrate.  Like 10-formylTHF synthetase, MTHFS activity 
requires Mg2+, which is involved in the binding of the ATP substrate to the enzyme 
(104).  The MTHFS reaction and the cSHMT-catalyzed synthesis of 5-formylTHF 
from 5,10-methenylTHF constitute a futile cycle that serves to buffer intracellular 5-
formylTHF concentrations (105). 
Mechanism - The MTHFS catalyzed reaction occurs via a sequential 
mechanism with a nucleophilic attack by the 5-formyl oxygen on the γ-phosphate of 
ATP to form an N5-imminium phosphate intermediate.  This intermediate undergoes 
cyclization via nucleophilic attack by N10 to form a phosphoimidazolidine tetrahedral 
intermediate, which is the rate-limiting step in catalysis (106,107).  The N10 attack on 
the N5-imminium phosphate is made possible through the hydrophobic and aromatic 
properties of a conserved active site Tyr.  This residue defines the architecture of the 
MTHFS active site, forming a pocket that restricts the motion of N10 (108).  The 
above steps in the MTHFS mechanism are all reversible.  The final step is the 
irreversible step, in which the phosphoimidazolidine tetrahedral intermediate is broken 
down through phosphate elimination to generate the 5,10-methenylTHF product (106). 
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Regulation –In humans, MTHFS is expressed in all tissues, with the highest 
mRNA levels found in the liver, heart, and kidney, and the lowest levels found in the 
brain (109).  MTHFS enzymatic activity is regulated primarily by folate coenzymes.  
5-methylTHF and 10-formylTHF, the latter of which is in chemical equilibrium with 
the product of the MTHFS reaction, act as tight binding inhibitors of MTHFS (110). 
Physiological Function/Gene Variants – To date, two metabolic roles have 
been ascribed to MTHFS.  Anguera et al (2003) found that the expression of human 
MTHFS cDNA in cell culture models led to an increase in the catabolism of 
monoglutamate forms of folate, indicating that MTHFS may regulate cellular folate 
concentrations by affecting rates of folate turnover.  MTHFS is also thought to 
regulate de novo purine biosynthesis through two distinct mechanisms.  First, MTHFS 
activity reduces levels of 5-formylTHF, an inhibitor of the purine-synthesizing 
enzyme phosphoribosylaminoimidazolecarboxamide formyltransferase (AICARFT) 
(111).  Second, MTHFS expression enhances purine biosynthesis either by enriching 
cellular 10-formylTHF pools or by channeling 10-formylTHF to AICARFT and/or 
phosphoribosylglycinamide formyltransferase (GARFT) (110).   
One MTHFS variant allele has been associated with a clinical outcome (112).   
The MTHFS T202A variant allele was associated with poorer prognosis in individuals 
with same-stage lung cancer.  The functional significance of this polymorphism, as 
well as its effect on folate levels and purine biosynthesis, has yet to be determined. 
 
4. 5,10-MethyleneTHF Reductase (MTHFR) 
Reaction -  MethyleneTHF reductase (MTHFR) is a flavoprotein consisting of 
two identical subunits.  The C-terminal domain of each subunit contains the binding 
site for AdoMet, an allosteric inhibitor; the N-terminal domain catalyzes the NADPH-
dependent reduction of 5,10-methyleneTHF to 5-methylTHF for use in the 
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remethylation of homocysteine to methionine.  The MTHFR reaction is virtually 
irreversible in vivo and therefore commits one-carbon units to methionine biosynthesis 
(1,4).   
Mechanism – The reaction catalyzed by MTHFR proceeds by two half 
reactions.  In the reductive half-reaction, the 4S-hydrogen of NADPH is transferred as 
a hydride to N5 of the FAD cofactor.  After NADP+ dissociates from the enzyme, 
5,10-methyleneTHF binds.  In the oxidative half-reaction, 5,10-methyleneTHF is 
protonated at the N10 position by a general acid catalyst (113) leading to the opening 
of the imidazolidine ring and generating the N5-iminium cation intermediate.  
Transfer of a hydride from N5 of the reduced FAD to C11 of the methylene group 
results in the production of 5-methylTHF (114). 
Regulation – Regulation of MTHFR is critical for AdoMet-dependent 
methylation reactions and to prevent elevated homocysteine levels in the cell.  The 
complexity of the MTHFR transcript allows for the regulation of its expression at 
several levels.  Exon 1 of MTHFR undergoes extensive alternative splicing, generating 
transcripts that vary in the length of their 5’UTR (115).  The length of the 5’UTR has 
been shown to influence translational efficiency, as longer, more GC-rich UTRs slow 
the scanning of the translation initiation machinery (116).  Multiple polyadenylation 
signals result in MTHFR transcripts that vary in the length of their 3’UTR.  
Additionally, two distinct promoters and translation start sites generate two isoforms 
of the MTHFR protein.  Transcription initiation from the upstream promoter followed 
by translation from the downstream AUG results in the production of a 70 kDa 
protein; transcription initiation from the downstream promoter followed by translation 
from the upstream AUG generates a 77 kDa protein (115).  MTHFR expression from 
the downstream promoter has been shown to be regulated by NF-κB in a tissue-
specific manner (117).  At the protein level, MTHFR activity is regulated by the 
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AdoMet/AdoHcy ratio in the cell (118).  AdoMet preferentially binds to MTHFR in 
the inactive T state and thus increases the T/R ratio in the cell (119).  Although 
AdoHcy does not itself alter MTHFR enzymatic activity, it can reverse the inhibitory 
effect of AdoMet by competing for its binding site (118).  Recently, phosphorylation 
of the MTHFR N-terminal domain at Thr34 was shown to reduce the inhibition of 
enzymatic activity by AdoMet by altering the equilibrium between the T and R states 
of the protein so that it favors the active R state (120).  NADPH, the reducing 
equivalent in the MTHFR reaction, binds to R subunits, and thus acts as an AdoMet 
antagonist (119).   
Physiological Function/Gene Variants – MTHFR serves as the link between 
nucleotide biosynthesis and AdoMet-dependent methylation reactions.  Its activity 
depletes one-carbon units that can be used for DNA synthesis and increases the 
concentration of one-carbon units available for the remethylation of homocysteine to 
methionine and for the subsequent production of AdoMet.  Thus, although MTFHR is 
expressed ubiquitously, its mRNA levels are the highest in the testis, where DNA 
methylation is critical for germ cell maturation and genomic imprinting (121).  Mild 
MTHFR deficiency, as characterized by an enzyme with 35-45% residual activity, is 
the most common inborn error of folate metabolism, affecting 5-20% of North 
Americans and Europeans (122).  The primary cause is a common C to T substitution 
at nucleotide 677, which results in the amino acid change A222V in the catalytic 
domain of the protein (123).  The C677T SNP does not affect the kinetic properties of 
MTHFR, but rather enhances the loss of the FAD cofactor by displacing helix α5 
(122,124,125).  This creates a thermolabile protein (126).  Mild MTHFR deficiency is 
associated with mild hyperhomocysteinemia, especially in those with low folate 
concentrations (127), and decreased plasma and red cell folate levels (128,129).  
Clinically, C677T has been shown, in some cases, to be associated with an increased 
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risk for cardiovascular disease (130-132), neural tube defects (133-135), cleft lip and 
palate (136,137), thrombosis (138-140) and schizophrenia (141-144).  It has also been 
shown to be protective against several types of cancers, including ALL (145), 
childhood acute leukemia (146), and colorectal cancer (147,148). 
Another common MTHFR SNP, A1298C (E429A), exists in strong linkage 
disequilibrium with C677T (149).  Unlike C677T which is located in the N-terminal 
domain of the protein, A1298C affects the regulatory (C-terminal) domain of the 
protein and is therefore catalytically indistinguishable from the wild-type enzyme 
(125).  Individuals with the A1298C polymorphism exhibit increased red cell folate 
levels, but have no significant change in vitamin B12, plasma folate, or homocysteine 
levels (129).   Clinically, the polymorphism was shown to be associated with a 
decreased risk for ALL (145) and childhood acute leukemia (146).  
 
C. Biosynthetic Enzymes 
 
1. Phosphoribosylglycinamide Formyltransferase (GARFT) and 
Phosphoribosylaminoimidazolecarboxamide Formyltransferase (AICARFT) 
Reaction – De novo purine biosynthesis is a ten-step reaction whereby 5-
phosphoribosylpyrophosphate (PRPP) is converted to inosine monophosphate (IMP), 
the precursor of adenine and guanine nucleotides.  Of the ten steps involved in de novo 
purine biosynthesis, two are catalyzed by folate-dependent enzymes.  In the third 
reaction, phosphoribosylglycinamide formyltransferase (GARFT) transfers the formyl 
group of 10-formylTHF to glycinamide ribotide (GAR) to form formylglycinamide 
ribonucleotide (FGAR) and THF.  In the ninth reaction, 
phosphoribosylaminoimidazolecarboxamide formyltransferase (AICARFT) transfers 
the formyl group of 10-formylTHF to aminoimidazolecarboxomide ribotide (AICAR) 
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to form formylaminoimidazolecarboxomide ribonucleotide (FAICAR) and THF.  In 
eukaryotic cells, GARFT and AICARFT activities are part of multi-functional 
enzymes.  GARFT activity comprises the C-terminal domain of a protein that also 
contains the active sites of GAR synthetase (GARS) and aminoimidazole ribotide 
synthetase (AIRS) (150,151), and AICARFT resides on the same polypeptide as IMP 
cyclohydrolase.  Substrate channeling among GARFT, GARS, and AIRS drives the 
AICARFT reaction forward by coupling the energetically unfavorable production of 
FAICAR to the highly favorable cyclohydrolase reaction (152). 
Mechanism – Despite performing similar reactions, GARFT and AICARFT act 
through distinct mechanisms.  The reaction catalyzed by GARFT occurs by an ordered 
sequential mechanism (153), with 10-formylTHF binding to the active site first 
through interactions with His108 and Asn106.  His108, which has a high the pKa due 
to the formation of a salt bridge with Asp144, aids in the nucleophilic attack of GAR 
on 10-formylTHF by withdrawing electrons from the formyl group of the cofactor.  A 
water molecule hydrogen bonded to Asp144 then catalyzes the transfer of a proton 
from the amino group of GAR to the N10 of THF (154,155).  
Unlike GAR, AICAR contains a relatively non-nucleophilic C5 amine that 
must first be activated in order for the formylation reaction to occur (152,156,157).  In 
one proposed mechanism, activation of the C5 amine results from Phe542 orienting 
the AICAR carboxamide upward and out of the imidazole ring plane, allowing the 
carboxamide to hydrogen bond to the C5 amino group and thus increases the 
nucleophilicity of the amine.  Proton abstraction from the amino group via His268 
then occurs concomitant with the nucleophilic attack of this group on 10-formylTHF.  
The transition state of this reaction is thought to be stabilized by Lys267, a residue that 
may also play a role in the subsequent protonation of THF (158).  These findings are 
in partial disagreement with earlier proposed mechanisms (159).   
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Regulation – To date, little is known about the tissue specific or genetic 
regulation of GARFT and AICARFT expression.  The putative promoter region of the 
gene encoding GARFT was found to have four SP1 sites, but the importance of these 
sites in transcriptional control has yet to be determined.  GARFT is developmentally 
regulated in the human cerebellum, with high expression found during prenatal 
development, and no expression detected in that tissue shortly after birth (160). 
Physiological Function – GARFT and AICARFT play a key role in de novo 
nucleotide biosynthesis by catalyzing the incorporation of formate into the C8 and C2 
positions of the purine ring, respectively.  Once formed, purine nucleotides function as 
precursors for DNA, RNA, coenzymes, energy transfer molecules, and regulatory 
factors.  Although the salvage pathway is thought to be the major source of purines in 
differentiated mammalian cells (161), the de novo pathway was found to supply most 
of the adenine and guanine nucleotides during human embryonic development (160). 
Compared to normal cells, cancer cells have an increased dependence on de 
novo purine biosynthesis for adenine and guanine nucleotides.  Thus, both GARFT 
and AICARFT are chemotherapeutic targets.  6-R-dideazatetrahydrofolate (DDATHF, 
Lometrexol) is an antifolate that specifically targets GARFT.  In contrast to the natural 
substrate of the enzyme, DDATHF contains carbon atoms at positions 5 and 10 which 
render it unable to serve as a substrate (162,163).  The antimetabolate methotrexate (4-
amino-10-methylpteroyglutamic acid) inactivates several folate-dependent enzymes, 
including both GARFT and AICARFT, by depleting 10-formylTHF (164).  Inhibition 
of AICARFT by methotrexate and dihydrofolate polyglutamates results in an anti-
inflammatory response (165-167).  A common SNP in the AICARFT gene, C347G 
(Thr116Ser), is associated with a better therapeutic response to methotrexate in 
patients with rheumatoid arthritis, although the mechanism by which the 
polymorphism influences drug efficacy remains unknown (168).   
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Another AICARFT gene variant, A1277G (K426R), completely abolishes 
AICARFT enzymatic activity, presumably by disrupting the binding of a potassium 
ion that plays a key role in tertiary structure stabilization.  To date, this mutation has 
only been identified in one allele of a 4-year old girl who presented with profound 
mental retardation, epilepsy, dysmorphic features, and congenital blindness.  Her other 
allele showed a frameshift in exon 2 due a duplication/deletion event (125-129dup 
GGGAT; 130-132 delGCT) that resulted in mRNA instability (169). 
 
2. Thymidylate Synthase 
Reaction – Thymidylate synthase (TS) catalyzes the 5,10-methyleneTHF-
dependent conversion of deoxyuridine monophosphate (dUMP) to the DNA precursor 
deoxythymidine monophosphate (dTMP).  This is the only folate-dependent reaction 
whereby the folate cofactor serves both as a one-carbon donor and source of reducing 
equivalents.  When 5,10-methyleneTHF is limiting in the cell, TS must compete with 
MTHFR for this cofactor.  Thus, in addition to its role in DNA synthesis, TS 
expression may also indirectly influence homocysteine levels (170).   
Mechanism –The TS reaction initiates with the opening of the imidazole ring 
and activation of the methyleneTHF cofactor to the reactive 5-iminium cation.  Ring 
opening is facilitated through either the TS-assisted protonation of N10, a protonated 
water molecule that acts as a general acid catalyst, or the formation of a hydrogen 
bond between N10 and an active site residue such as Glu60.  dUMP must also be 
activated by the thiol group of Cys198, which either directly attacks C6 of the 
substrate to produce a nucleophilic enolate, or transfers a hydrogen to a water 
molecule that acts as a base.  The enolate then attacks C6 of the iminium cation to 
form a ternary covalent intermediate complex.  Tyr146-assisted deprotonation of C5 
(171) followed by the elimination of THF from this complex results in an exocyclic 
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methylene intermediate.  Hydride transfer from THF to this intermediate yields the 
products dTMP and dihydrofolate (172). 
Regulation – TS is a housekeeping gene but its expression is increased 
markedly in dividing cells.  (173,174).  Although protein and mRNA levels increase as 
cells progress from the G1 to the S phase of the cell cycle, TS gene transcription 
remains constant, suggesting that regulation occurs primarily at the post-
transcriptional level (175-177).  The cell cycle-directed regulation of TS is thought to 
be controlled by a spliceable intron located downstream of the transcription start site 
(178,179) and several transcriptional control elements in the promoter region (180).  
The transcription factor GABP, acting synergistically with Sp1, stimulates TS 
promoter activity by binding to the Ets site (181).  The mouse LSF element has been 
shown to be necessary for the S phase-specific expression of the gene in growth-
stimulated cells (182).  In the G0 and G1 stages, E2F interacts with the retinoblastoma 
tumor suppressor, histone deacetylase, and SWI/SF chromatin remodeling proteins, 
forming a repressor complex that inhibits the enzyme’s transcription (183).  This 
inhibition can be overcome by the ectopic expression of E2F (184).   
In addition to regulation by various promoter elements, TS expression can also 
be controlled through polyadenylation, site-specific cleavage, and translational 
repression.  TS contains two polyadenylation signals which affect the length of the 
3’UTR and thus have an impact on mRNA stability (185).  A naturally occurring 
antisense RNA (rTSα) produced from a gene (rTS) that overlaps with the 3’end of the 
TS gene down-regulates TS expression by inducing the site-specific cleavage of TS 
RNA (186).  In the absence of bound folate cofactors, TS can also bind to its own 
mRNA and repress its translation (187). 
Physiological Function/Gene Variants - The reaction catalyzed by TS is the 
only source of de novo dTMP synthesis, making TS indispensable for DNA 
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replication and repair.  Impairments in TS enzymatic activity, whether due to 
polymorphisms or pharmacological agents, are associated with decreased DNA 
synthesis, increased uracil misincorporation into DNA, chromosome damage, fragile 
site induction, and apoptotic cell death (188). 
Because of its importance in DNA synthesis, TS is the target of several anti-
neoplastic agents   including the fluoropyrimidines 5-fluorouracil (5-FU) and 5-fluoro-
2-deoxyuridine (FdUrd), and the anti-folates ralitrexed, premetrexed, and 
methotrexate.  These chemotherapeutic drugs generate metabolites that inhibit TS 
enzymatic activity and have been effective in the treatment of head, neck, breast, 
stomach, and colon cancers (189).  Although these agents decrease TS catalytic 
function, they also increase its intracellular concentration (190,191) either by 
inhibiting the binding of TS to its mRNA or by decreasing the rate of ubiquitin-
independent enzyme degradation (192,193).  This phenomenon is thought to lead to 
cellular resistance and decreased drug efficacy. 
Within the 5’UTR of TS, there is a common 28-nucleotide G/C-rich tandem 
repeat polymorphism that is thought to influence a patient’s response to TS-based 
chemotherapy.  The number of these repeats can vary, with the most common number 
being two (2R) or three (3R).  These repeat regions contain USF-1 transcription 
factor-binding sites (194) and act as TS promoter enhancers; they also serve to 
increase its translation.  Thus, individuals with the 2R/2R genotype produce 
significantly less TS protein than those with the 3R/3R genotype (195,196) and show a 
better response to fluoropyrimidine and mexotrexate therapy.  However, they also 
suffer increased toxicity due to cytotoxic damage to normal tissues (197,198).  Within 
the second repeat of the 3R allele and the first repeat of the 2R allele, there is a G→C 
polymorphism that results in a reduction in TS expression, presumably due to the 
disruption of a USF-1 binding site (194,199,200). 
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Another TS gene variant results from a 6 base pair insertion/deletion in the 
3’UTR of the transcript (201).  This deletion affects mRNA stability and translation 
(186), and results in the reduction of TS expression (202).  It also leads to an increase 
in red blood cell folate concentrations and a decrease in homocysteine levels (203).  
The homozygous insertion genotype has been found to be associated with an increased 
risk for spina bifida, especially when present in combination with the 2R/2R genotype 
(204).  
 
3. Methionine Synthase (MS) 
Reaction – Methionine Synthase (MS) is a cobalamin (vitamin B12)-dependent 
enzyme that, in mammalian tissue, functions within the transmethylation cycle by 
catalyzing the 5-methylTHF-dependent remethylation of homocysteine to methionine.  
The MS catalyzed reaction occurs via three separate methyl transfer reactions that take 
place in different binding domains of the four functional modules that comprise MS.  
The N-terminal module utilizes a (Cys)3Zn+2 cluster to bind homocysteine.  A second 
module binds and activates 5-methylTHF for methyl transfer.  A third module binds 
cobalamin.  The C-terminal module binds S-adenosylmethionine (AdoMet) and is 
required for reductive reactivation of the cobalamin cofactor (205-208).  Each methyl 
transfer requires a different arrangement of modules which is made possible by the 
interdomain connectors of the enzyme (209). 
Mechanism – The catalytic mechanism initiates with the methylation of 
cob(I)alamin by 5-methylTHF to form an enzyme-bound methylcob(III)alamin 
intermediate and THF.  Methyl transfer from methylcob(III)alamin to homocysteine 
produces methionine and regenerates cob(I)alamin for use in subsequent methylation 
cycles (210).  Cob(I)alamin and methylcob(III)alamin are susceptible to oxidation and 
photolysis, respectively, resulting in the occasional formation of a cob(II)alamin 
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species that inactivates the enzyme.  Mammalian MS is reactivated through reducing 
equivalents that are generated by methionine synthase reductase, a P450-reductase like 
protein that binds NADPH, FAD, and FMN (211). 
Regulation – MS expression is regulated by several factors, including vitamin 
B12, cis-acting elements located within its mRNA and nitrous oxide.  Vitamin B12 
was found to stimulate MS translation by interacting (via an auxiliary protein) with an 
Internal Ribosome Entry Site (IRES) located within the 5’UTR of the transcript (212).  
The 5’ leader sequence of human MS mRNA also contains two upstream open reading 
frames that recruit the 40S ribosomal subunit and cause it to stall on the UTR, thus 
inhibiting the translation of MS (213).   
Loss of vitamin B12, due to nutritional deficiency or nitrous oxide exposure, 
inhibits nucleotide biosynthesis because of the accumulation of cytoplasmic folate 
cofactors as 5-methylTHF.   The effect of vitamin B12 deficiency on 5-methylTHF 
accumulation is referred to as “methyl trap” (214,215).  5-methylTHF accumulates 
because the MTHFR reaction is irreversible in vivo, and MS is the only 5-methylTHF 
utilizing enzyme.  When cellular vitamin B12 levels are adequate, the regulation of 
MTHFR by AdoMet protects against a methyl trap by inhibiting the 5-methylTHF 
synthesis and preventing the depletion of 5,10-methyleneTHF pools required for 
thymidylate biosynthesis.  The feedback inhibition of AdoMet also ensures that, 
during times when methionine is abundant, one carbon units are spared for the 
synthesis of DNA precursors (118). 
Physiological Function/Gene Variants – MS serves three important 
physiological functions: 1) the regeneration the THF cofactor,  2)  the synthesis of the 
essential amino acid methionine and 3) the removal of cellular homocysteine, which is 
a risk factor for cardiovascular disease (216), neural tube defects (136), and 
Alzheimer’s disease (217).  MS is an essential enzyme as evidenced by the embryonic 
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lethality of the MS knockout mouse (218).  Although betaine homocysteine 
methyltransferase (BHMT) can also remethylate homocysteine to form methionine, its 
expression is limited primarily to the liver and kidney, whereas MS displays 
ubiquitous expression (219).   
Rare mutations in the MS gene, such as P1173L, result in an autosomal 
recessive disease that is associated with homocysteinemia, homocysteinuria, 
hypomethioninemia, megaloblastic anemia, neural dysfunction, and mental retardation 
(220).  More subtle clinical outcomes are associated with the common polymorphic 
variant, A2756G, which affects the domain involved in methylation and reactivation 
of the B12 cofactor (221) and results in decreased plasma homocysteine levels (222).  
A2756G was found to be positively associated with aberrant methylation in patients 
with colorectal, breast, or lung tumors (223) and has been implicated as a risk factor 
for systemic lupus erythematosus (224), bipolar disorder, schizophrenia (225), and for 
having a child with spina bifida (226), oralfacial clefts (227), and Down Syndrome 
(228). 
 
D. Folate Binding Proteins 
 
1.  Glycine N-Methyltransferase (GNMT) - GNMT is a relatively abundant 
methytransferase that catalyzes the AdoMet-dependent methylation of glycine to 
sarcosine.  Its metabolic role is to govern transmethylation reactions by regulating and 
buffering the AdoMet/AdoHyc ratio.  GNMT activity is allosterically regulated by 5-
methylTHF, which is a tight-binding inhibitor of GNMT.   Under conditions of 
adequate AdoMet concentrations, AdoMet inhibits MTHFR and limits 5-methylTHF 
synthesis to decrease rates of methionine synthesis.  GNMT remains active under 
these conditions and metabolizes excess AdoMet.  In contrast, when AdoMet levels 
 29
are low, the production of 5-methylTHF by MTHFR inhibits GNMT activity and 
conserves the limited amount of methionine for essential methylation reactions (8). 
 
Part IV:  Introduction to Mitochondrial One-Carbon Metabolism 
Relatively little is known about one-carbon metabolism in the mitochondria 
compared to one-carbon metabolism in the cytoplasm, and virtually nothing is known 
about its regulation.  Interestingly, many of the enzyme activities associated with the 
interconversion of THF-activated one-carbons in the cytoplasm are also found in the 
mitochondrial compartment.  However, unlike the cytoplasm, the interconversion of 
one-carbon substituted folates in mitochondria is driven in the oxidative direction 
towards formate production and/or differs with respect to the source of reducing 
equivalents (1,30).  Approximately 40% of total cellular folate polyglutamates are 
present in mitochondria as a stable pool that does not exchange with the cytoplasmic 
compartment (229,230).  The primary functions of mitochondrial one-carbon 
metabolism are: 1) to generate one-carbon units in the form of formate for cytoplasmic 
one-carbon metabolism, 2) to generate the amino acid glycine, and 3) to synthesize 
formylmethionyl-tRNA for protein synthesis.  Communication between mitochondrial 
and cytoplasmic folate metabolism is facilitated through the exchange of one-carbon 
donor substrates including serine, glycine and formate (1).   
The essentiality of mitochondrial folate metabolism for glycine synthesis was 
revealed when complementation groups of glycine auxotrophs were isolated from 
mutagenic screens of Chinese Hamster Ovary Cells (CHO).  Cell lines were identified 
with mutations in the genes that encode the mitochondrial folate-dependent proteins 
SHMT2 (glyA) (231) and the mitochondrial folate transporter (glyB) (232).  Other 
studies have demonstrated that mitochondria effectively convert serine to glycine and 
formate; isolated mitochondria from rats are capable of synthesizing formate from 
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serine (71,233).  However, the definitive pathway for mitochondrial synthesis of 
formate from serine has yet to be established (30), and not all of the enzymes required 
for this pathway have been identified.   
 
A. Enzymes that Generate One-Carbon Units 
 
1. Mitochondrial Serine Hydroxymethyltransferase (SHMT2) 
Serine is a primary source of one-carbon units carried by THF for folate-dependent 
biosynthetic reactions in humans (234).  The metabolism of serine to formate and 
glycine in mitochondria is initiated by the pyridoxal-phosphate-dependent 
mitochondrial isozyme of serine hydroxymethyltransferase (SHMT2).  Although the 
cytoplasmic and mitochondrial isozymes share similar physical and catalytic 
properties, their physiological functions appear to be distinct.  As mentioned 
previously, CHO cells lacking SHMT2 are autotrophic for glycine; the C3 of serine is 
also a primary source of one-carbon units for cytoplasmic one-carbon metabolism in 
human MCF-7 cells (31,231).  SHMT2 may also function in the conversion of glycine 
to serine during gluconeogenesis (30,33).   
Little is known about the regulation of SHMT2 expression and activity.  
Unlike the cytoplasmic cSHMT isozyme, SHMT2 is ubiquitously expressed in human 
tissues (2).  Its activity is sensitive to pyridoxal-phosphate levels (44,103).  SHMT2 
transcription is myc responsive consistent with its role in generating one-carbons for 
cytoplasmic metabolism; expression of the SHMT2 cDNA in c-myc-null cells 
partially complements growth inhibition associated with loss of myc expression (235). 
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2. Glycine Cleavage System, Aminomethyltransferase (GCS, AMT) 
The glycine cleavage system is a multienzyme complex that catalyzes the 
reversible oxidation of glycine to CO2, ammonia and 5,10-methyleneTHF (236).  The 
complex consists of 4 proteins: 1) the P-protein, which catalyzes the pyridoxal-
phosphate-dependent decarboxylation of glycine, 2) the H-protein, a lipoic acid-
requiring hydrogen carrier, 3) the T-protein which is a THF-dependent 
aminomethyltransferase (AMT) and 4) the L-protein, a lipoamide dehydrogenase.  The 
complex is located in the inner mitochondrial membrane and expressed in the liver, 
kidney, the glia-astrocyte lineage of the brain and the neuroepithelium during 
development (237).  Recent stable isotope tracer studies in human subjects 
demonstrate that GCS accounts for nearly 40% of overall glycine flux and that the 
5,10-methyleneTHF produced from glycine catabolism makes major contributions to 
cytoplasmic THF-dependent purine and thymidylate biosynthesis (238) 
Little is known regarding the regulation of GCS, but it has been shown to be 
essential for normal embryonic development.  Nonketotic hyperglycinemia (NKH) is 
an autosomal recessive inborn error of metabolism whose clinical manifestations 
include severe mental retardation, seizures, apnea, and hypotonia and result from the 
accumulation of glycine in all tissues including the central nervous system.  NKH is 
usually associated with mutations in the P-protein or T-protein (239).   
 
3. Dimethylglycine Dehydrogenase (DMGDH) and Sarcosine Dehydrogenase 
(SDH) 
The oxidative catabolism of choline occurs through the sequential conversion 
of choline Æ betaine Æ dimethylglycine Æ sarcosine Æ glycine; dimethylglycine and 
sarcosine catabolism occurs in liver mitochondria matrix through the activity of 
dimethylglycine dehydrogenase (DMGDH) and sarcosine dehydrogenase (SDH) 
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respectively.  Both enzymes contain a covalently bound flavin adenine dinucleotide 
(FAD) and are major folate-binding proteins in liver (240).  The reaction mechanisms 
are not established (8) but the electrons generated are transferred ultimately to the 
electron-transport chain.  The quantitative contribution of choline degradation to the 
cytoplasmic folate-activated one-carbon pool is not known.   
Inborn errors of metabolism are associated with both DMGDH and SDH 
deficiency.  DMGDH deficiency results in muscle fatigue and body odor; 
sarcosinemia is a rare autosomal disorder with a broad and variable spectrum of 
symptoms including mental retardation and growth failure (241).   
 
4. 10-FormylTHF Synthetase (FTHFS) 
The final step in the putative conversion of the hydroxymethyl group of serine 
to formate in mitochondria requires the generation of formate from 10-formylTHF (1).  
This reaction can occur in mitochondria through the reverse reaction of 10-formylTHF 
synthetase, driven by a favorable ADP/ATP ratio in mitochondria (1).  Mitochondria 
contain a monofunctional FTHFS enzyme that is encoded by MthfdL1, which is 
expressed ubiquitously in mammalian cells (242-244).  Further studies of this 
recently-identified FTHFS enzyme will determine if its primary function is to generate 
formate from 10-formylTHF. 
 
B. Folate Interconverting Enzymes 
 
1.  5,10-MethenylTHF Cyclohydrolase and 5,10-methyleneTHF Dehydrogenase 
(MTHFC, MTHFD) 
Human mitochondria contain isozymes of MTHFD and MTHFC activities 
encoded by a single gene, Mthfd2, which is believed to have evolved through gene 
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duplication and mutation of Mthfd1 (245,246).   Mthfd2 does not encode FTHFS 
activity, and the mitochondrial MTHFD activity is distinguished from its cytoplasmic 
counterpart by its NAD-dependence which serves to drive the reaction in the oxidative 
direction to generate 10-formylTHF (30).  Mthfd2 is an essential gene during mouse 
development, but is not found in adult tissues.  Its expression appears to be limited to 
embryonic and transformed cells (247). Deletion in murine embryonic fibroblasts 
creates a glycine auxotrophy, indicating a role for this enzyme in generating 
unsubstituted THF for SHMT2 and potentially generating fomate from serine.  
Therefore, while a complete folate-dependent pathway for generating formate from 
serine exists in embryonic cells, the lack of identified MTHFD and MTHFC activities 
in adult tissues represents a gap in our understanding of mitochondrial folate 
metabolism and/or the interaction between cytoplasmic and mitochondrial one-carbon 
metabolism in adult tissues. 
 
C. Biosynthetic Enzymes 
 
1.  Methionyl-tRNAfMet Formyltransferase (MFT). 
Protein synthesis in mitochondria and prokaryotes is initiated with formyl-
methionyl-tRNA (fMet-tRNA), which is formed by the 10-formylTHF-dependent 
formylation of Met-tRNA catalyzed Methionyl-tRNAfMet Formyltransferase (MFT) 
(248,249).  This is the only known biosynthetic reaction that occurs in mitochondria, 
other than amino-acid interconversion reactions (Figure 1.1).  Although MFT-deficient 
Saccharomyces cerevisiae display normal mitochondrial function and mitochondrial 
protein synthesis (250), MFT does offer selective advantage under severe growth 
conditions (251).  Formylation of Met-tRNA confers specificity to its interaction with 
initiation factor 2 (IF-2); bovine IF-2 binds fMet-tRNA with 25-fold greater affinity 
 34
than Met-tRNA and mitochondrial ribosomes bind fMet-tRNA 50-fold tighter than 
Met-tRNA in the presence of IF-2 (252).    
 
Part V:  Nuclear Folate-Mediated One-Carbon Metabolism 
There is increasing evidence that folate-mediated thymidylate synthesis occurs 
in both the nucleus and cytoplasm (Figure 1.1).  Approximately ten percent of cellular 
folate is present in the nucleus, and TS and cSHMT have been localized to the nucleus 
in several mammalian cell types in S-phase (51,253-257).  The three enzymes that 
constitute the thymidylate synthase cycle (cSHMT, TS, and dihydrofolate reductase 
(DHFR)) are all substrates for UBC9-mediated modification with the small ubiquitin-
like modifier (SUMO), which targets proteins for nuclear localization during S-phase 
(9,51).   Nuclear TS was shown to form part of a putative “replitase complex” along 
with DNA polymerase α, ribonucleotide reductase, thymidylate kinase, NDP kinase, 
the folate-dependent enzyme DHFR (254,258,259), and possibly cSHMT (9).  
Because cSHMT exhibits a narrow range of tissue-specific expression compared to TS 
and DHFR, it is unlikely that all cells synthesize thymidylate in the nucleus.  Although 
the biological significance of nuclear dTMP synthesis at the cellular level remains 
unclear, it has been hypothesized that its association with the replitase complex allows 
for de novo thymidylate synthesis directly at the replication fork during S-phase and 
may lower uracil misincorporation into DNA.   
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CHAPTER 2 
 
INTRODUCTION TO INTERNAL RIBOSOME  
ENTRY SITE-MEDIATED TRANSLATION INITIATION 
 
Part I: Abstract 
Translation initiation can occur by two distinct mechanisms: cap-dependent 
ribosome scanning and internal ribosome entry.  In cap-dependent translation 
initiation, the 40S ribosomal subunit binds to the 5’ cap structure of the mRNA and 
scans through the 5’ untranslated region (UTR) to reach the start codon of the open 
reading frame.  During internal ribosome entry, the 40S ribosomal subunit binds to the 
5’UTR of the transcript at a position close to or directly at the initiation codon.  This 
position is termed the internal ribosome entry site (IRES).  This chapter discusses the 
identification of IRES elements, the mechanisms whereby they may function, and the 
cellular situations where they are required.  Special emphasis is placed on IRESes that 
regulate folate-mediated one-carbon metabolism. 
  
Part II: Mechanisms of Translation Initiation 
 
Cap-Dependent Translation  
For the majority of eukaryotic mRNAs, translation initiation proceeds by a 
cap-dependent mechanism (Figure 2.1).  The 43S initiation complex (which contains 
the 40S ribosomal subunit, the initiator methionine-tRNA bound to eukaryotic 
initiation factor 2 (eIF2) and GTP, eIF1A, and eIF3) is recruited to the 7-methyl-
guanosine (m7G) cap structure located at the 5’ terminus of the transcript through 
interactions with eIF4F (1,2).  eIF4F is a three-subunit complex composed of the cap- 
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Figure 2.1.  Cap-dependent translation initiation.  Cap-dependent translation 
initiation begins with the recruitment of the 43S complex, which consists of the 
small 40S ribosomal subunit, GTP-bound eIF2, methionine-bound initiator tRNA, 
eIF1A, and eIF3, to the m7G cap at the 5’ end of an mRNA transcript.  eIF3 acts 
as a bridge between the 43S complex and eIF4G, which is bound to the cap via 
interaction with eIF4E and to the poly(A) tail of the transcript via interaction with 
the poly(A)-binding protein (PABP).  Through the coordinated activities of 
eIF1A, eIF4B, and the ATP-dependent helicase eIF4A, the 43S complex then 
scans along the 5’UTR of the mRNA until the AUG start codon of the open 
reading frame is paired with the anticodon of the initiator tRNA (48S complex).  
Upon 48S complex formation, GTP is hydrolyzed by eIF2.  This triggers the 
release of eIF2, eIF3, and eIF1A, and enables the eIF5B-mediated joining of the 
large 60S ribosomal subunit.  The resulting 80S ribosome is poised to begin 
translation elongation. 
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binding protein eIF4E, the DEA(D/H)-box RNA helicase eIF4A, and eIF4G, which 
serves as a scaffold for the coordinated assembly of the translation initiation 
machinery.  Upon binding to the cap structure, eIF1A, eIF4A, and eIF4B act 
synergistically to enable the ATP-dependent scanning of the 43S complex along the 5’ 
untranslated region (UTR) of the mRNA in the 5’ to 3’ direction (3,4).  Ribosome 
scanning culminates in the formation of the 48S complex in which the initiator AUG 
is base paired to the anticodon of the initiator tRNA.  Once positioned on the initiation 
codon, the eIFs bound to the 40S ribosomal subunit are displaced (2,5), and eIF5B 
mediates the joining of the 60S ribosomal subunit to the 40S subunit (6,7).  This 
results in the formation of the protein synthesis-competent 80S ribosome in which the 
initiator tRNA is positioned in the ribosomal P site. 
 
Internal Ribosome Entry Site-Mediated Translation 
Because cannonical cap-dependent translation requires ribosome scanning, it is 
generally not efficient when any of the eIFs is limiting (8) and when the 5’UTR of the 
mRNA transcript is greater than 150 nucleotides in length (9), has a secondary 
structure with a change in Gibb’s free energy (∆G) of less than -50 kcal/mol (10), and 
contains multiple non-conserved AUG triplets upstream of the initiation codon (8).  
Yet picornaviruses, which possess all of these barriers to ribosome scanning and lack a 
7-methyl-guanosine cap structure, are efficiently translated following infection, 
suggesting that picornaviral mRNAs are translated by a cap-independent initiation 
mechanism.  In 1988 it was discovered that the 40S ribosomal subunit can be recruited 
to a cis-element located within the 5’ UTR of the picornaviral transcript.  These 
elements, now called internal ribosome entry sites (IRESes), allow for the assembly of 
the translational machinery at a position close to or directly at the initiation codon, and 
thereby circumvent ribosome scanning through a long and structured 5’UTR.  IRES 
 57
elements also allow for 40S recruitment in a manner that is independent of eIF4F 
integrity (11,12).   
Shortly after the identification of IRESes within the viral genome, it became 
evident that many cellular mRNAs from yeast, Drosophila, birds, and mammals can 
also be translated via internal initiation.  As with the picornaviral transcripts, a number 
of these cellular mRNAs possess structural features in their 5’UTRs that would 
impede a cap-dependent ribosome scanning mechanism.  It is now estimated that 3-5% 
of cellular mRNAs contain IRESes (13).   
 
Part III: Identifying IRES Elements 
IRESes cannot be recognized by a specific RNA sequence or structural motif; 
however, the majority of the IRESs identified to date are GC-rich and exhibit complex 
stem loop structures (14).  The current protocol for the identification of IRES elements 
involves inserting the 5’UTR of a transcript into the intercistronic spacer region of a 
bicistronic construct.  Expression of the downstream cistron indicates the ability of the 
5’UTR to promote internal ribosome binding.  When performing such experiments, 
extreme care must be taken to 1) rule out the existence of cryptic promoter activity and 
cryptic splice sites within the 5’UTR that would result in the synthesis of a 
functionally monocistronic mRNA, 2) ensure the integrity of the translated bicistronic 
mRNA, and 3) control for other mechanisms such as termination-reinitiation that 
could result in the translation of the downstream cistron (15,16). 
As an alternative to bicistronic constructs, a suspected IRES element can also 
be inserted into a circularized mRNA engineered to contain a single continuous open 
reading frame (17,18).  The spatial constraints imposed by circularization of the 
mRNA molecule do not interfere with IRES function, but cannot support a cap-
dependent mechanism of translation initiation.   
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Part IV: Mechanism of IRES-Mediated Translation 
Just as there are few similarities that exist among IRESes in terms of sequence 
and structure, there is no universal mechanism for internal ribosome entry.  For 
example, whereas the IRES-mediated translation of the encephalomyocarditis virus 
requires all of the canonical initiation factors except eIF4E (19,20), the IRES-mediated 
translation of the hepatitis C and cricket paralysis viruses is eIF-independent (21-23); 
and whereas some IRESes are stimulated by the 3’UTR of the transcript (24-26), 
others are not.  Despite their differences, a couple of commonalities do exist among 
the known mechanisms of IRES-mediated translation: many IRES activities are 
stimulated by the poly(A) tail of the transcript, and almost all cellular IRESes require 
one or more IRES trans-acting factors (ITAFs).   
 
The Poly(A)Tail   
Almost all eukaryotic mRNAs possess a 3’ poly(A) that is 50-300 nucleotides 
in length.  The poly(A) tail of most transcripts is bound with multiple copies of the 
poly(A)-binding protein (PABP), a 70 kDa protein with four highly conserved RNA 
recognition motifs (27,28).  During translation initiation, PABPs interact with eIF4G, 
bringing together the 5’ and 3’ ends of the transcript to form a “closed loop” (Figure 
2.1) (29-32).  PABP-mediated circularization of the mRNA is known to stimulate both 
cap-dependent and IRES-mediated translation (29-35), although the exact mechanism 
by which it does so is still a matter of debate.  It has been suggested that the “closed 
loop” improves translation efficiency by facilitating the utilization or recycling of 40S 
ribosomal subunits (30,36), promoting 60S ribosomal subunit joining at the start 
codon (37), and/or causing a conformational change that stimulates eIF4F activity 
(38).   
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ITAFs 
ITAFs are non-canonical initiation factors that bind directly to the mRNA and 
are thought to facilitate the recruitment of the 40S ribosomal subunit to the IRES 
either by interacting with the translation initiation machinery or by modulating the 
conformation of the transcript (8,39,40).  The list of known ITAFs is continually 
growing.  Whereas some ITAFs such as La autoantigen and the polypyrimidine tract 
binding protein have been shown to be involved in the IRES-mediated translation of 
numerous transcripts (41-50), others seem to function more specifically.  Surprisingly, 
most of the ITAFs identified to date belong to the group of heterogeneous nuclear 
ribonucleoproteins (hnRNPs).  These include hnRNP A1, C1/C2, I, E1/E2, K, and L 
(43,51-53).  hnRNPs are known to play a role in nuclear RNA processing and thus 
reside primarily in the nucleus of the cell.  However, following the appropriate cellular 
signal, they relocalize to the cytoplasm where they participate in IRES-mediated 
translation (54).  Such compartmentalization of ITAFs allows for the precise 
regulation of IRES-mediated translation. 
 
Part V: The Function of Cellular IRESes 
Cap-dependent translation initiation is a highly regulated process that is 
controlled by the availability of eIF4F and the delivery of the ternary complex (eIF2-
GTP- initiator methionine-tRNA) to the 43S ribosomal subunit (55).  The availability 
of eIF4E is governed by the concentration of eIF4E-binding proteins.  In their 
hypophosphorylated state, eIF4E-binding proteins interact with eIF4E and prevent its 
association with eIF4G (56-60).  eIF4G itself is controlled by proteolysis.  Cleavage of 
eIF4G disrupts its function by separating the cap and poly(A)-binding domains of the 
protein from the eIF3 and eIF4A-binding sites (61).  Finally, the α subunit of eIF2 can 
be phosphorylated at Ser51 by the protein kinase HCR, PKR, or GCN2.  
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Phosphorylation of eIF2α increases the affinity of eIF2 for the guanine-nucleotide-
exchange factor eIF2B, and thereby decreases the amount of available ternary 
complexes (55,62,63). 
The sequestration of eIF4E, cleavage of eIF4G, and phosphorylation of eIF2α 
all inhibit cap-dependent protein synthesis and occur during mitosis, quiescence, 
differentiation, and apoptosis, and in response to stress conditions such as amino acid 
starvation, hypoxia, heat/cold shock, viral infection, and exposure to UV radiation 
(reviewed in (64)).  These mechanisms that regulate cap-dependent translation do not 
affect IRES-mediated translation (58,59).  Thus, many of the mRNAs whose 
expression is required for programmed cell death, cell cycle progression, development, 
and stress response have been found to harbor IRES elements in their 5’UTRs (Table 
2.1).  Since internal initiation escapes eIF-mediated translational control, it is believed 
that IRES-mediated translation has evolved as a regulatory mechanism that enables 
cells to respond to diverse physiological states against the background of a general 
reduction in protein synthesis. 
 
Part VI: IRESes that Regulate Folate-Mediated One-Carbon Metabolism 
 As discussed in Chapter 1, folate-mediated one-carbon metabolism is essential 
for the de novo biosynthesis of purines and thymidylate and for the remethylation of 
homocysteine to methionine.  Purine nucleotides function as precursors for DNA, 
RNA, coenzymes, energy transfer molecules, and regulatory factors, and their de novo 
biosynthesis is required during human embryonic development (65).  Thymidylate is 
necessary for faithful DNA replication and repair.  Decreased levels of thymidylate 
result in increased uracil misincorporation into DNA, which in turn leads to 
chromosome damage, fragile site induction, and apoptotic cell death (66).  The 
remethylation of homocysteine to methionine serves to remove cellular homocysteine,  
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Gene Product Cellular Function Reference 
cat-1 mediates uptake of arginine and lysine (67) 
p58 PITSLRE regulates cell cycle progression (68) 
p27 regulates cell cycle progression (69) 
c-, N-, L-myc Control cell growth, differentiation, and apoptosis (70-72) 
p53 regulates cell cycle arrest and apoptosis (73) 
Apaf-1 initiates apoptosis (74) 
Bag-1 inhibits apoptosis (75) 
XIAP inhibits apoptosis (76) 
DAP-5 mediates apoptosis induced by INFγ (77) 
VEGFA increases vascular permeability and angiogenesis (78) 
HIF-1α plays key role in homeostatic responses to hypoxia (79) 
BiP aids in folding of nascent proteins upon heat shock (80) 
Rbm3 regulates protein synthesis in response to cold shock (81) 
PDGF2/c-sis autocrine and paracrine growth factor (82) 
FGF2 controls cell proliferation and differentiation (83) 
SNM1 repairs DNA interstrand crosslinks (84) 
elg1 regulates genome stability (85) 
Table 2.1.  Mammalian mRNAs that contain IRES 
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which is a risk factor for cardiovascular disease (86), neural tube defects (87), and 
Alzheimer’s disease (88), and to generate the methyl groups required for 
transcriptional control.  Given the important roles of the folate-dependent enzymes in 
development, the maintenance of genome stability, and gene expression, it is 
imperative that they continue to be produced under a variety of physiological and 
environmental conditions.  As some of these conditions may result in the suspension 
of global cap-dependent protein synthesis, it is no surprise that several of the enzymes 
involved in folate-mediated one-carbon metabolism have been found to contain IRES 
elements within their 5UTRs.    
 
The Thymidylate Synthase IRES 
Thymidylate synthase (TS) catalyzes the 5,10-methyleneTHF-dependent 
conversion of deoxyuridine monophosphate (dUMP) to the DNA precursor 
deoxythymidine monophosphate (dTMP).  The 5’UTR of TS varies in length from 
140-200 nucleotides depending on the number of tandem repeats, and has a GC 
content of 76% resulting in extensive secondary structure (Figure 2.2A).  Insertion of 
the TS 5’UTR into a bicistronic mRNA results in expression of the downstream 
cistron.  This expression occurs at a level significantly higher than that of a control β-
globulin 5’UTR and is not affected by the presence of an ApppG cap, a structure that 
is not recognized by eIF4E.  The 5’UTR of TS is able to initiate IRES-mediated 
translation irrespective of the number of tandem repeats present (89). 
 
The Methionine Synthase IRES 
Methionine synthase (MS) is a cobalamin (vitamin B12)-dependent enzyme 
that catalyzes the 5-methyltetrahydrofolate (5-methylTHF)-dependent remethylation 
of homocysteine to methionine.  It is an essential protein as evidenced by the  
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Figure 2.2.  The 5’UTRs of transcripts encoding folate-dependent enzymes.  
(A) The TS 5’UTR is 140 nucleotides in length and has a ∆G of -147 kcal/mol.  
(B) The MS 5’UTR is 423 nucleotides in length and has a ∆G of -175 kcal/mol.  
(C) The cSHMT 5’UTR is 190 nucleotides in length and has a ∆G of -90 
kcal/mol.  Note that although all three 5’UTRs have been shown to contain IRES 
elements, they do not share common structural motifs.  The secondary structures 
of the UTRs were predicted using the Mfold program (version 3.2) developed by 
Zuker and Turner. 
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embryonic lethality of the MS knockout mouse (90).  The human MS 5’UTR is 423 
nucleotides in length.  It contains two upstream open reading frames and has a 
complex secondary structure with an estimated ∆G of -175 kcal/mol (Figure 2.2B).  
Insertion of the MS 5’UTR into a bicistronic construct results in expression of the 
downstream cistron at a level comparable to that of the well-characterized 
immunoglobulin heavy-chain binding protein (BiP) IRES.  Translation of the 
downstream cistron is not affected by the introduction of a hairpin that inhibits cap-
dependent translation or by the rapamycin-induced activation of the eIF4E-binding 
protein.  Northern blot analysis of the mRNA following transfection did not reveal any 
smaller products arising from a cryptic splice site, and the MS 5’UTR did not exhibit 
any promoter activity.  Treatment of cells with vitamin B12 increased the IRES 
activity of MS by 60%, presumably by activating a B12-responsive ITAF.  Although 
the physiological significance of the MS IRES is currently unknown, it has been 
hypothesized that it has evolved as an adaptation to the presence of the rare, but 
essential, vitamin B12 (91).   
 
The Cytoplasmic Serine Hydroxymethyltransferase IRES 
 Cytoplasmic serine hydroxymetyltransferase (cSHMT) catalyzes the 
production of glycine and 5,10-methyleneTHF from serine and THF.  The 5,10-
methyleneTHF derived from the cSHMT reaction is ultimately used by TS to produce 
thymidylate at the expense of S-adenosylmethionine (AdoMet) synthesis (92,93).  
Although cSHMT knockout mice are viable and fertile, they do exhibit elevated levels 
of uracil in their DNA and decreased levels of AdoMet in their livers (94).     
The human cSHMT mRNA has two alternatively spliced forms of its 5’UTR 
that are encoded by exons 1-3 (95).  Exon 2, which encodes an Alu J SINE insertion in 
reverse orientation (96), is alternatively spliced in a cell-specific manner (97).  The 
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5’UTR that lacks exon 2 is 190 nucleotides in length and contains 71% GC content.  It 
exhibits complex secondary structure with a predicted ∆G of - 90 kcal/mol (Figure 
2.2C).  When this cSHMT 5’UTR is inserted into a bicistronic construct, the 
downstream cistron is expressed 15% and 3% relative to expression of the upstream 
cistron in vitro and in unstressed cells, respectively (26).  When the 3’UTR of cSHMT 
is added to the bicistronic construct at the 3’ end of the downstream cistron, the 
downstream cistron is expressed 40% and 6% relative to expression of the upstream 
cistron in vitro and in unstressed cells, respectively (26).  Translation of the 
downstream cistron is not the result of termination-reinitiation, as it is abolished by the 
replacement of the 5’UTR with the reverse complement of the 5’UTR.   It is also not 
affected by the rapamycin-induced activation of the eIF4E-binding protein, and cannot 
be explained by cryptic splicing or promoter activity, as in vitro transcribed RNA was 
used instead of DNA in all experiments.  The IRES activity of cSHMT is comparable 
to that of BiP (26), but like all cellular IRES activities, is much less than the IRES 
activity of viruses (98). 
Like the MS IRES, the cSHMT IRES is nutrient-responsive.  Overexpression 
of the iron-storage protein heavy chain ferritin (H ferritin) markedly elevates cSHMT 
IRES activity and protein levels (26).  Furthermore, when bicistronic mRNAs 
containing the human cSHMT 5’UTR are transfected into mouse embryonic 
fibroblasts isolated from H ferritin+/- embryos, the human cSHMT 5’UTR exhibits 
30% less IRES activity than when it is transfected into mouse embryonic fibroblasts 
isolated from  H ferritin+/+ embryos (26). 
The IRES-mediated translation of cSHMT is also stimulated by CUG-binding 
protein 1 (CUGBP1), an isoform of the hnRNP hNab50 (99).  CUGBP1-depleted 
HeLa cells have reduced cSHMT IRES activity compared to control cells.  However, 
the decrease in IRES activity is only significant when the 3’UTR of cSHMT is 
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included in the bicistronic mRNA, suggesting that CUGBP1 acts through the 3’ end of 
the transcript (26).     
 
Part VII: Summary 
 Until 1988, one of the cardinal rules of translation initiation was that 
eukaryotic ribosomes could only bind to the 5’ end of an mRNA transcript.  The 
discovery of an IRES element within the 5’UTR of picornaviral mRNA drastically 
altered this dogma and paved the way for the identification of numerous IRESes in 
cellular transcripts.  Over the past 20 years, great strides have been made in 
understanding the cap-independent mechanism of ribosome recruitment.  It is now 
known that IRES activity requires one or more ITAFs and can be stimulated by the 
poly(A) tail of the transcript.  In terms of functionality, it has become clear that IRES-
mediated translation allows protein synthesis to escape the controls that regulate cap-
dependent initiation and enables translation to occur when ribosome scanning would 
otherwise be inhibited by a long and structured 5’UTR. 
 Of the various transcripts shown to contain IRESes, many produce proteins 
that are involved in the control of cell proliferation, cell growth, gene expression, and 
cell death.  Among them are TS, MS, and cSHMT, which, through their involvement 
in folate-mediated one-carbon metabolism, play key roles in de novo nucleotide 
biosynthesis, DNA repair, and cellular methylation reactions.  Although the TS, MS, 
and cSHMT IRESes have been extensively characterized and some of the factors that 
influence their activity have been identified, many questions still remain.  For 
example, what are the physiological conditions that stimulate the cap-independent 
translation of these transcripts?  And what is the mechanism by which the mRNA, 
potential ITAFs, and translation initiation factors interact and recruit ribosomes?  The 
studies presented herein aim to answer these questions for the cSHMT IRES by 1) 
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elucidating the interactions among the 5’UTR, 3’UTR, poly(A) tail, 40S ribosomal 
subunit, and CUGBP1 that contribute to the IRES-activity (Chapter 3),  
2) investigating the role of H ferritin in IRES-mediated translation (Chapter 4), and  
3) determining physiological function of the cSHMT IRES (Chapter 5).  
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CHAPTER 3 
 
MECHANISM OF THE INTERNAL RIBOSOME ENTRY SITE-MEDIATED 
TRANSLATION OF CYTOPLASMIC SERINE 
HYDROXYMETHYLTRANSFERASE 
 
 Abstract 
The 5’ untranslated region (UTR) of cytoplasmic serine 
hydroxymethyltransferase (cSHMT) contains an internal ribosome entry site (IRES) 
that regulates thymidylate biosynthesis.  IRESes permit efficient 5’-cap-independent 
translation by interacting with IRES trans-acting factors (ITAFs) and recruiting the 
40S ribosomal subunit, although the mechanism of IRES-mediated translation has yet 
to be established.  In this study, we show that the cSHMT IRES is the first example of 
a cellular IRES that is poly(A) tail-independent.  Interactions between the 5’UTR and 
3’UTR functionally replace interactions between the poly(A) tail and the poly(A) 
binding protein (PABP) to achieve maximal IRES-mediated translational efficiency.  
Depletion of the cSHMT ITAF CUG-Binding Protein 1 (CUGBP1) from in vitro 
translation extracts or deletion of the CUGBP1-binding site on the 3’UTR of the 
cSHMT transcript decreases the IRES activity of non-polyadenylated biscistronic 
mRNAs relative to polyadenylated biscistronic mRNAs and results in a requirement 
for PABP.  We also identify a novel ITAF, heterogeneous nuclear ribonucleoprotein 
H2 (hnRNP H2), that stimulates cSHMT IRES activity by binding to the 5’UTR of the 
transcript and interacting with CUGBP1.  Collectively, these data support a model for 
the IRES-mediated translation of cSHMT whereby the circularization of the mRNA 
typically provided by the eukaryotic initiation factor (eIF)4G/PABP/poly(A) tail 
interaction is instead achieved through the hnRNP H2/CUGBP1-mediated interaction 
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of the 5’ and 3’UTRs of the cSHMT transcript.  This circularization enhances the 
IRES activity of cSHMT by facilitating the recruitment and/or recycling of 40S 
ribosomal subunits, which bind to the transcript in the middle of the 5’UTR and 
migrate to the initiation codon via eIF4A-mediated scanning. 
 
 Introduction 
Internal ribosome entry sites (IRESes) are cis-acting elements that enable the 
cap-independent recruitment of 40S ribosomal subunits to the 5’ untranslated region 
(UTR) of an mRNA transcript.  Although originally identified in viruses (1,2), IRESes 
have recently been discovered in many cellular mRNAs, particularly in those encoding 
proteins involved in development, differentiation, cell cycle progression, cell growth, 
apoptosis, and stress response (reviewed in (3,4)).  It is now estimated that as many as 
3-5% of cellular mRNAs can be translated by a cap-independent mechanism (5).  
Although the list of cellular IRESes continues to grow, little is known about their 
mechanism of action.  However, there is increasing evidence that in addition to the 
40S ribosomal subunit and canonical initiation factors, the poly(A) tail of the 
transcript and IRES-specific trans-acting factors (ITAFs) play major roles during cap-
independent translation. 
Almost all eukaryotic mRNAs possess a 3’ poly(A) tail that can enhance both 
cap-dependent and IRES-mediated translation initiation (6,7).  The interaction of 
Poly(A) Binding Protein (PABP) with eukaryotic initiation factor (eIF) 4G results in 
the formation of a “closed loop” by linking the poly(A) tail and either the 5’-cap (in 
cap-dependent translation) or the 5’UTR (in IRES-mediated translation).  Looping 
through the 5’ and 3’ ends of the transcript is thought to increase translation rates by 
facilitating the recycling of 40S ribosomal subunits, promoting 40S recruitment, 
and/or stimulating the formation of the 80S ribosome (8-16).  It has also recently been 
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reported that the poly(A) tail can enhance 48S complex assembly through a process 
that is independent of PABP (17).  
ITAFs are RNA-binding proteins that functionally interact with IRES elements 
to positively or negatively regulate internal initiation.  Many of the ITAFs identified to 
date belong to the group of heterogeneous nuclear ribonucleoproteins (hnRNPs).  
These include hnRNP A1, C1/C2, I, E1/E2, K, and L (18-21).  hnRNPs are located 
primarily in the nucleus, but are known to translocate to the cytoplasm in specific cell 
or tissue types and as part of certain stress responses.  It is hypothesized that hnRNPs 
and other ITAFs exert their effect on IRES activity by aiding in the recruitment of the 
40S ribosomal subunit through their interactions with the canonical initiation factors 
or ribosomal components, or by acting as RNA chaperones to control the 
configuration of the IRES (Reviewed in (4,22)).  Studies of viral IRESes have 
suggested that ITAFs can also establish an RNA/protein bridge between the IRES and 
the 3’ end of the transcript (23). 
In this study, we investigate the role of the poly(A) tail, ITAFs, and the 40S 
ribosomal subunit in the IRES-mediated translation of cytoplasmic serine 
hydroxymethyltransferase (cSHMT), an enzyme that regulates folate-dependent de 
novo thymidylate biosynthesis during S-phase (24,25) and in response to UV exposure 
(Chapter 5).  The data presented here lead to the development of a model for the 
IRES-mediated translation of cSHMT and provide a mechanism that accounts for the 
previously reported finding that cSHMT IRES activity is stimulated by the cSHMT 
3’UTR (25).   
 
Materials and Methods 
Cell culture and preparation of extracts- Mammary adenocarcinoma (MCF-7) 
cells were obtained from ATCC (HTB22) and were cultured in α-MEM (Hyclone 
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Laboratories) containing 11% fetal bovine serum (Hyclone Laboratories) at 37oC and 
5% CO2.  When the cells reached approximately 95% confluence, they were harvested 
by trypsinization and washed in phosphate-buffered saline.  To obtain whole cell 
extract, cells were resuspended in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% 
NP-40, 5 mM EDTA, 1 mM PMSF, 1:100 dilution of Sigma Protease Inhibitor 
Cocktail) and lysed on ice for 30 min.  When necessary, the cell extract was treated 
with λ phosphatase (Sigma) in the presence of 2 mM MnCl2 for 30 min at 30oC.  λ 
phosphatase activity was then inhibited by the addition of EDTA to a final 
concentration of 50 mM followed by heating at 65oC for 1h.  The protein 
concentration of the extract was determined using the Lowry Assay as modified by 
Bensadoun (26).   
Vectors- The generation of bicistronic DNA templates containing the BiP 
IRES, the cSHMT 5’UTR, the full length cSHMT 3’UTR, and the reverse 
complement of the cSHMT 5’UTR is described elsewhere (25).  The paip2 coding 
sequence (27) was subcloned into the pGEX4T-2 vector (GE Healthcare) using the 
primers 5’-TAGGATCCATGAAAGATCCAAGTCGCAG-3’ and 5’- 
TAGTCGACTCAAATATTTCCGTACTTCAC-3’ 
where the BamHI and SalI restriction sites are shown in bold.  The CUGBP1-pMAL 
vector was a gift from Lubov Timchenko.  The hnRNP H2 cDNA (a gift from Jeffrey 
Wilusz) was subcloned into the pMAL-c2E vector (New England BioLabs) using the 
primers 5’-TCGGATCCATGATGCTGAGCACGGAAG-3’ and 5’-
TAGTCGACCTAAGCAAGGTTTGACTG-3’ where the BamHI and SalI restriction 
sites are shown in bold. The cSHMT 3’UTR truncations were cloned using the 
following primers:  3’UTR Fwd = 5’-AGGAGCGGGCCCACTCTGGAC-3’, 3’UTR 
(157) Rev = 5’-GTGAAGAAAACATGAAAAAAG-3’, 3’UTR (200) Rev = 5’-
GTCCCAGAATTACTAACAATGAG-3’, 3’UTR (236) Rev = 5’-
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GAAAGCCAGGTTCAAATTTAAATCC-3’, 3’UTR (317) Rev = 5’-
TTGCCCTACACCACCATCTA-3’ 
3’UTR (477) Rev = 5’-AGCCTCAGAAGCTAATTCAG-3’, 3’UTR (637) Rev = 5’-
CTGGTTGCTTCTCACACCAG-3’.  The cSHMT 5’UTR truncations were cloned 
using the following primers: 5’UTR Fwd= 5’-
GCCTGGCGCGCAGAGTGCACCTTCC-3’, 5’UTR Rev = 5’-
TGCACTGGTTCGAAGCTGCCTAGCGAC-3’, 5’UTR (104) Rev = 5’-
GCGCACCGCCGCGGGCCAGCCACG-3’, 5’UTR (105) Fwd= 5’-
GGGGCGTTGGGTCAGCGGGTCTGGG-3’, 5’UTR (50) Fwd = 5’-
TTCGGGGTTTGGGGTTGGAGCGGCTG-3’, 5’UTR (150) Rev = 5’-
GCCGCCGCCGGTGCCACCAGTCCC-3’, 5’UTR (114) Rev = 5’-
CCAACGCCCCGCGCACCGCCGCGG-3’, 5’UTR (131) Rev = 5’-
GTCCCAGACCCGCTGACCCAACGCC-3’.  The pcDNA 3 template containing the 
HCV IRES 3’ of the Renilla luciferace reporter gene and 5’ of the Firefly luciferase 
reporter gene was a gift from the laboratory of Partho Ray.   
In vitro transcription- DNA templates were linearized and purified using the 
Roche PCR clean-up column.  The templates were transcribed using Ambion’s 
MEGAscript kit (for uncapped mRNA) or mMESSAGE mMACHINE kit (for capped 
mRNA) according to the manufacturer’s protocol.  For preparation of radiolabeled 
mRNA for electrophoretic gel mobility shift assays, 50µCi of [α−32P]-labeled rUTP 
(800Ci/mM, Perkin Elmer) was included in in vitro transcription reactions.  The crude 
mRNA was treated with DNase I (Ambion) for 15 min at 40°C and precipitated in 2 M 
LiCl at -80°C.  All RNA procedures were conducted under RNase-free conditions and 
all mRNA was stored with Recombinant RNasin® Ribonuclease Inhibitor (Promega).  
The mRNA was quantified by spectrophotometry and its quality verified by 
electrophoresis.  
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RNA affinity chromatography- 1.0 nmol of the indicated in vitro transcribed 
mRNA (uncapped and polyadenylated) was incubated with 1.0 nmol biotinylated 
oligo (dT) probe (Promega) and 200 µl packed streptavidin agarose (Novagen) in 
TMK buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 150 mM KCl) for 1 h at 4oC.  After 
extensive washing with TMK buffer, the agarose was resuspended in TMK buffer 
containing 1.0 nmol of in vitro transcribed RevUTR mRNA (competitor mRNA, 
uncapped and non-polyadenylated), 3.0 mg whole cell extract, 150 µg yeast tRNA 
(Ambion), and 600 units Recombinant RNasin® Ribonuclease Inhibitor (Promega).  
Following incubation for 1 h at 4oC, the agarose was washed extensively with TMK 
buffer, and bound proteins were eluted in 2X SDS-PAGE sample buffer (160 mM Tris 
pH 6.8, 20 mM DTT, 4% SDS, 20% glycerol) at 95oC for 5 min.  The eluted proteins 
were separated by SDS-PAGE and either stained with coomassie blue or subjected to 
western blot analysis.  Sequencing was performed at the Harvard Microchemistry 
Facility by microcapillary reverse-phase HPLC nano-electrospray tandem mass 
spectrometry (µLC/MS/MS).  
RNA immunoprecipitation- MCF-7 cells were grown to approximately 95% 
confluence and then treated with 10,000 µJ/cm2 UVC (254 nm) using the Stratagene 
UV Stratalinker 2400.  22h following UV treatment, the cells were treated with 
formaldehyde at a final concentration of 1%.  After a 20 min incubation at room 
temperature, the crosslinking reaction was quenched by the addition of glycine to a 
final concentration of 125 mM.  Following a 10 min incubation at room temperature, 
the cells were washed in cold phosphate-buffered saline and resuspended in lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 
1:100 dilution of Sigma Protease Inhibitor Cocktail, 1 unit/mL Recombinant RNasin® 
Ribonuclease Inhibitor (Promega)).  Following a 30 min incubation on ice and 
centrifugation at 13,000 rpm for 10 min at 4oC, the supernatant was removed and 
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diluted 1:10 in IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris pH 8, 167 mM NaCl, 1 mM PMSF, 1:100 dilution of Sigma Protease Inhibitor 
Cocktail, 1 unit/mL Recombinant RNasin® Ribonuclease Inhibitor (Promega)).  1 mL 
aliquots of the diluted lysate were incubated with 10 µg antibody overnight at 4oC.  
The antibodies used include ImmunoPure goat IgG (Pierce), ImmunoPure mouse IgG 
(Pierce), goat anti-hnRNP H (N-16, Santa Cruz Biotechnology), and mouse anti-
CUGBP1 (3B1, Santa Cruz Biotechnology).  100 µl packed Immobilized Protein G 
(Pierce) was then added and the lysate incubated for 2 h at 4oC in the presence of 0.1 
mg/mL BSA.  After washing the beads once in low-salt wash buffer (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris pH 8, 150 mM NaCl), once in high-salt wash 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8, 500 mM NaCl), 
once in LiCl wash buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 
10 mM Tris pH 8) and twice in TE (10 mM Tris pH 8, 1 mM EDTA), bound proteins 
were eluted in elution buffer (1% SDS, 0.1 M NaHCO3, 1 unit/mL Recombinant 
RNasin® Ribonuclease Inhibitor (Promega)) at room temperature for 15 min.  To 
reverse the crosslinking, NaCl was added to a final concentration of 200 mM, and the 
samples were heated at 65oC for 3h.  Following treatment with Proteinase K for 45 
min at 42oC, the nucleic acids were purified by phenol/chloroform extraction followed 
by ethanol precipitation.  DNA was then removed by treatment with DNase I 
(Promega) according to the manufacturer’s protocol.  Reverse transcription was 
carried out on the remaining RNA using the SuperScript III First-Strand Synthesis 
System for RT-PCR (Invitrogen) according to the manufacturer’s protocol.  The 
resulting cDNA was amplified using the 5’UTR (50) Fwd, 5’UTR (150) Rev, 3’UTR 
Fwd, and 3’UTR (236) Rev primers described above. 
Western blotting- Proteins were separated by SDS-PAGE and transferred to a 
PVDF membrane.  The membrane was blocked with 5% non-fat dry milk in 
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phosphate-buffered saline containing 1% NP-40 for 1 hour at room temperature, 
incubated with primary antibody overnight at 4oC, and incubated with horseradish 
peroxidase-conjugated anti-IgG for 1-3 h at room temperature.  After each incubation, 
the membrane was washed with phosphate-buffered saline/0.1% Tween20.  Proteins 
were visualized using Super Signal® substrate (Pierce) followed by autoradiography.  
When necessary, membranes were stripped with 0.2 M NaOH.  Mouse anti-CUGBP1 
(3B1, Santa Cruz Biotechnology) was used at a 1:10,000 dilution, sheep anti-human 
cSHMT was used at a 1:40,000 dilution, goat anti-hnRNP H (N-16, Santa Cruz 
Biotechnology) was used at a 1:500 dilution, mouse anti-PABP (10E10, Santa Cruz 
Biotechnology) was used at a 1:1000 dilution, mouse anti-phospho-serine/threonine 
(BD Transduction Laboratories) was used at a 1:1000 dilution, and mouse anti-
GAPDH (Novus Biologicals) was used at a 1:40,000 dilution. Goat anti-mouse IgG, 
rabbit anti-sheep IgG, and rabbit anti-goat IgG were all purchased from Pierce and 
used at a 1:5,000 dilution. 
Purification of recombinant proteins- BL21* cells were transformed with the 
pMAL, CUGBP1-pMAL, hnRNP H2-pMAL, paip2-pGEX, or pGEX vector and 
grown to mid-log phase.  Protein synthesis was induced with isopropyl β-D-
thiogalactopyranoside (final concentration 0.1 mM) for 16 h at 18oC.  The cells were 
lysed in B-PER (Pierce) followed by sonication with a Branson Digital Sonifier at 
50% amplitude with intermittent icing.  After removal of the insoluble material, the 
clarified supernatant was applied directly to an Amylose Resin (New England 
BioLabs) for purification of MBP-tagged proteins or GST-Bind Resin (Novagen) for 
purification of GST-tagged proteins, and the protein was purified according to the 
manufacturer’s protocol.  The purity of the protein was determined by SDS-PAGE, 
and its concentration was determined using the Lowry Assay as modified by 
Bensadoun (26). 
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RNA electrophoretic gel mobility shift assays- 20 nM [α−32P]-labeled RNA 
and the indicated amount of recombinant protein were added to binding buffer (20 
mM Tris pH 7.5, 5 mM MgCl2, 1 mM EDTA, 8 mM DTT, 2 µg BSA, 1.25 µg yeast 
tRNA (Ambion), 10% glycerol, 40 units Recombinant RNasin® Ribonuclease 
Inhibitor (Promega)) for a total volume of 10 µL.  The binding reaction was incubated 
at 37oC for 15 min and then run on a 4% native polyacrylamide gel at 32 mA.  
Electrophoresis buffer contained 25 mM Tris base, 0.2 M glycine, and 1 mM EDTA.  
For competition experiments, 200 nM, 1 µM, or 2 µM unlabeled RNA was pre-
incubated with the protein for 5 min prior to its addition to the binding reaction. 
  Depletion of proteins from rabbit reticulocyte lysate and in vitro translation 
reactions- To deplete PABP, Flexi® Rabbit Reticulocyte Lysate (Promega) was 
incubated with GST-paip2-bound resin for 1 h at 4oC.  The resin was then collected by 
centrifugation and the supernatant was subjected to a second incubation with GST-
paip2-bound resin for 1 h at 4oC.  The resin was then collected by centrifugation, and 
the supernatant used in in vitro translation reactions.  To immunodeplete CUGBP1 or 
hnRNP H, Flexi® Rabbit Reticulocyte Lysate was incubated with mouse anti-
CUGBP1 (3B1, Santa Cruz Biotechnology) or goat anti-hnRNP H (N-16, Santa Cruz 
Biotechnology) for 1 h at 4oC.  Immobilized Protein A/G beads (Pierce) were then 
added.  Following a 1 h incubation at 4oC, the beads were collected by centrifugation 
and the supernatant was used in in vitro translation reactions.  In vitro translation 
reactions (25 µl) contained 12.5 µl Flexi® Rabbit Reticulocyte Lysate, 20 µM amino 
acids, 2 mM DTT, 100 ng yeast tRNA (Ambion), 80 mM KCl, 0.5 mM Mg acetate, 20 
units Recombinant RNasin® Ribonuclease Inhibitor (Promega), and 125 ng in vitro 
transcribed mRNA.  When necessary, the mRNA was pre-incubated with recombinant 
protein for 10 min at room temperature prior to its addition to the in vitro translation 
reaction.  Reactions were carried out at 30ºC for 20 min.  Renilla and Firefly 
 84
Luciferase expression was quantified on a Veritas Microplate Luminometer (Turner 
Biosystems) using the Dual-Glo Luciferase Assay System (Promega) according to the 
manufacturer’s protocol. 
siRNA and mRNA transfections- MCF-7 cells were grown to approximately 
40% confluence in 6-well plates.  The cells were transfected with 5 nM of either 
negative control siRNA (Ambion) or hnRNP H2 siRNA (Qiagen, sense: r(CAU GAG 
AGU ACA UAU UGA A)dTdT, antisense: r(UUC AAU AUG UAC UCU CAU 
G)dGdG)  using the HiPerFect transfection reagent (Qiagen) according to the 
manufacturer’s instructions.  Following incubation with siRNA for approximately 50 
h at 37oC and 5% CO2, the cells were treated with 10,000 µJ/cm2 UVC (254 nm) using 
the Stratagene UV Stratalinker 2400.  12 h after UV treatment, the cells were 
incubated in Opti-MEM (Invitrogen) containing a 1:100 dilution of DMRIE-C 
transfection reagent (Invitrogen) and 5 µg/mL mRNA (capped and polyadenylated) for 
4 h at 37oC and 5% CO2.  The Opti-MEM was then replaced with α-MEM and the 
cells incubated for an additional 6 h at 37oC and 5% CO2.  Renilla and Firefly 
Luciferase expression was quantified on a Veritas Microplate Luminometer (Turner 
Biosystems) using the Dual-Glo Luciferase Assay System (Promega) according to the 
manufacturer’s protocol. 
Yeast two-hybrid assay- CUGBP1 cDNA was amplified and cloned into the 
pGBK plasmid (Clontech) using the following primers: 5’-
TCGAATTCATGAACGGCACCCTGGA-3’ and 5’-
TCGGATCCTCAGTAGGGCTTGCTGT-3’.  The EcoRI and BamHI sites are shown 
in bold.  hnRNP H2 cDNA was amplified and cloned into the pGAD plasmid 
(Clontech) using the following primers: 5’-
TCCATATGATGATGCTGAGCACGGAAG -3’ and 5’-
TCCTCGAGCTAAGCAAGGTTTGACTG -3’.  The NdeI and XhoI sites are shown 
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in bold.  The pGBK-CUGBP1 vector was transformed into yeast strain AH109 and 
stable clones were maintained in Trp- dropout medium.  The pGAD-hnRNP H2 vector 
was transformed into yeast strain Y187 and stable clones were maintained in Leu- 
dropout medium.  The transformed yeast were then mated following the Clontech 
Matchmaker protocol.  After a 24 h mating, cells were plated on His-, Leu-, Trp- 
dropout medium containing X-α-gal, and incubated at 30°C for 4 days.  Clones were 
validated against negative controls according to the Matchmaker protocol. 
Coimmunoprecipitation- MCF-7 cells were grown to approximately 95% 
confluence and formaldehyde was added at a final concentration of 1%.  After a 20 
min incubation at 37oC, the crosslinking reaction was quenched by the addition of 
glycine to a final concentration of 125 mM.  After a 10 min incubation at 37oC, the 
cells were washed in cold Tris-buffered saline, harvested, and resuspended in lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 
1:100 dilution of Sigma Protease Inhibitor Cocktail).  The cells were sonicated 5 X 30 
sec with a Branson Digital Sonifier at 25% amplitude with intermittent icing.  
Following centrifugation at 13,000 rpm for 32 min at 4oC, the supernatant was 
removed and incubated with 10 µg antibody overnight at 4oC.  The antibodies used 
include ImmunoPure Goat IgG (Pierce), mouse anti-HA (Santa Cruz Biotechnology), 
goat anti-hnRNP H (N-16, Santa Cruz Biotechnology), and mouse anti-CUGBP1 
(3B1, Santa Cruz Biotechnology).  100 µl packed Immobilized Protein G (Pierce) was 
then added and the lysate incubated for 3 h at 4oC.  After washing the beads 
extensively with lysis buffer, bound proteins were eluted in elution buffer (50 mM 
Tris pH 7.5, 10 mM EDTA, 1%SDS) at 95oC for 10 min.  To reverse the crosslinking, 
6X SDS-PAGE sample buffer (480 mM Tris pH 6.8, 60 mM DTT, 12% SDS, 60% 
glycerol) was added to a final concentration of 1X, and the samples were heated at 
95oC for 20 min.  For the recombinant protein immunoprecipitation, 1 µg MBP-
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CUGBP1 was combined with 1 µg MBP-hnRNP H2 and 4 µg antibody in a final 
volume of 1 mL.  Following an overnight incubation at 4oC, 100 µl packed 
Immobilized Protein G (Pierce) was added and the mixture incubated for 3 h at 4oC.  
After washing the beads extensively with lysis buffer, bound proteins were eluted in 
2X SDS-PAGE sample buffer (160 mM Tris pH 6.8, 20 mM DTT, 4% SDS, 20% 
glycerol) at 95oC for 10 min. 
Hippuristanol treatment- MCF-7 cells were transfected with in vitro 
transcribed mRNA according to the protocol above.  10 h after transfection, the 
indicated amount of hippuristanol (a gift from Junichi Tanaka) or an equal volume of 
vehicle (DMSO) was added to the culture medium and the cells were incubated at 
37oC and 5% CO2 for an additional 11 h.  Luciferase activity was then quantified as 
stated above. 
Introduction of ORFs into the cSHMT 5’UTR- A stop codon was introduced 
into the 5’UTR of the bicistronic construct lacking the 3’UTR according to the Quick 
Change II Site Directed Mutagenesis protocol (Stratagene) using the following 
primers: Stop Fwd= 5’-GTCGCTAGGCAGCTTCGAACTAGTGCAATG-3’ and  
Stop Rev= 5’-CATTGCACTAGTTCGAAGCTGCCTAGCGAC-3’.   Start codons 
were then introduced into the resulting construct via Quick Change II Site Directed 
Mutagenesis using the following primers: 52 AUG Fwd= 5’-
GGTCCAGCGCCAAGTATGGGGTTTGGGGTTGG-3’, 52 AUG Rev= 5’-
CCAACCCCAAACCCCATACTTGGCGCTGGACC-3’, 70 AUG Fwd= 5’-
GGGTTTGGGGTTGGAATGGCTGGTCACGTGGC-3’, 70 AUG Rev= 5’-
GCCACGTGACCAGCCATTCCAACCCCAAACCC-3’, 82 AUG Fwd= 5’-
GGAGCGGCTGGTAACATGGCTGGCCCGC-3’, 82 AUG Rev= 5’-
GCGGGCCAGCCATGTTACCAGCCGCTCC-3’, 103 AUG Fwd= 5’-
GGCTGGCCCGCGGCGGAGCATGGGGCGTTGGGTCAGC-3’, 103 AUG Rev= 
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5’-GCTGACCCAACGCCCCATGCTCCGCCGCGGGCCAGCC-3’, 118 AUG Fwd= 
5’-GGGCGTTGGGTCATGGGGTCTGGGACTGG-3’, 118 AUG Rev= 5’-
CCAGTCCCAGACCCCATGACCCAACGCCC-3’, 139 AUG Fwd= 5’-
GGGACTGGTGGCATGGGCGGCGGCGTAG-3’, 139 AUG Rev= 5’- 
CTACGCCGCCGCCCATGCCACCAGTCCC-3’, 151 AUG Fwd= 5’-
GCACCGGCGGCGGCATGGGACGGAGGCGTCG-3’, 151 AUG Rev= 5’-
CGACGCCTCCGTCCCATGCCGCCGCCGGTGC-3’, 169 AUG Fwd= 5’-
GGACGGAGGCGTGGCATGGCAGCTTCGAAC-3’, and 169 AUG Rev= 5’-
GTTCGAAGCTGCCATGCCACGCCTCCGTCC-3’.  The stop and start codons are 
shown in bold.  To determine if the introduction of the start codon affected the 
secondary structure of the mRNA, each start codon was mutated via Quick Change II 
Site Directed Mutagenesis using the following primers: 52 GUG Fwd= 5’-
GGTCCAGCGCCAAGTGTGGGGTTTGGGGTTGG-3’, 52 GUG Rev= 5’-
CCAACCCCAAACCCCACACTTGGCGCTGGACC-3’, 70 UUG Fwd= 5’-
GGGTTTGGGGTTGGATTGGCTGGTCACGTGGC-3’, 70 UUG Rev= 5’-
GCCACGTGACCAGCCAATCCAACCCCAAACCC-3’, 82 UUG Fwd= 5’-
GGAGCGGCTGGTAACTTGGCTGGCCCGC-3’, 82 UUG Rev= 5’-
GCGGGCCAGCCAAGTTACCAGCCGCTCC-3’, 103 UUG Fwd= 5’-
GGCTGGCCCGCGGCGGAGCTTGGGGCGTTGGGTCAGC-3’, 103 UUG Rev= 
5’-GCTGACCCAACGCCCCAAGCTCCGCCGCGGGCCAGCC-3’, 118 AUA 
Fwd= 5’-GGGCGTTGGGTCATAGGGTCTGGGACTGG-3’, 118 AUA Rev= 5’-
CCAGTCCCAGACCCTATGACCCAACGCCC-3’, 139 AUA Fwd= 5’-
GGGACTGGTGGCATAGGCGGCGGCGTAGG-3’, 139 AUA Rev= 5’- 
CCTACGCCGCCGCCTATGCCACCAGTCCC-3’, 151 UUG Fwd= 5’-
GCACCGGCGGCGGCTTGGGACGGAGGCGTCG-3’, 151 UUG Rev= 5’-
CGACGCCTCCGTCCCAAGCCGCCGCCGGTGC-3’, 169 UUG Fwd= 5’-
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GGACGGAGGCGTGGCTTGGCAGCTTCGAAC-3’, and 169 UUG Rev= 5’-
GTTCGAAGCTGCCAAGCCACGCCTCCGTCC-3’.  The mutated start codons are 
shown in bold.  All mutations were verified by sequencing at the Cornell 
Biotechnology Resource Center. 
 
Results 
The poly(A) tail and PABP are not required for maximal cSHMT IRES activity.  
To investigate the influence of the poly(A) tail on the cap-independent translation of 
cSHMT, the IRES activity of bicistronic mRNAs with and without the stimulatory 
cSHMT 3’UTR (25) and with and without an A30 tail (Figure 3.1A) was determined in 
vitro using nuclease-treated rabbit reticulocyte lysate.  This cell-free system was 
selected over a cell culture model as it eliminates the potential for artificially reduced 
translation efficiency of the non-polyadenylated bicistronic mRNA resulting from 
decreased competition with endogenous polyadenylated mRNAs.  IRES-mediated 
translation, as measured by the ratio of Firefly Luciferase (Fluc) to Renilla Luciferase 
(Rluc) activity, was independent of the poly(A) tail when the cSHMT 3’UTR was 
present in the transcript (Figure 3.1B).  However, removal of the 3’UTR resulted in a 
40% decrease in the IRES-mediated translation of non-polyadenylated RNA relative 
to RNA containing a poly(A) tail (Figure 3.1B).  Changes in the stability of the 
bicistronic mRNA lacking the 3’UTR were not responsible for the observed 
stimulatory effect of the poly(A) tail (Figure 3.1C). 
The poly(A) tail affects IRES activity through its interaction with PABP (8-
15).  Depletion of PABP from rabbit reticulocyte lysate with immobilized poly(A)-
interacting protein 2 (paip2) (27) significantly reduced PABP protein levels (Figure 
3.1D).  Depletion of PABP by this procedure has been shown not to affect the 
concentration of other initiation factors (7).  PABP-depletion had no significant effect  
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Figure 3.1. The poly(A) tail and PABP are not required for maximal cSHMT 
IRES activity.  (A)  The bicistronic construct used to quantify cSHMT IRES 
activity.  It consists of (in the 5’ to 3’ direction) a cap analog, the Renilla luciferase 
(Rluc) reporter gene, the human cSHMT 5’UTR, the Firefly luciferase (Fluc) 
reporter gene, and, where indicated, the human cSHMT 3’UTR and a 30 nucleotide 
poly(A) tail.  (B)  In vitro translation assays were carried out using rabbit 
reticulocyte lysate and in vitro transcribed bicistronic mRNAs with (5’UTR + 
3’UTR) and without (5’UTR) the cSHMT 3’UTR.  The white bars represent the 
ratio of IRES-mediated translation (Fluc) to cap-dependent translation (Rluc) of 
bicistronic mRNA containing a 30 nucleotide poly(A) tail, and the dark bars 
represent the Fluc/Rluc of bicistronic mRNA lacking a poly(A) tail.  The relative 
ratio for each bicistronic mRNA containing a poly(A) tail was given a value of 1.0.  
The data represent the average of three independent experiments + standard error. 
(C) The bicistronic mRNAs described in (A) were labeled with 32P, and in vitro 
translation assays were performed as described in Materials and Methods. The 
RNAs were resolved on an agarose gel and transferred to a positively charged nylon 
membrane.  For each transcript, the left lane represents the mRNA before the in vitro 
translation reaction and the right lane represents the transcript after the in vitro 
translation reaction.  (D)  Rabbit reticulocyte lysate was incubated with either GST 
(control) or GST-paip2 (PABP-depleted).  The depletion of PABP by GST-paip2 but 
not GST alone was confirmed by immunoblotting (right) using an antibody against 
PABP.  GAPDH served as a control for equal protein loading.  The graph on the left 
shows the relative IRES activity (as measured by Fluc/Rluc) of the bicistronic 
mRNAs in control (striped bars) and PABP-depleted (black bars) rabbit reticulocyte 
lysate.  The relative luminosity for each bicistronic mRNA in the control reaction 
was given a value of 1.0.  The data represent the average of three independent 
experiments + standard error. 
 90
 91
on the IRES-mediated translation of the polyadenylated bicistronic mRNA containing 
the cSHMT 3’UTR, but reduced the IRES activity of the polyadenylated bicistronic 
mRNA lacking the 3’UTR by 45% (Figure 3.1D).  These results led to the formulation 
of a model for the IRES-mediated translation of cSHMT in which interactions 
between ITAFs bound to the 5’UTR of the transcript and ITAFs bound to the 3’UTR 
serve to circularize the transcript, thereby eliminating the need for both the poly(A) 
tail and PABP (Figure 3.2). 
CUGBP1 binds to the cSHMT 3’UTR.  A promising candidate for the 3’UTR-
binding protein in our model was CUG-Binding Protein 1 (CUGBP1), an isoform of 
the hnRNP hNab50 (28) that has been shown to stimulate the IRES-mediated 
translation of cSHMT (25).  The effect of CUGBP1 on IRES activity is significant 
only when the 3’UTR of cSHMT is included in the transcript (25), indicating that the 
protein might act by binding to the 3’UTR of the mRNA.  The binding of CUGBP1 to 
the cSHMT 3’UTR was confirmed in UV-treated mammary adenocarcinoma (MCF-7) 
cells by RNA immunoprecipitation using an antibody against CUGBP1, and 
amplification of the immunoprecipitated RNA with PCR primers specific to the 
cSHMT 3’UTR (Figure 3.3A).   
The binding of CUGBP1 to the cSHMT 3’UTR was also confirmed in vitro by 
RNA electrophoretic mobility shift assays (EMSAs) using recombinant MBP-
CUGBP1 and an excess of non-specific competitor tRNA (Figure 3.3B).  The addition 
of MBP alone had no effect on the mobility of the cSHMT 3’UTR (data not shown), 
and MBP-CUGBP1 binding was abolished upon the addition of a molar excess of 
unlabeled 3’UTR (Figure 3.3B), indicating that the interaction is specific.  As the 
EMSA was performed in the absence of other proteins, the results of the experiment 
indicate that CUGBP1 is capable of binding to the 3’UTR of cSHMT independent of  
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Figure 3.2. Proposed model for the IRES-mediated translation of cSHMT.  
In this model, an interaction between an ITAF bound to the 5’UTR of the 
cSHMT transcript and another ITAF bound to the 3’UTR of the cSHMT 
transcript serves to circularize the mRNA.  This results in the formation of a 
“closed loop” similar to the one that is typically formed by the 
eIF4G/PABP/poly(A) tail interaction. 
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Figure 3.3.  The interaction of CUGBP1 with the cSHMT UTRs.  (A)  RNA 
was immunoprecipitated from UV-treated MCF-7 whole cell extract using an 
antibody against IgG (control for non-specific binding) or CUGBP1.  The RNA in 
lanes 1-3 (+RT) was reverse-transcribed into cDNA and then analyzed by PCR 
using primers specific to either the cSHMT 5’UTR or the cSHMT 3’UTR.  The 
RNA in lanes 4-6 (-RT) did not undergo the reverse-transcription step.  Rather, 
they were analyzed directly by PCR to control for DNA contamination in the 
immunoprecipitates.  Lanes 1 and 4 (input) represent 1% of the RNA used in the 
immunoprecipitation.  (B)  Electrophoretic mobility shift assays were carried out 
in the presence of yeast tRNA using radiolabeled cSHMT 3’UTR and recombinant 
MBP-CUGBP1.  A 10X, 50X, and 100X molar excess of unlabeled cSHMT 
3’UTR was also added in lanes 3, 4, and 5, respectively, to determine binding 
specificity.  (C)  Electrophoretic mobility shift assays were carried out using 
radiolabeled cSHMT 3’UTR and increasing concentrations of MBP-CUGBP1.  
The fraction of the 3’UTR bound by the recombinant protein was quantified using 
ChemiImager 4400 from Alpha Innotech Corp.  The dissociation constant (Kd) 
was determined using GraphPad Prism.  (D)  Electrophoretic mobility shift assays 
were carried out using radiolabeled cSHMT 3’UTR truncation mutants in the 
absence and presence of MBP-CUGBP1.  The nucleotides of the 3’UTR that 
comprise the truncation mutant are listed above each gel.  The nucleotide at the 5’ 
end of the 3’UTR is labeled 1.  The nucleotide at the 3’ end of the 3’UTR is 
labeled 637.  (E)  MCF-7 whole cell extract was either not treated or treated with λ 
phosphatase (PPase) and analyzed by western blot using antibodies against 
CUGBP1 and phosphorylated serine and threonine residues.  GAPDH serves as a 
control for equal protein loading.  (F)  The extracts from (E) were applied to RNA 
affinity columns to which either the cSHMT 5’UTR or the reverse complement of 
the cSHMT 5’UTR (RevUTR) had been attached.  Proteins that bound to the 
UTRs were eluted and analyzed by western blotting using an antibody against 
CUGBP1.   
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any auxiliary factors.  The dissociation constant (Kd) of CUGBP1 binding to the 
5’UTR was determined to be 150 nM (Figure 3.3C).  
CUGBP1 has been reported to bind several consensus sequences including 
(CUG)n triplet repeats (28), GU rich elements (GREs, UGUUUGUUUGU) (29), and 
Bruno response elements (BREs, AAUGUAUGUUAAUUGUAUGUAUUA) (30).  
The 3’UTR of cSHMT contains a partial BRE (UGUAUGUU) at nucleotide positions 
496-503.  However, mutation of this sequence did not affect the Kd of CUGBP1 
binding in EMSAs (data not shown).  To map the CUGBP1 binding site on the 
cSHMT 3’UTR, the ability of recombinant protein to bind a series of 3’UTR 
truncation mutants was determined by EMSA.  Addition of MBP-CUGBP1 had no 
effect on the mobility of 3’UTR(1-157), but did decrease the mobility of 3’UTR(1-
200), 3’UTR(1-236), 3’UTR(1-317), 3’UTR(1-477), and the full-length 3’UTR 
(3’UTR(1-637)) (Figure 3.3D).  These results indicate that CUGBP1 binds to the 5’ 
end of the cSHMT 3’UTR, between nucleotides 157 and 200.  This region contains a 
partial GRE (UUUGUUU) located at nucleotide positions 167-173. 
CUGBP1 binding to the cSHMT 5’UTR requires an auxiliary factor.  MBP-
CUGBP1 did not bind to the cSHMT 5’UTR in EMSAs (data not shown).  However, 
the results from RNA immunoprecipitation experiments using an antibody against 
CUGBP1 revealed that the endogenous protein is associated with the cSHMT 5’UTR 
in UV-treated MCF-7 cells (Figure 3.3A).  Taken together, these data suggest that 
CUGBP1 binding to the cSHMT 5’UTR requires either a post-translational 
modification that is absent from the bacterially-expressed protein or an auxiliary factor 
that binds to both the cSHMT 5’UTR and to CUGBP1.   
CUGBP1 is known to be phosphorylated in vivo (31,32).  To determine if the 
phosphorylation status of CUGBP1 affects its interaction with the cSHMT 5’UTR, 
RNA affinity chromatography was carried out using in vitro transcribed RNA and 
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either untreated or phosphatase-treated MCF-7 whole cell extract (Figure 3.3E).  
Phosphatase treatment did not interfere with the ability of the cSHMT 5’UTR to pull 
down CUGBP1 (Figure 3.3F), making it unlikely that a CUGBP1 post-translational 
modification is required for the RNA-protein interaction.  We therefore hypothesized 
that CUGBP1 interacts with the 5’UTR through its association with a novel cSHMT 
ITAF that binds directly to the 5’UTR.   
Identification of hnRNP H2 as a cSHMT 5’UTR-binding protein.  To identify 
the cSHMT 5’UTR binding protein, RNA affinity chromatography was carried out 
using in vitro transcribed mRNA.  The reverse complement of the cSHMT 5’UTR 
(RevUTR), which lacks IRES activity (25), was used as a control for non-specific 
binding.  Analysis of the eluate revealed that a protein of approximately 50 kDa bound 
to the cSHMT 5’UTR but not the RevUTR (Figure 3.4A).  Microcapillary reverse-
phase HPLC nano-electrospray tandem mass spectrometry (µLC/MS/MS) identified 
this protein as heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2).  
Immunoblotting using an antibody against hnRNP H confirmed these results (Figure 
3.4B), although the antibody cannot distinguish between hnRNP H1 and hnRNP H2, 
which are 96% identical (33).   
To further investigate the binding of hnRNP H2 to the cSHMT 5’UTR, 
EMSAs were carried out using recombinant MBP-hnRNP H2 and an excess of non-
specific competitor tRNA.  The results revealed that MBP-hnRNP H2 (but not MBP 
alone, data not shown) binds directly and specifically to the 5’UTR (Figure 3.4C) with 
a Kd of 260 nM (Figure 3.4D).  To map the hnRNP H2 binding site, the ability of the 
recombinant protein to bind several different 5’UTR truncation mutants was 
determined by EMSA.  MBP-hnRNP H2 bound to 5’UTR(105-190), 5’UTR(50-150), 
5’UTR(1-114), 5’UTR(1-131) and the full-length 5’UTR (5’UTR(1-190)), but not to 
5’UTR(1-104) (Figure 3.4E), indicating that nucleotides 105-114 comprise the hnRNP  
 97
Figure 3.4.  The interaction of hnRNP H2 with the cSHMT UTRs.  (A)  MCF-7 
whole cell extract was applied to RNA affinity columns to which either the cSHMT 
5’UTR or the reverse complement of the cSHMT 5’UTR (RevUTR) had been 
attached.  Proteins that bound to the UTRs were eluted, separated by SDS-PAGE, 
and visualized by coomassie blue staining.  The protein marked with an (*) was 
excised from the gel and analyzed by reverse-phase HPLC nano-electrospray tandem 
mass spectrometry (µLC/MS/MS).  (B)  The SDS-PAGE gel from (A) was 
transferred to a PVDF membrane and analyzed by western blotting using an 
antibody against hnRNP H.  (C)  Electrophoretic mobility shift assays were carried 
out in the presence of yeast tRNA using radiolabeled cSHMT 5’UTR and 
recombinant MBP-hnRNP H2.  A 10X, 50X, and 100X molar excess of unlabeled 
cSHMT 5’UTR was also added in lanes 3, 4, and 5, respectively, to determine 
binding specificity.  (D)  Electrophoretic mobility shift assays were carried out in 
using radiolabeled cSHMT 5’UTR and increasing concentrations of MBP-hnRNP 
H2.  The fraction of the 5’UTR bound by the recombinant protein was quantified 
using ChemiImager 4400 from Alpha Innotech Corp.  The dissociation constant 
(Kd) was determined using GraphPad Prism.  (E)  Electrophoretic mobility shift 
assays were carried out in using radiolabeled cSHMT 5’UTR truncation mutants in 
the absence and presence of MBP-hnRNP H2.  The nucleotides of the 5’UTR that 
comprise the truncation mutant are listed above each gel.  The nucleotide at the 5’ 
end of the 5’UTR is labeled 1.  The nucleotide at the 3’ end of the 5’UTR is labeled 
190.  (F) RNA was immunoprecipitated from UV-treated MCF-7 whole cell extract 
using an antibody against IgG (control for non-specific binding) or hnRNP H.  The 
RNA in lanes 1-3 (+RT) was reverse-transcribed into cDNA and then analyzed by 
PCR using primers specific to either the cSHMT 5’UTR or the cSHMT 3’UTR.  The 
RNA in lanes 4-6 (-RT) did not undergo the reverse-transcription step.  Rather, they 
were analyzed directly by PCR to control for DNA contamination in the 
immunoprecipitates.  Lanes 1 and 4 (input) represent 1% of the RNA used in the 
immunoprecipitation.  (G)  Whole cell extract (WCE) from cells that were treated 
with either negative control siRNA (- CUGBP1 siRNA) or siRNA directed against 
CUGBP1 were applied to RNA affinity columns to which either the cSHMT 5’UTR 
or the cSHMT 3’UTR had been attached.  Proteins that bound to the UTRs were 
eluted, separated by SDS-PAGE, and visualized by western blotting using antibodies 
against CUGBP1 or hnRNP H.  For the WCE, equal protein loading was confirmed 
by using an an antibody against GAPDH.  For the affinity column elutions, equal 
protein loading was confirmed by staining the gel with coomassie blue after transfer.  
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H2 binding site on the cSHMT 5’UTR.  This region contains a run of Gs followed by 
a C (GGGGC), a sequence that has been shown to specifically promote hnRNP H1 
and hnRNP H2 binding (34).  RNA immunoprecipitation from UV-treated cells using 
an antibody against hnRNP H verified that the association between hnRNP H1/H2 and 
the cSHMT 5’UTR occurs in vivo (Figure 3.4F).  It also revealed that hnRNP H2 
interacts with the 3’UTR of cSHMT (Figure 3.4F), although it does not bind to the 
3’UTR directly in EMSAs (data not shown).  In vitro, the binding of hnRNP H2 to the 
3’UTR decreases upon CUGBP1 depletion (Figure 3.4G).  These results are consistent 
with a role for hnRNP H2 as the auxiliary factor that enables CUGBP1 to interact with 
the cSHMT 5’UTR. 
hnRNP H2 interacts with CUGBP1.  If hnRNP H2 indeed serves as the 
auxiliary factor for the interaction between CUGBP1 and the cSHMT 5’UTR, hnRNP 
H2 and CUGBP1 must physically interact.  To test this hypothesis, a yeast two-hybrid 
analysis was performed.  An hnRNP H2-GAL4 activating domain fusion and a 
CUGBP1-GAL4 DNA-binding domain fusion were expressed in the Saccharomyces 
cerevisiae strains Y187 and AH109, respectively.  The mating of these strains 
activated the HIS3 and MEL1 reporter genes (as evidenced by the growth of blue 
colonies on SD/-Leu/-Trp/-His medium containing X-α-gal, data not shown), 
providing evidence that the two proteins interact.  The results of the yeast two-hybrid 
were confirmed by both the coimmunoprecipitation of CUGBP1 with the hnRNP H 
antibody (Figure 3.5A), and the coimmunoprecipitation of hnRNP H with the 
CUGBP1 antibody (Figure 3.5B) from MCF-7 cell extracts.  Although it has 
previously been reported that hnRNP H and CUGBP1 interact in an RNA-dependent 
manner in myoblasts (35), our data suggest that the interaction is RNA-independent, 
as the two proteins coimmunoprecipitated from a mixture containing only recombinant 
hnRNP H2 and recombinant CUGBP1 (Figure 3.5C and 3.5D). 
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Figure 3.5.  hnRNP H2 binds to CUGBP1 in an RNA-independent 
manner.  CUGBP1 (A) and hnRNP H (B) were coimmunoprecipitated from 
MCF-7 whole cell extracts using antibodies against hnRNP H and CUGBP1, 
respectively.  The no antibody, IgG, and HA coimmunoprecipitations serve as 
controls for non-specific binding.  CUGBP1 (C) and hnRNP H (D) were 
coimmunoprecipitated from a mixture of recombinant hnRNP H2 and 
recombinant CUGBP1 using antibodies against hnRNP H and CUGBP1, 
respectively.  The no antibody and IgG coimmunoprecipitations serve as 
controls for non-specific binding. 
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            hnRNP H2 is a cSHMT ITAF.  In order to determine if hnRNP H2 is involved 
in the IRES-mediated translation of cSHMT, siRNA was used to deplete hnRNP H2 
protein levels in MCF-7 cells (Figure 3.6A).  Following UV treatment, which activates 
the cSHMT IRES (Chapter 5), these cells were transfected with polyadenylated 
bicistronic mRNAs containing either the cSHMT 5’UTR or the cSHMT 5’ and 
3’UTRs.  Although hnRNP H2 depletion had no effect on the IRES activity of the 
mRNA containing the 5’UTR alone, the IRES activity of the mRNA containing the 5’ 
and 3’UTRs decreased 33% in hnRNP H2 siRNA-treated cells compared to control 
cells (Figure 3.6B).  This reduction in IRES activity correlates with the decrease in 
cSHMT protein levels observed upon hnRNP H2 knockdown (Figure 3.6A).  The 
stimulatory effect of hnRNP H2 on IRES activity was determined to be specific to 
cSHMT, as hnRNP H2 depletion had no significant effect on the IRES activity of the 
immunoglobulin heavy-chain binding protein (BiP) or the hepatits C virus (HCV) 
(Figure 3.6C). 
Depletion of CUGBP1 or hnRNP H2 results in a decrease in the IRES-
mediated translation of non-polyadenylated cSHMT mRNA.  If an interaction between 
hnRNP H2 bound to the 5’UTR of the mRNA and CUGBP1 bound to the 3’UTR 
functions to circularize the cSHMT transcript, then removal of these factors from 
nuclease-treated rabbit reticulocyte lysate should reveal a requirement for the poly(A) 
tail.  Indeed, the immunodepletion of CUGBP1 (Figure 3.7A) and hnRNP H2 (Figure 
3.7B) reduced the IRES activity of the non-polyadenylated bicistronic mRNA 
containing the cSHMT 3’UTR to similar levels obtained when the IRES activity of the 
non-polyadenylated bicistronic mRNA lacking the 3’UTR was measured in rabbit 
reticulocyte lysate containing both factors.  The immunodepletion of CUGBP1 and 
hnRNP H2 had no effect on the IRES activity of the non-polyadenylated bicistronic 
mRNA lacking the cSHMT 3’UTR.  The addition of MBP-tagged recombinant protein  
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Figure 3.6.  hnRNP H2 stimulates cSHMT IRES activity.  (A)  MCF-7 cells 
were treated with negative control siRNA or hnRNP H2 siRNA and subjected to 
western blot analysis using antibodies against hnRNP H2, cSHMT, and CUGBP1.  
GAPDH serves as a control for equal protein loading.  (B)  Control (white bars) 
and hnRNP H2 siRNA-treated cells (dark bars) were transiently transfected with 
bicistronic mRNAs with and without the cSHMT 3’UTR.  The relative ratio of 
Fluc/Rluc for each bicistronic mRNA in the control cells was given a value of 1.0.  
The data represent the average of three independent experiments + standard error.  
(C)  Control (white bars) and hnRNP H2 siRNA-treated cells (dark bars) were 
transiently transfected with bicistronic mRNAs where the human cSHMT 5’UTR 
was replaced with either the BiP IRES or the HCV IRES.  The relative ratio of 
Fluc/Rluc for each bicistronic mRNA in the control cells was given a value of 1.0.  
The data represent the average of three independent experiments + standard error. 
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Figure 3.7.  CUGBP1 and hnRNP H2 depletion result in a dependence on the 
poly(A) tail.  CUGBP1 (A) and hnRNP H (B) were immunodepleted from rabbit 
reticulocyte lysate as described in Materials and Methods.  The depletion of these 
proteins was confirmed by immunoblotting (right) using antibodies against 
CUGBP1 (A) and hnRNP H (B).  GAPDH serves as a control for equal protein 
loading.  The graphs on the left show the IRES activities of the bicistronic mRNAs 
containing a 30 nucleotide poly(A) tail (white bars) or lacking a poly(A) tail (dark 
bars) as measured in control rabbit reticulocyte, CUBBP1 (A) or hnRNP H (B)-
depleted rabbit reticulocyte lysate, or immunodepleted lysate supplemented with 
recombinant CUGBP1 (A) or hnRNP H2 (B).  The relative ratio of Fluc/Rluc for 
each bicistronic mRNA containing a poly(A) tail was given a value of 1.0.  The data 
represent the average of three independent experiments + standard error.  (C)  The 
3’UTR of the bicistronic mRNA was truncated by removal of nucleotides from the 
3’ end, and the IRES activity of these truncation mutants was measured in rabbit 
reticulocyte lysate.  The white bars represent the IRES activity of the truncated 
bicistronic mRNA containing a 30 nucleotide poly(A) tail, and the dark bars 
represent the IRES activity of the truncated bicistronic mRNA lacking a poly(A) tail.  
The relative ratio for each truncated bicistronic mRNA containing a poly(A) tail was 
given a value of 1.0.  The data represent the average of three independent 
experiments + standard error. 
 105
 106
(Figure 3.7A and 3.7B), but not MBP alone (data not shown), to the immunodepleted 
extracts restored the IRES activity of the non-polyadenylated bicistronic mRNA 
containing the cSHMT 3’UTR to the levels of its polyadenylated counterpart, 
demonstrating that the immunodepletion procedure did not completely remove any 
other factor required for cap-independent translation.  However, consistent with an 
RNA-independent interaction between CUGBP1 and hnRNP H2, the 
immunodepletion of CUGBP1 did reduce the levels of hnRNP H present in the 
nuclease-treated rabbit reticulocyte lysate (Figure 3.7A) and vice versa (Figure 3.7B). 
Like the immunodepletion of CUGBP1 from rabbit reticulocyte lysate, the 
deletion of all but the first 157 nucleotides from the cSHMT 3’UTR in the bicistronic 
mRNA resulted in a 50% decrease in the IRES activity of non-polyadenylated mRNA 
relative to that of its polyadenylated counterpart (Figure 3.7C).  This requirement for 
the poly(A) tail was not observed when the cSHMT 3’UTR contained nucleotides 1-
200, 1-236, 1-317, and 1-477 (Figure 3.7C).  As only the 1-157 3’UTR truncation 
mutant is incapable of binding CUGBP1 (Figure 3.3D), these results further support a 
role for CUGBP1 in circularizing the cSHMT transcript. 
The IRES-mediated translation of cSHMT involves ribosome scanning.  
Internal initiation has previously been shown to proceed by a “land and scan” 
mechanism, whereby the 40S ribosomal subunit binds upstream of the initiation codon 
and then migrates in a 5’-3’ direction until AUG recognition occurs (36-38).  
Consistent with this mechanism, most cellular IRESes have been found to require 
eIF4A (7), a DEAD box helicase that unwinds mRNA secondary structure and thereby 
facilitates ribosome binding and scanning (39,40).  To determine if ribosome scanning 
is involved in the IRES-mediated translation of cSHMT, cells were treated with 
hippuristanol, a small molecule inhibitor of the eIF4A helicase (41).  As in previous 
reports (41), hippuristanol treatment did not reduce the IRES activity of HCV (Figure 
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3.8A) which is known to be eIF4A-independent (42).  However, it did result in a 
significant decrease in the IRES-mediated translation of cSHMT (Figure 3.8B).   
To locate the “landing” point of the ribosome within the cSHMT 5’UTR, a 
series of open reading frames (ORFs) were introduced throughout the IRES by site-
directed mutagenesis of the bicistronic construct.  A common stop codon (UAG) was 
placed at the 3’ end of the IRES, but the locations of the start codon (AUG) varied.  
The ORFs were engineered within the 5’UTR so that they were out of frame with the 
downstream ORF of Fluc.  All AUG codons were placed in a sequence context that is 
highly favorable for initiation (with a purine three nucleotides upstream of the AUG 
and a G in position +4) (43) in order to eliminate leaky scanning by the 40S ribosomal 
subunit (Figure 3.8C).  It was anticipated that if the inserted ORFs are located 
downstream of the ribosome entry site, IRES activity would decrease.  However, if the 
ORFs are located upstream of the ribosome entry site, IRES activity would be 
unaffected.     
The mRNA produced from each mutated bicistronic construct was transiently 
transfected into MCF-7 cells, and IRES activity was measured and compared to 
wildtype (WT) and stop codon only controls (Figure 3.8D).  The introduction of start 
codons at positions 52, 70, 82, and 103 resulted in similar reductions in IRES activity.  
However, the mutation of these AUGs to GUG or UUG also resulted in reduced IRES 
activity, indicating that mutations at these positions affect luciferase expression simply 
by perturbing the RNA structure.  In contrast, the introduction of start codons at 
positions 118, 139, 151, and 169 resulted in reduced IRES activity that could be 
completely rescued by mutation of the AUGs to AUA or UUG, indicating that the 40S 
ribosomal subunit begins scanning between nucleotides 103 and 118 of the cSHMT 
5’UTR.  The gradual increase in IRES activity of the 118, 139, 151, and 169 AUG 
mutants is consistent with reinitiation, a process by which ribosomes remain  
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Figure 3.8.  Ribosome scanning occurs between nucleotides 103 and 118 of the 
cSHMT 5’UTR.  (A)  MCF-7 cells were transiently transfected with polyadenylated 
bicistronic mRNAs containing the HCV IRES (A) or the cSHMT 5’UTR (B) and 
then treated with the indicated amount of hippuristanol.  11 h following treatment, 
Fluc (white bars) and Rluc (dark bars) expression was quantified as described in 
Materials and Methods.  The relative luminosity in untreated cells was given a value 
of 1.0.  The data represent the average of three independent experiments + standard 
error.  (C) The sequence of the cSHMT 5’UTR indicating the positions of the 
inserted open reading frames.  The location of each start and stop codon is 
underlined, and the letters above the underlined nucleotides indicate changes to the 
wildtype sequence that were made by site directed mutagenesis.  (D)  MCF-7 cells 
were transiently transfected with bicistronic mRNAs containing the mutated cSHMT 
5’UTRs.  The number of each mutant represents the position of the A in the AUG or 
AUA, or the U in the UUG.  The relative ratio of Fluc/Rluc for each the wildtype 
(WT) bicistronic mRNA was given a value of 100%.  The data represent the average 
of at least three independent experiments + standard error. 
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associated with the mRNA following the translation of an upstream ORF and then 
reinitiate at a downstream ORF.  The shorter the upstream ORF, the greater the 
efficiency of reinitiation (44).  
   
Discussion 
There are few conserved properties shared among cellular IRESes in terms of 
their sequence, size, or structure, indicating that a universal mechanism for their mode 
of action is unlikely.  This is evidenced by the growing list of ITAFs, many of which 
have only been implicated in the cap-independent translation of a small percentage of 
the known IRES-containing mRNA transcripts.  In this study, we provided evidence 
that the IRES-mediated translation of cSHMT proceeds by a unique mechanism in that 
it involves two novel ITAFs, CUGBP1 and hnRNP H2, and does not require either the 
poly(A) tail or PABP. 
The direct binding of hnRNP H2 to the cSHMT 5’UTR, the direct binding of 
CUGBP1 to the cSHMT 3’UTR, and the RNA-independent interaction between 
hnRNP H2 and CUGBP1 are all consistent with a model for the IRES-mediated 
translation of cSHMT whereby an hnRNP H2-CUGBP1 bridge results in the 
circularization of the mRNA.  Formation of this bridge would replicate a function of 
the eIF4G/PABP/poly(A) tail interaction and would account for the  finding that both 
the poly(A) tail and PABP are dispensable when the cSHMT 3’UTR, CUGBP1, and 
hnRNP H2 are present, but are required for maximal cSHMT IRES activity in the 
absence of any one of these factors.  It would also explain the previously observed 
stimulatory effect of the cSHMT 3’UTR on IRES activity (25).  Such a model of 
IRES-mediated translation is not unprecedented.  The finding that several non-
polyadenylated viral RNAs contain sequences in their 3’UTRs that are required for 
efficient IRES-mediated translation led to the hypothesis that an RNA/RNA or 
 111
RNA/protein bridge can be established between the IRES and the 3’UTR (23,45-47).  
However, this is the first report, to our knowledge, that demonstrates a cellular 
IRES/protein bridge experimentally. 
Since endogenous cSHMT mRNA is polyadenylated and therefore can 
presumably bind PABP, why would it utilize an alternative set of factors to form a 
“closed loop”?  One hypothesis comes from examining the CUGBP1 binding site on 
the 3’UTR.  The data from this study indicate that CUGBP1 binds between 
nucleotides 157 and 200, which is more than 400 nucleotides upstream of the start of 
the poly(A) tail.  Consequently, the interaction of CUGBP1 with the IRES would 
result in the formation of a much smaller “closed loop” than an interaction between 
PABP and the IRES.  A smaller “closed loop” would likely increase the efficiency of 
40S ribosomal subunit recycling. 
It remains to be determined whether hnRNP H2 and CUGBP1 serve any 
additional role(s) in the IRES-mediated translation of cSHMT aside from circularizing 
the transcript.  The proximity of the hnRNP H2 binding site (between nucleotides 105 
and 114) and the 40S ribosomal subunit binding site (between nucleotides 103 and 
118) on the cSHMT 5’UTR, combined with the previously reported association 
between CUGBP1 and the α and β subunits of eIF2 (48), raise the possibility that the 
ITAFs may physically recruit the translation initiation machinery to the 5’UTR.  In 
support of this, preliminary results from our laboratory suggest that hnRNP H2 and 
CUGBP1 interact with eIF4A (data not shown).  Further work is needed to investigate 
the requirement of the other canonical initiation factors in the IRES-mediated 
translation of cSHMT and to determine whether the essential initiation factors bind to 
the cSHMT ITAFs. 
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CHAPTER 4 
 
THE ROLE OF HEAVY CHAIN FERRITIN IN THE INTERNAL  
RIBOSOME ENTRY SITE-MEDIATED TRANSLATION OF CYTOPLASMIC 
SERINE HYDROXYMETHYLTRANSFERASE 
 
Abstract 
Heavy chain ferritin (H ferritin) is an iron chelator that has been shown to 
enhance the internal ribosome entry site (IRES)-mediated translation of the folate-
dependent enzyme cytoplasmic serine hydroxymethyltransferase (cSHMT).  Although 
it is well established that cells overexpressing H ferritin exhibit increased cSHMT 
IRES activity, and that mouse embryonic fibroblasts heterozygous for H ferritin 
expression display a reduction in IRES activity, the mechanism by which H ferritin 
acts has yet to be determined.  In this study, the role of H ferritin in the IRES-
mediated translation of cSHMT was investigated.  We show that H ferritin does not 
participate directly in cSHMT IRES-mediated translation, nor does it stimulate 
cSHMT IRES activity by affecting cellular iron pools, altering the cytoplasmic levels 
of the IRES trans-acting factors (ITAFs), or activating the iron-loading protein poly 
r(C) binding protein 1 (PCBP1).  Rather, H ferritin may function in the assembly of 
the ITAFs prior to the commencement of translation initiation. 
 
Introduction 
Ferritin is a multimeric protein composed of 24 heavy and light chain subunits, 
the ratio of which varies depending on cell type and function (1).  Whereas the heavy 
chain subunit (H ferritin) sequesters iron through its ferroxidase active sites, the light 
chain subunit functions to mineralize the iron core of the ferritin polymer (2).  Ferritin 
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plays a critical role in the regulation of intracellular iron homeostasis.  When iron 
levels are low, Fe2+ is released from the protein so it can contribute to the labile iron 
pool; when iron levels are high, Fe2+ is oxidized to Fe3+ at the surface of the protein 
and deposited in the in the core of the ferritin polymer to prevent iron-mediated 
oxidative damage (1). 
In agreement with results from clinical and epidemiological studies that 
suggest an interaction among iron status and folate (3-5), it has previously been shown 
that the expression of the H ferritin cDNA in cultured cells markedly elevates the 
expression of cytoplasmic serine hydroxymethyltransferase (cSHMT), an enzyme that 
regulates folate metabolism (6).  The H ferritin-mediated stimulation of cSHMT 
expression occurs at the translational level through an internal ribosome entry site 
(IRES) located in the 5’ untranslated region (UTR) of the cSHMT transcript (6,7).  
IRESes are cis-acting regulatory elements that allow for the cap-independent 
translation of an mRNA.  With the aid of one or more IRES trans-acting factors 
(ITAFs), they recruit the 43S pre-initiation complex to a location close to or directly at 
the initiation codon.  In doing so, they enhance the translation rates of transcripts that 
contain a long and/or structured 5’UTR and circumvent many of the controls that 
regulate cap-dependent translation (8-10).   
Although the mechanism by which the majority of cellular IRESes function 
has yet to be explored, several recent studies have shed light on the mechanism of the 
IRES-mediated translation of cSHMT.  It is now known that, in addition to H ferritin, 
cSHMT cap-independent translation involves the ITAFs CUG-binding protein 1 
(CUGBP1) and heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2).  According 
to the present model, hnRNP H2 binds directly to the 5’UTR of the cSHMT mRNA 
and interacts with CUGBP1, which is bound directly to the 3’UTR.  The interaction 
among hnRNP H2, CUGBP1, and the UTRs stimulates cSHMT IRES activity by 
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circularizing the transcript (Chapter 3).  How H ferritin fits into this model is currently 
unknown.  Because H ferritin can stimulate cSHMT IRES-activity in the absence of 
the 3’UTR of the transcript (7), and because it can interact with both CUGBP1(7) and 
hnRNP H2 (11),  it has been hypothesized that H ferritin acts by binding directly to 
the 5’UTR of the cSHMT mRNA and indirectly to the 3’UTR through the auxiliary 
factor CUGBP1 (7).  The following studies were conducted to test this hypothesis and 
to further investigate the role of H ferritin in cSHMT IRES-mediated translation. 
 
Materials and Methods 
Vectors- The generation of bicistronic DNA templates containing the cSHMT 
5’UTR, the cSHMT 3’UTR, the reverse compliment of the cSHMT 5’UTR, and the 
reverse compliment of the cSHMT 3’UTR is described elsewhere (7).  The H ferritin 
coding sequence (6) was subcloned into the pGEX4T-2 vector (GE Healthcare) using 
the primers 5'-TAGGATCCATGACGACCGCGTCC-3'  and 5'-
TACTCGAGTTAGCTTTCATTATCACTG-3' where the BamHI and XhoI 
restriction sites are shown in bold. 
Purification of recombinant protein- BL21* cells were transformed with the H 
ferritin-pGEX vector and grown to mid-log phase.  Protein synthesis was induced with 
isopropyl β-D-thiogalactopyranoside (final concentration 0.1 mM) for 16 h at 18oC.  
The cells were lysed in B-PER (Pierce) followed by sonication on a Branson Digital 
Sonifier at 50% amplitude with intermittent icing.  After removal of the insoluble 
material, the clarified supernatant was applied directly to a GST-Bind Resin 
(Novagen), and the protein was purified according to the manufacturer’s protocol.  The 
purity of the protein was determined by SDS-polyacrylamide gel electrophoresis, and 
its concentration was determined using the Lowry Assay as modified by Bensadoun 
(12). 
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In vitro transcription- DNA templates were linearized and purified using the 
Roche PCR clean-up column.  The templates were transcribed using Ambion’s 
MEGAscript kit (for uncapped mRNA) or mMESSAGE mMACHINE kit (for capped 
mRNA) according to the manufacturer’s protocol.  For preparation of radiolabeled 
mRNA for electrophoretic gel mobility shift assays, 50µCi of [α−32P]-labeled rUTP 
(800Ci/mM, Perkin Elmer) was included in in vitro transcription reactions.  The crude 
mRNA was treated with DNase I (Ambion) for 15 min at 40°C and precipitated in 2 M 
LiCl at -80°C.  All RNA procedures were conducted under RNase-free conditions and 
all mRNA was stored with Recombinant RNasin® Ribonuclease Inhibitor (Promega).  
The mRNA was quantified by spectrophotometry and it’s quality verified by 
electrophoresis. 
RNA electrophoretic gel mobility shift assays- 20 nM [α−32P]-labeled RNA 
and either the indicated amount of recombinant protein, 25 ng ferritin (type IV) from 
human liver (Sigma), or 25 ng ferritin (type VII) from human heart (Sigma) were 
added to binding buffer (20 mM Tris pH 7.5, 5 mM MgCl2, 1 mM EDTA, 8 mM DTT, 
2 µg BSA, 10% glycerol, 40 units Recombinant RNasin® Ribonuclease Inhibitor 
(Promega)) for a total volume of 10 µL.  The binding reaction was incubated at 37oC 
for 15 min and then run on a 4% native polyacrylamide gel at 32 mA.  Electrophoresis 
buffer contained 25 mM Tris base, 0.2 M glycine, and 1 mM EDTA. 
Cell culture and preparation of extracts- Mammary adenocarcinoma (MCF-7) 
cells were obtained from ATCC (HTB22).  The generation of the stable cell lines 
expressing H ferritin cDNA is described elsewhere (7).  All cells were cultured in α-
MEM (Hyclone Laboratories) containing 11% fetal bovine serum (Hyclone 
Laboratories) at 37oC and 5% CO2.  When the cells reached approximately 95% 
confluence, they were harvested by tripsinization and washed in phosphate-buffered 
saline.  To obtain whole cell extract, cells were resuspended in lysis buffer (50 mM 
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Tris pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 1:100 dilution of 
Sigma Protease Inhibitor Cocktail) and lysed on ice for 30 min.  Nuclear and 
cytoplasmic extracts were obtained using the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Pierce) according to the manufacturer’s protocol. The concentration of 
the protein in all the extracts was determined using the Lowry Assay as modified by 
Bensadoun (12). 
RNA affinity chromatography- 1.0 nmol of the indicated in vitro transcribed 
mRNA (uncapped and polyadenylated) was incubated with 1.0 nmol biotinylated 
oligo (dT) probe (Promega) and 200 µl packed streptavidin agarose (Novagen) in 
TMK buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 150 mM KCl) for 1 h at 4oC.  After 
extensive washing with TMK buffer, the agarose was resuspended in TMK buffer 
containing 1.0 nmol of the corresponding in vitro transcribed reverse compliment 
UTR mRNA (competitor mRNA, uncapped and non-polyadenylated), 3.0 mg cell 
extract, 150 µg yeast tRNA (Ambion), and 600 units Recombinant RNasin® 
Ribonuclease Inhibitor (Promega).  Following incubation for 1 h at 4oC, the agarose 
was washed extensively with TMK buffer, and bound proteins were eluted in 2X SDS-
PAGE sample buffer (160 mM Tris pH 6.8, 20 mM DTT, 4% SDS, 20% glycerol) at 
95oC for 5 min.  The eluted proteins were separated by SDS-PAGE and subjected to 
western blot analysis.  Equal loading was confirmed by staining the PVDF membrane 
with coomassie blue following protein transfer.  
Western blotting- Proteins were separated by SDS-PAGE using a Tris-glycine 
gel and transferred to a PVDF membrane.  The membrane was blocked with 5% non-
fat dry milk in phosphate-buffered saline containing 1% NP-40 for 1 hour at room 
temperature, incubated with primary antibody overnight at 4oC, and incubated with 
horseradish peroxidase-conjugated anti-IgG for 1-3 h at room temperature.  After each 
incubation, the membrane was washed with phosphate-buffered saline/0.1% Tween20.  
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Proteins were visualized using Super Signal® substrate (Pierce) followed by 
autoradiography.  When necessary, membranes were stripped with 0.2 M NaOH.  
Affinity purified sheep anti-H ferritin was used at a 1:500 dilution, mouse anti-
CUGBP1 (3B1) (Santa Cruz Biotechnology) was used at a 1:10,000 dilution, sheep 
anti-human cSHMT was used at a 1:40,000 dilution, goat anti-hnRNP H (N-16, Santa 
Cruz Biotechnology) was used at a 1:500 dilution, rabbit anti-PCBP1 (Abcam) was 
used at a 1:1000 dilution, rabbit anti-Lamin A (H-102, Santa Cruz Biotechnology) was 
used at a 1:1000 dilution, and mouse anti-GAPDH (Novus Biologicals) was used at a 
1:40,000 dilution. Goat anti-mouse IgG, rabbit anti-sheep IgG, and rabbit anti-goat 
IgG were all purchased from Pierce and used at a 1:5,000 dilution. 
 Polysome profile analysis- MCF-7 cells at approximately 80% confluence were 
washed twice with phosphate-buffered saline and then exposed to 10,000 µJ/cm2 UV 
(254 nm) using the Stratagene UV Stratalinker 2400.  The medium was then replaced 
and the cells cultured under normal conditions.  22 h following UV exposure, the cells 
were treated with 50 µg/mL cycloheximide (Sigma) for 30 min at 37oC and 5% CO2.  
The cells were scraped from the plate and then lysed in polysome extraction buffer (10 
mM Tris pH 7.5, 10 mM NaCl, 1.5 mM MgCl2, 1% Triton X-100, 1% deoxycholate, 
2% Tween 20, 1000u Recombinant RNasin® Ribonuclease Inhibitor (Promega)) for 
10 min on ice.  Nuclei were pelleted by brief centrifugation and the resulting 
supernatant was fractionated through a 10-50% sucrose gradient by ultracentrifugation 
in a SW41-Ti rotor for 2 h at 36,000 rpm and 4oC.  1 mL fractions were collected with 
a density gradient fractionation system (Brandel) and the absorbance at 254 nm was 
measured continuously as a function of gradient depth.  Protein was isolated each 
fraction by TCA precipitation and analyzed by western blotting as described above. 
 Deferoxamine treatment- MCF-7 cells were grown in 6 well plates until 
approximately 50% confluent.  Deferoxamine (Sigma) was then added to the cell 
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culture media at a final concentration of 12.5, 25, 50, or 100 µM.  24 or 48 h following 
treatment, the cells were either harvested and subjected to western blot analysis, or 
transfected with bicistronic mRNA as described below. 
 Ferric citrate treatment- MCF-7 cells were grown in 6 well plates until 
approximately 85% confluent.  Ferric citrate (Sigma) was then added to the cell 
culture media at a final concentration of 0.1, 1 10, or 100 µM.  24 h following 
treatment, the cells were either harvested and subjected to western blot analysis, or 
transfected with bicistronic mRNA as described below. 
 mRNA transfections- MCF-7 cells were incubated in Opti-MEM (Invitrogen) 
containing a 1:100 dilution of DMRIE-C transfection reagent (Invitrogen) and 5 
µg/mL mRNA (capped and polyadenylated) for 4 h at 37oC and 5% CO2.  The Opti-
MEM was then replaced with α-MEM and the cells incubated for an additional 6 h at 
37oC and 5% CO2.  Renilla and Firefly Luciferase expression was quantified on a 
Veritas Microplate Luminometer (Turner Biosystems) using the Dual-Glo Luciferase 
Assay System (Promega) according to the manufacturer’s protocol.  Where indicated, 
the cells were treated with 10,000 µJ/cm2 UVC (254 nm) using the Stratagene UV 
Stratalinker 2400 12h prior to transfection. 
 siRNA transfections- MCF7 cells were grown to approximately 40% 
confluence and then transfected with 5 nM of either negative control siRNA (Ambion) 
or PCBP1 siRNA (Qiagen, sense strand: 5’-GGGAGAGUCAUGACCAUUCTT-3’, 
antisense strand: 5’-GAAUGGUCAUGACUCUCCCTT-3’)  using the HiPerFect 
transfection reagent (Qiagen) according to the manufacturer’s instructions.  Following 
incubation with siRNA for approximately 50 h at 37oC and 5% CO2, some of the cells 
were harvested and subjected to western blot analysis to confirm PCBP1 knockdown.  
The remainder of were or transfected with bicistronic mRNA according to the protocol 
above. 
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Results 
 H ferritin does not bind to cSHMT mRNA.  It has previously been suggested 
that H ferritin stimulates the IRES-mediated translation of cSHMT by binding directly 
to the 5’UTR of the transcript and interacting with the 3’UTR through the ITAF 
CUGBP1 (7).  This proposal is based largely on the measurement of IRES-mediated 
translation in H ferritin overexpressing MCF-7 cell lines and H ferritin +/- mouse 
embryonic fibroblasts (MEFs) (7), and has not been verified by binding assays.  In 
order to test the model, RNA electrophoretic mobility shift assays (EMSAs) were 
carried out using recombinant protein.  Although the dissociation constants for the 
binding of the cSHMT ITAFs CUGBP1 and hnRNP H2 to the cSHMT UTRs are in 
the nanomolar range (Chapter 3), no binding to either the cSHMT 5’UTR or the 
cSHMT 3’UTR could be detected upon the addition of micromolar amounts of H 
ferritin (Figure 4.1A).  The same results were obtained when EMSAs were carried out 
using ferritin isolated from human liver and heart (data not shown). 
 Since the EMSAs were performed in the absence of other proteins, the 
negative results of the experiment could indicate that H ferritin requires an auxiliary 
factor to interact with the cSHMT mRNA.  However, when MCF-7 whole cell extract 
was applied to RNA affinity columns containing immobilized cSHMT 5’ or 3’UTRs, 
no H ferritin binding could be detected (Figure 4.1B).  The absence of H ferritin 
binding was not due to degradation of the protein during the course of the experiment, 
as H ferritin was detected in the flowthrough fraction (data not shown). 
 As an alternative to in vitro binding assays, the association of H ferritin with 
actively translating mRNAs within a cell was investigated by polysome profile 
analysis.  Whereas CUGBP1and hnRNP H2 were observed in both monosomal and 
polysomal fractions, H ferritin was only present in the non-ribosomal fractions (Figure 
4.1C).  These results, combined with the data from the EMSAs and RNA affinity  
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Figure 4.1.  The interaction of H ferritin with the cSHMT UTRs.  (A) 
Electrophoretic mobility shift assays were carried out using radiolabeled cSHMT 
5’UTR (left) and cSHMT 3’UTR (right) and increasing concentrations of GST-
tagged H ferritin.  The arrows indicate the position of the unbound UTR.  (B)  
MCF-7 whole cell extract was applied to RNA affinity columns to which either the 
cSHMT 5’UTR or the cSHMT 3’UTR had been attached.  Proteins that bound to 
the UTRs were eluted and analyzed by western blotting using antibodies against H 
ferritin, CUGBP1, and hnRNP H.  (C) Monosomal and polysomal fractions were 
separated from MCF-7 cells using a sucrose density gradient.  Total protein was 
extracted from each fraction and subjected to western blot analysis using 
antibodies against H ferritin, CUGBP1, and hnRNP H. 
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columns, indicate that the role of H ferritin in the IRES-mediated translation of 
cSHMT is indirect.  Rather than stimulating the cap-independent translation of 
cSHMT by binding to the cSHMT UTRs as previously proposed (7), H ferritin could 
exert its effect by causing changes in the labile iron pool, influencing the function 
CUGBP1 and/or hnRNP H2, or activating a novel cSHMT ITAF. 
 Neither ferric citrate nor iron chelators affect cSHMT IRES activity.  Since H 
ferritin is an iron storage protein, a change in its concentration can have a dramatic 
effect on the labile iron pool within a cell.  Thus, it is possible that the stimulation of 
cSHMT IRES activity observed upon H ferritin overexpression (7), and the decrease 
in cSHMT IRES activity seen in H ferritin +/- MEFs (7) is not caused by the H ferritin 
protein per se, but rather is due to H ferritin-induced changes in cellular iron status.   
To mimic the decrease in the labile iron pool that occurs upon H ferritin 
overexpression (13,14), MCF-7 cells were treated with the iron chelator deferoxamine 
(DFO) for 24 or 48 h.  Although H ferritin protein levels were not affected by DFO 
treatment, transferrin receptor (TfR) protein levels were elevated in DFO-treated cells 
(Figure 4.2A), indicating that iron depletion had occurred (15,16).  DFO-treated cells 
were then transfected with bicistronic mRNA containing the cSHMT 5’UTR inserted 
between the Renilla luciferase (Rluc) and Firefly luciferase (Fluc) reporter genes, and 
the cSHMT 3’UTR 3’ of the Fluc gene (Figure 4.2B).  Whereas expression of the first 
cistron in this transcript (Rluc) is cap-dependent, expression of the second cistron 
(Fluc) is dependent on IRES activity.  The results of the transfection experiments 
revealed that iron chelation by DFO does not affect cSHMT IRES activity, as 
quantified by the Fluc/Rluc ratio (Figure 4.2C).  Similar data were obtained when 
mRNA transfections were performed using a bicistronic mRNA that lacks the cSHMT 
3’UTR (Figures 4.2B and 4.2D).  In agreement with the IRES activity measurements, 
cSHMT protein levels remained unchanged following DFO treatment (Figure 4.2A). 
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Figure 4.2.  The effect of DFO on cSHMT IRES activity.  (A) MCF-7 cells were 
treated with the indicated amounts of the iron chelator DFO.  24 or 48 h following 
treatment, total protein lysates were prepared and resolved by SDS-PAGE.  Protein 
levels were determined by immunoblotting using antibodies against H ferritin, TfR, 
and cSHMT.  GAPDH serves as a control for equal protein loading.  (B) The two 
bicistronic mRNAs used to quantify cSHMT IRES activity.  Both consist of (in the 
5’ to 3’ direction) a cap analog, the Renilla luciferase (Rluc) reporter gene followed 
by three sequential in-frame stop codons, the human cSHMT 5’UTR which contains 
the IRES element, the Firefly luciferase (Fluc) reporter gene, and a 30 nucleotide 
poly(A) tail.  The bicistronic mRNA on the left also contains the human cSHMT 
3’UTR inserted between Fluc and the poly(A) tail  (C) MCF-7 cells were transfected 
with bicistronic mRNA containing the cSHMT 3’UTR 24 h (white) or 48 h (grey) 
following DFO treatment.  Fluc and Rluc activities were then quantified as described 
in Materials and Methods.  The ratio of total Fluc activity divided by total Rluc 
activity in untreated cells was given a value of 1.0.  The data represent the average 
of three independent experiments + standard error.  (D) The IRES activity of 
bicistronic mRNAs lacking the cSHMT 3’UTR as measured in MCF-7 cells 24 h 
(striped bars) or 48 h (black bars) following DFO treatment.  The ratio of Fluc/Rluc 
in untreated cells was given a value of 1.0.  The data represent the average of three 
independent experiments + standard error.   
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To mimic the increased iron availability that occurs upon decreased H ferritin 
expression, MCF-7 cells were cultured with supplemental ferric citrate for 24 h.  As 
expected based on previous findings (15), H ferritin protein levels exhibited a 
concentration-dependent increase following ferric citrate addition to the cell culture 
media (Figure 4.3A).  However, consistent with earlier reports (6), cSHMT protein 
levels remained unchanged (Figure 4.3A).  Treatment with ferric citrate also did not 
have a significant effect on cSHMT IRES activity, regardless of whether the 3’UTR 
was present (Figure 4.3B) or absent (Figure 4.3C) from the transcript.  Taken together, 
the data from the DFO and ferric citrate studies suggest that H ferritin does not 
stimulate the IRES-mediated translation of cSHMT by altering the labile iron pool. 
H ferritin does not affect CUGBP1 or hnRNP H2 protein levels or cellular 
localization.  Because it is well established that the stimulation of many cellular 
IRESes depends on an increase in concentration and/or cytoplasmic localization of 
ITAFs (17), we next investigated the effect of H ferritin on CUGBP1 and hnRNP H2 
protein levels and cellular compartmentation.  Whole cell, cytoplasmic, and nuclear 
extract were isolated from three MCF-7cell lines that had been stably transfected with 
H ferritin cDNA, and two control MCF-7cell lines.  The cell lines expressing the H 
ferritin cDNA had been analyzed previously and found to exhibit a 3.4 to 4-fold 
increase in H ferritin protein levels compared to control cells (7).  Clones 1 and 2 also 
displayed a statistically significant increase in cSHMT IRES activity (7).  However, 
none of the three clonal cell lines tested showed an increase in the overall levels of 
CUGBP1 or hnRNP H2, or the relocalization of these factors from the nucleus, where 
they primarily reside under normal cellular conditions (18,19), to the cytoplasm, 
where translation occurs (Figure 4.4). 
Depletion of PCBP1 does not affect cSHMT IRES activity.  Since the above 
results suggest that H ferritin does not stimulate cSHMT IRES activity indirectly by  
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Figure 4.3.  The effect of ferric citrate on cSHMT IRES activity.  (A) MCF-7 
cells were treated with the indicated amounts of ferric citrate.  24 h following 
treatment, total protein lysates were prepared and resolved by SDS-PAGE.  
Protein levels were determined by immunoblotting using antibodies against H 
ferritin and cSHMT.  GAPDH serves as a control for equal protein loading.  (B 
and C) MCF-7 cells that had been incubated with the indicated amount of ferric 
citrate for 24 h were transfected with bicistronic mRNA containing (B) or 
lacking (C) the cSHMT 3’UTR, and the ratio of Fluc to Rluc activity was 
measured. The Fluc/Rluc value in untreated cells was given a value of 1.0.  The 
data represent the average of three independent experiments + standard error.
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Figure 4.4.  CUGBP1 and hnRNP H2 protein levels and 
localization in H ferritin overexpressing cell lines.  (A) Nuclear 
(NE) and cytoplasmic (CE) extracts were isolated from three MCF-
7cell lines that had been stably transfected with H ferritin cDNA (1, 
2, and 3), and two control MCF-7cell lines (C).  Whole cells 
extracts (WCE) were also obtained from the same cell lines.  All 
extracts were subjected to immunoblotting using an anti-H ferritin, 
anti-CUGBP1, or anti-hnRNP H antibody.  GAPDH is shown as a 
control to demonstrate that the nuclear fractions are free of 
cytoplasmic contamination.  Lamin A is shown as a control to 
demonstrate that the cytoplasmic fractions are free of nuclear 
contamination.  Both GAPDH and Lamin A serve as controls for 
protein loading. 
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increasing the cytoplasmic concentrations of the two known cSHMT ITAFs, it is 
possible that it exerts its effect through a currently unidentified cSHMT ITAF.  The 
best candidate for this novel ITAF is poly r(C) binding protein 1 (PCBP1).  PCBP1 
was recently identified as an iron chaperone that delivers iron to H ferritin (20).  It is 
also an RNA-binding protein that has been implicated in the IRES-mediated 
translation of several transcripts (21-23).  To determine if PCBP1 plays a role in the 
IRES-mediated translation of cSHMT, siRNA was used to knockdown PCBP1 protein 
levels in MCF-7 cells, and IRES activity was measured using the bicistronic 
constructs.  Although PCBP1 protein levels were reduced by at least 50% compared to 
cells treated with negative control siRNA (Figure 4.5A), cSHMT IRES activity 
remained unchanged (Figure 4.5B), even when the cells were exposed to UV 
radiation, which is known to activate the cSHMT IRES (Chapter 5). 
 
Discussion 
 The experiments described in this report were conducted to determine the 
mechanism by which H ferritin stimulates the IRES-mediated translation of cSHMT.  
Although they all produced negative results, they did succeed in casting doubt on 
many of the possible roles of H ferritin in cap-independent translational regulation.  H 
ferritin’s effect on cSHMT IRES-mediated translation appears to be unrelated to its 
catalytic activity.  Alterations in the labile iron pool induced upon the addition of 
ferric citrate and the iron chelator DFO had no effect on cSHMT IRES activity, 
although we cannot rule out the possibility that Fe2+ bound to the outer surface of the 
ferritin molecule affects IRES stimulation by H ferritin.  PCBP1, the iron chaperone 
that delivers iron to H ferritin, likewise does not play a role in the IRES-mediated 
translation of cSHMT.      
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Figure 4.5.  PCBP1 does not affect cSHMT IRES activity.  (A) MCF-
7 cells were transfected with negative control siRNA (- PCBP1 siRNA) 
or PCBP1 siRNA and then treated with UV.  22 h after UV treatment, 
PCBP1 knockdown was confirmed by western blotting.  GAPDH serves 
as a control for equal protein loading. (B) The activity of the cSHMT 
IRES was quantified as the Fluc/Rluc ratio in MCF-7 cells treated with 
negative control siRNA (white bars) or PCBP1 siRNA (grey bars).  Cells 
were transfected with the biscistronic mRNAs described in Figure 4.2B 
containing or lacking the cSHMT 3’UTR in the presence and absence of 
UVC exposure.   For each experimental condition, values obtained from 
negative control siRNA-treated cells were given a value of 1.0.  The data 
represent the average of two independent experiments + standard error. 
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             Previous studies have shown that CUGBP1 and hnRNP H2 are ITAFS that 
stimulate cSHMT IRES activity by binding to the 5’ and 3’UTRs of the transcript,  
respectively (Chapter 3) (7).  CUGBP1 and hnRNP H2 physically interact, and their 
interaction functions to circularize the cSHMT mRNA, thereby facilitating the 
recycling and/or recruitment of the translation initiation complex (Chapter 3).  Both of 
these ITAFs have been shown to interact with H ferritin in immunoprecipitation 
experiments and yeast two-hybrid assays (7,11), but surprisingly, the results of this 
study demonstrate that the interactions among CUGBP1, hnRNP H2, and H ferritin do 
not play a direct role in cSHMT IRES-mediated translation.  H ferritin is not present 
with CUGBP1 and hnRNP H2 in polysomes that contain actively translating mRNA 
and it does not bind to the cSHMT 5’UTR or 3’UTR in vitro.  H ferritin also does not 
influence IRES activity by altering the cellular levels or localization of CUGBP1 or 
hnRNP H2.  However, it is still possible H ferritin functions to facilitate the assembly 
of the CUGBP1-hnRNP H2 complex prior to the binding of the translation initiation 
machinery.  This would be consistent with an indirect role of H ferritin in cSHMT 
IRES-mediated translation, and would fit nicely into the previously determined model 
of cSHMT IRES activation.  Further work is needed to test the influence of H ferritin 
on the CUGBP1-hnRNP H2 interaction.   
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CHAPTER 5 
 
A UV-RESPONSIVE INTERNAL RIBOSOME ENTRY SITE ENHANCES 
CYTOPLASMIC SERINE HYDROXYMETHYLTRANSFERASE EXPRESSION 
FOR DNA DAMAGE REPAIR 
 
Abstract 
Thymidine nucleotides are required for faithful DNA synthesis and repair, and 
their de novo biosynthesis is regulated by cytoplasmic serine 
hydroxymethyltransferase (cSHMT).  The cSHMT transcript contains a heavy chain 
ferritin (H ferritin), heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2), and 
CUG-Binding Protein 1 (CUGBP1)-responsive internal ribosome entry site (IRES) 
that regulates cSHMT translation.  In this study, a non-lethal dose of UVC is shown to 
increase cSHMT IRES activity and cSHMT protein levels.  The mechanism for the 
UV-induced activation of the cSHMT IRES involves an increase in H ferritin and 
hnRNP H2 expression and the translocation of CUGBP1 from the nucleus to the 
cytoplasm.  The UV-induced increase in cSHMT translation is accompanied by an 
increase in the Small Ubiquitin-Like Modifier (SUMO)-dependent nuclear localization 
of the de novo thymidylate biosynthesis pathway and a decrease in DNA strand 
breaks, indicating a role for cSHMT and nuclear folate metabolism in DNA repair. 
 
Introduction 
 UV radiation is mutagenic and damages cellular macromolecules, including 
proteins, lipids and DNA.  Thymine bases within DNA are sensitive to UV-induced 
damage, forming cyclobutane-type pyrimidine dimers and (6-4)-photoproducts (2).  
These lesions hinder RNA polymerase processivity and thus inhibit transcription (3).  
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In mammalian cells, cyclobutane-type pyrimidine dimers and (6-4)-photoproducts are 
repaired by nucleotide excision repair (NER).  NER involves the removal of 
approximately 30 nucleotides surrounding the damage site, resulting in a single-strand 
gap that requires DNA synthesis and ligation to complete the repair process (4). 
 Thymidine triphosphate is required for faithful DNA synthesis.  Insufficient 
pools of thymidine nucleotides during DNA replication and NER result in elevated 
rates of uracil misincorporation into DNA, which ultimately leads to DNA strand 
breaks and genome instability (7).  Thymidine nucleotides can either be synthesized 
through a salvage pathway or can be synthesized de novo through folate-mediated 
one-carbon metabolism (Figure 5.1).  In the de novo biosynthetic pathway, 5,10-
methylenetetrahydrofolate (5,10-methyleneTHF) provides the activated one-carbon 
units and reducing equivalents for the thymidylate synthase (TS)-catalyzed conversion 
of deoxyuridine monophosphate (dUMP) to thymidylate.  5,10-methyleneTHF can be 
generated by two alternative pathways: the reduction of 10-formylTHF, or through the 
activity of cytoplasmic serine hydroxymethyltransferase (cSHMT), which catalyzes 
the conversion of THF and serine to glycine and 5,10-methyleneTHF.   
 The cSHMT enzyme is a key regulator of de novo thymidylate biosynthesis and 
is poised to play a role in the repair of UV-induced DNA damage.  In addition to 
providing one-carbon units for the synthesis of thymidylate, cSHMT-derived 5,10-
methyleneTHF can be reduced by methyleneTHF reductase (MTHFR) to form 5-
methylTHF, a cofactor utilized in the remethylation of homocysteine to methionine 
(Figure 5.1).  The concentration of free folate in the cell is negligible, and therefore TS 
and MTHFR compete for limiting pools of the 5,10-methyleneTHF cofactor (8-11).  
Several studies have demonstrated that whereas the majority of 5,10-methyleneTHF 
derived from the reduction of 10-formylTHF is directed toward the synthesis of 
methionine (12,13), cSHMT-derived 5,10-methyleneTHF is partitioned to TS (14)  
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Figure 5.1.  Folate-mediated one-carbon metabolism.  Folate-mediated one-carbon 
metabolism is required for the de novo synthesis of purines and thymidylate and for 
the remethylation of homocysteine to methionine.  Mitochondrial-derived formate can 
enter the cytoplasm and function as a one-carbon donor through the conversion of 
tetrahydrofolate (THF) to 10-formylTHF.  5,10-methyleneTHF, which can be 
generated through the reduction of 10-formylTHF or through the catalytic activity of 
cytoplasmic serine hydroxymethyltransferase (cSHMT), provides the one-carbon 
units for the thymidylate synthase (TS)-catalyzed conversion of deoxyuridine 
monophosphate (dUMP) to thymidylate.  It also serves as a substrate for 
methyleneTHF reductase (MTHFR), which reduces 5,10-methyleneTHF to ultimately 
form S-adenosylmethionine (AdoMet), the one-carbon donor in numerous cellular 
methylation reactions.  De novo thymidylate biosynthesis also occurs in the nucleus 
through the SUMO-dependent import of the thymidylate synthesis pathway during S-
phase. 
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through the cell cycle-dependent and Small Ubiquitin-Like Modifier (SUMO)-
mediated nuclear localization of the thymidylate biosynthesis pathway (15,16) (Figure 
5.1). 
 The DNA damage caused by UV radiation evokes adaptive cellular responses 
which include cell cycle arrest (17) and changes in transcription (18,19) and 
translation.  At the translational level, UV radiation inhibits global cap-dependent 
protein synthesis by inducing the phosphorylation of eukaryotic initiation factor (eIF) 
2α (5,20,21) and thereby preventing the recycling of the ternary complex (eIF2-GTP-
Met-tRNAi) (22).  Despite the reduction in cap-dependent translation, several mRNAs 
whose protein products are essential for the UV-induced stress response (for example 
p53 (23) and Apaf-1 (24)) have evolved alternative mechanisms of protein synthesis 
that allow for their continued expression following exposure to UV.  One such 
mechanism involves ribosome recruitment to an internal ribosome entry site (IRES) 
located within the 5’untranslated region (UTR) of the transcript (25,26). 
 We have previously shown that the cSHMT 5’UTR contains an IRES whose 
activity is stimulated by heavy chain ferritin (H ferritin) (1) and the IRES trans-acting 
factors (ITAFs) heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2) and CUG-
Binding Protein 1 (CUGBP1) (Chapter 3) (1).  However, the responsiveness of the 
IRES to stress stimuli that inhibit cap-dependent translation has not been explored.  In 
the present study, we demonstrate the role of the cSHMT IRES and folate-dependent 
nuclear thymidylate biosynthesis in the provision of one-carbon units during UV-
induced DNA damage repair. 
 
Materials and Methods 
 Cell culture-  Human MCF-7 mammary adenocarcinoma cells (HTB22), HeLa 
cells (CCL2), and pagetoid sarcoma skin fibroblasts (CRL-7677) were obtained from 
 140
ATCC.  The human SH-SY5Y neuroblastoma, a subline of the SK-N-SH 
neuroblastoma, was obtained from June Biedler (Fordham University).  MCF-7, HeLa, 
and SH-SY5Y cells were cultured in α-MEM (Hyclone Laboratories) containing 11% 
fetal bovine serum (Hyclone Laboratories).  Pagetoid sarcoma skin fibroblasts were 
cultured in DMEM (Gibco) containing 11% fetal bovine serum (Hyclone 
Laboratories).  All cells were maintained at 37oC and 5% CO2.   
 Treatment and preparation of cell extracts-  MCF-7 cells at 30% confluence 
were arrested at the G2/M phase of the cell cycle by treatment with 60 ng/mL 
nocodazole (Calbiochem) for 24 h.  Cell cycle analysis was carried out by 
fluorescence-activated cell sorting using 3 mM sodium citrate containing 1% Triton 
X-100 and 50 ng/mL propidium iodide as the lysis/DNA binding reagent.  For 
experiments involving UV treatment, cells at 95% confluence were washed twice with 
phosphate-buffered saline and then exposed to 10,000 µJ/cm2 UV (254 nm) using the 
Stratagene UV Stratalinker 2400.  The medium was then replaced and the cells 
cultured under normal conditions.  At the indicated time intervals following treatment, 
the cells were harvested by trypsinization and washed in phosphate-buffered saline.  
To obtain whole cell extracts, the cells were resuspended in lysis buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 1:100 dilution of 
Sigma Protease Inhibitor Cocktail, 10 mM N-ethylmalemide) and lysed on ice for 30 
min.  Nuclear and cytoplasmic extracts were obtained using the NE-PER Nuclear and 
Cytoplasmic Extraction Kit (Pierce) according to the manufacturer’s protocol.  The 
protein concentration of all extracts was determined using the Lowry Assay as 
modified by Bensadoun (27). 
 Trypan Blue Exclusion-  MCF-7 cells were treated with UV according to the 
protocol above.  24 h after UV exposure, the cells were harvested by trypsinization, 
pelleted by centrifugation, and then resuspended in serum-free α-MEM.  The 
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suspension was then diluted 1:1 with 0.4% Trypan Blue (Invitrogen), and the viable 
and non-viable cells were counted using a hemocytometer. 
 Metabolic labeling-  Control and UV-irradiated cells were labeled with 100 
µCi/mL EasyTagTM EXPRESS 35S Protein Labeling Mix (Perkin Elmer, 1175 
Ci/mmol) for 30 min in methionine/cysteine-free DMEM (Sigma).  Cells were then 
harvested and lysed as described above.  The protein concentration of all extracts was  
determined using the Lowry Assay as modified by Bensadoun (27), and equal amounts 
of extract were separated by 12% SDS-PAGE.  The gel was stained with Coomassie 
Blue (R-250), dried, and autoradiographed.  To quantify the amount of 35S 
incorporation, equal amounts of protein were precipitated with TCA, and radioactivity 
was quantified in a LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter). 
 Western blotting-  Proteins were separated by SDS-PAGE using a Tris-glycine 
gel and transferred to a PVDF membrane.  The membrane was blocked with 5% non-
fat dry milk in phosphate-buffered saline containing 1% NP-40 for 1 h at room 
temperature, incubated with primary antibody overnight at 4oC, and then incubated 
with horseradish peroxidase-conjugated anti-IgG for 1-3 h at room temperature.  After 
each incubation, the membrane was washed with phosphate-buffered saline/0.1% 
Tween 20.  Proteins were visualized using Super Signal® substrate (Pierce) followed 
by autoradiography.  Mouse anti-phospho-p53 (Ser15, Cell Signaling) was used at a 
1:1000 dilution, rabbit anti-phospho-eIF2α (Ser51, Cell Signaling) was used at a 
1:1000 dilution, affinity purified sheep anti-human cSHMT was used at a 1:40,000 
dilution, sheep anti-TS (Abcam) was used at a 1:2000 dilution, mouse anti-CUGBP1 
(3B1, Santa Cruz Biotechnology) was used at a 1:10,000 dilution, affinity purified 
sheep anti-H ferritin was used at a 1:500 dilution, goat anti-hnRNP H (N-16, Santa 
Cruz Biotechnology) was used at a 1:1000 dilution, rabbit anti-SUMO-1 (Active 
Motif) was used at a 1:1000 dilution, rabbit anti-p53 (Active Motif) was used at a 
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1:1000 dilution, goat anti-eIF2α (Santa Cruz Biotechnology) was used at a 1:1000 
dilution, rabbit anti-Lamin A (H-102, Santa Cruz Biotechnology) was used at a 1:1000 
dilution, and mouse anti-GAPDH (Novus Biologicals) was used at a 1:40,000 dilution. 
Goat anti-mouse IgG, rabbit anti-sheep IgG, rabbit anti-goat IgG, and goat anti-rabbit 
IgG were all purchased from Pierce and used at a 1:5,000 dilution.  When necessary, 
membranes were stripped with 0.2 M sodium hydroxide. 
 Real time PCR-  RNA was extracted from cells using Trizol (Invitrogen) 
according to the manufacturer’s protocol.  After incubating with DNaseI for 1 h at 
37oC to remove any residual DNA, the RNA was purified using the RNeasy Mini Kit 
(Qiagen) and reverse transcribed into cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems).  The PCR was carried out using either the 2X 
Taqman Universal PCR mix and FAM-labeled Taqman probes complimentary to 
cSHMT (Hs00541038_m1) and GAPDH (Hs99999905_m1), or the QuantiFast SYBR 
Green PCR Kit (Qiagen) and primers complimentary to Fluc (5’-
ATTTATCGGAGTTGCAGTTGCGCC-3’; 5'-
GCTGCGAAATGCCCATACTGTTGA-3') and Rluc (5'-
AACGCGGCCTCTTCTTATTT-3’; 5'-ATTTGCCTGATTTGCCCATA-3').  PCR 
products were quantified using the Applied Biosystems 7500 Real-Time PCR System. 
 Polysome profile analysis- MCF-7 cells at approximately 80% confluence were 
treated with UVC following the protocol above.  22 h following UV exposure, the 
cells were treated with 50 µg/mL cycloheximide (Sigma) for 30 min at 37oC and 5% 
CO2.  The cells were scraped from the plate and then lysed in polysome extraction 
buffer (10 mM Tris pH 7.5, 10 mM NaCl, 1.5 mM MgCl2, 1% Triton X-100, 1% 
deoxycholate, 2% Tween 20, 1000u Recombinant RNasin® Ribonuclease Inhibitor 
(Promega)) for 10 min on ice.  Nuclei were pelleted by brief centrifugation and the 
resulting supernatant was fractionated through a 10-50% sucrose gradient by 
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ultracentrifugation in a SW41-Ti rotor for 2 h at 36,000 rpm and 4oC.  1 mL fractions 
were collected with a density gradient fractionation system (Brandel) and the 
absorbance at 254 nm was measured continuously as a function of gradient depth.  
RNA was isolated by phenol-chloroform extraction, treated with DNaseI for 1 h at 
37oC, and then reverse transcribed using the SuperScriptIII First-Strand Synthesis 
System (Invitrogen) according to the manufacturer’s protocol.  The PCR was carried 
out using primers specific to cSHMT (Fwd = 5’-
ATGCCCTACAAGGTGAACCCAGAT-3’ and Rev = 5’-
ACCACATGGCAGTGTTCAAATGGG-3’), CUGBP1 (Fwd= 5’-
TCACTTGGAGCCCTGCAGACATTA-3’ and Rev=5’-
AGCAGCATATTGCTGGATACCCGA-3’), and ATF4 (Fwd= 5’-
CCAACAACAGCAAGGAGGATGCCTTCTC-3’ and Rev= 5’-
GGATCATGGCAACGTAAGCAGTGTAGTC-3’).    
 Generation of capped bicistronic mRNA for use in MCF-7 cell transfections- 
The generation of pSP64 polyA DNA templates containing the Renilla and Firefly 
luciferase reporter genes and either the cSHMT 5’UTR, cSHMT 5’UTR and 3’UTR, 
the reverse complement of the cSHMT 5’UTR (Rev UTR), or the mouse cSHMT 
5’UTR is described elsewhere (1).  The DNA templates were linearized with EcoRI 
and purified using the Roche PCR clean-up column.  The templates were transcribed 
using the T7 mMESSAGE mMACHINE kit (Ambion) according to the 
manufacturer’s protocol.  The crude mRNA was treated with DNaseI (Ambion) for 
15 min at 40°C and precipitated in 2 M LiCl at -80°C.  All RNA procedures were 
conducted under RNase-free conditions and all mRNA was stored with Recombinant 
RNasin® Ribonuclease Inhibitor (Promega).  The mRNA was quantified by 
spectrophotometry and its quality verified by electrophoresis.  
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  mRNA transfections-  Cells were cultured in 6-well plates and then treated with 
UVC or nocodazole according to the protocol above.  12 h after UV treatment or 24 h 
after nocodazole treatment, the cells were incubated in Opti-MEM (Invitrogen) 
containing a 1:100 dilution of DMRIE-C transfection reagent (Invitrogen), and 5 
µg/mL bicistronic mRNA (capped and polyadenylyated) for 4 h at 37oC and 5% CO2.  
The Opti-MEM was then replaced with α-MEM or DMEM and the cells incubated for 
an additional 6 h at 37oC and 5% CO2.  Renilla and Firefly Luciferase activity was 
quantified on a Veritas Microplate Luminometer (Turner Biosystems) using the Dual-
Glo Luciferase Assay System (Promega) according to the manufacturer’s protocol. 
siRNA transfections-  MCF-7 cells were grown to approximately 40% 
confluence in 6-well plates.  The cells were transfected with 5 nM of either negative 
control siRNA (Ambion), CUGBP1 siRNA (Qiagen, sense: 
r(GGAACUCUUCGAACAGUAU)dTdT, antisense: 
r(AUACUGUUCGAAGAGUUCC)dCdG), or cSHMT siRNA (Qiagen, sense: 
r(CUAGGCUCUUGCUUAAAUA)dTdT, antisense: 
r(UAUUUAAGCAAGAGCCUAG)dGdG)  using the HiPerFect transfection reagent 
(Qiagen) according to the manufacturer’s instructions.  Following incubation with 
siRNA for 48-55 h at 37o C and 5% CO2, the cells were treated with UVC according to 
the protocol above.  At the indicated time following UV treatment, the cells were 
lysed and subjected to SDS-PAGE/immunoblot analysis to determine knockdown 
efficiency.  
 Immunofluorescence-  MCF-7 cells were grown on sterile coverslips to 
approximately 30% confluence and then exposed to 10,000 µJ/cm2 UV (254 nm) 
according to the protocol above.  22 h following UV treatment, the coverslips were 
incubated in phosphate-buffered saline containing 10 µM DRAQ5 (Biostatus Limited) 
for 5 min at room temperature and then fixed with 100% methanol for 5 min.  After a 
 145
brief wash in phosphate-buffered saline, the coverslips were blocked with phosphate-
buffered saline containing 2% bovine serum albumen and 0.1% Triton X-100.  After 2 
h, the blocking solution was removed and the coverslips incubated in phosphate-
buffered saline containing 2% bovine serum albumen and a 1:250 dilution of mouse 
anti-CUGBP1 (3B1, Santa Cruz Biotechnology) for 2 h at room temperature.  
Following extensive washing with phosphate-buffered saline, the coverslips were 
incubated in phosphate-buffered saline containing 2% bovine serum albumen and a 
1:500 dilution of an Alexa-Fluor 488-conjugated goat anti-mouse IgG secondary 
antibody (Invitrogen) for 1 hour.  The coverslips were then washed extensively with 
phosphate-buffered saline and mounted to slides using Fluoromount-G (Southern 
Biotech).  The cells were visualized using a Leica TCS SP2 confocal microscope at 
the Cornell University Microscopy and Imaging Facility.  
 Comet assay- MCF-7 cells were treated with either negative control siRNA or 
cSHMT siRNA and then exposed to 10,000 µJ/cm2 UVC according to the protocol 
above.  At the indicated times following UV treatment, the cells were scraped from the 
plate.  Half of the cells were subjected to western blot analysis to confirm cSHMT 
knockdown.  The other half were resuspended in α-MEM (Hyclone Laboratories) 
supplemented with 10% DMSO and 20 mM EDTA pH 7.5, dispensed into cryogenic 
tubes, frozen in liquid nitrogen, and stored at -80oC.  
 The cryopreserved cells from above were thawed at room temperature and then 
diluted to a final concentration of 105 cells/mL with phosphate-buffered saline, pH 7.4.  
The diluted cells were then combined 1:10 with 1% low-melting point agarose and 
dispensed onto a CometSlide (Trevigen).  After the agarose solidified, the slides were 
immersed in lysis solution (10% DMSO, 1% Triton X-100, 2.5 M NaCl, 100 mM 
EDTA, 10 mM Tris pH 10.2) for 1-3 h at 4oC.  Following a 10 min incubation in 0.4 
M Tris pH 7.5, the slides were placed in an electrophoresis tank and incubated in 
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alkaline (pH 13) electrophoresis buffer (0.3M NaOH, 1 mM EDTA pH 8.0) for 20 min 
at 4oC to allow for the unwinding of supercoiled DNA.  Electrophoresis was carried 
out at 27 V for 40 min at 4oC.  The slides were then incubated in 0.4 M Tris pH 7.5 for 
15 min, washed for 5 min in 100% ethanol, and dried overnight.  To assess DNA 
damage, the dried slides were flooded with SYBR GoldTM (Invitrogen) and then 
visualized at 20X magnification using a fluorescent microscope (Olympus BX-50) at 
the Cornell University Microscopy and Imaging Facility.  Cells were photographed 
using a QImaging Retiga EXi cooled CCD camera and analyzed using Komet 5.5 
Software (Andor Technology).  The parameters analyzed included % tail DNA (the 
proportion of DNA that has migrated from the nucleoid core), tail length (the distance 
(microns) of DNA migration from the nucleoid core), extent tail moment (% tail DNA 
x tail length/100), and olive tail moment ([tail center of gravity – head center of 
gravity] x % tail DNA/100). The olive tail moment value captures both the smallest 
detectable size of migrating DNA (which is quantified in the comet tail length) and the 
number of strand breaks (quantified by the intensity of DNA in the tail).  The mean 
value from 75 scored cells was taken as an index of damage for a given sample.  
Sensitivity of the assay was established by incubating untreated MCF-7 cells in 0, 50, 
100, or 200 µM hydrogen peroxide for 15 min prior to lysis and then quantifying the 
resulting comets as stated above.  The concordance of each measured parameter in 
relation to hydrogen peroxide concentration (R2) ranged from 0.92 to 0.96. 
 MTT Assay - MCF-7 cells were treated with either negative control siRNA or 
cSHMT siRNA and then exposed to 10,000 µJ/cm2 UVC according to the protocol 
above.  24 h following UV treatment, MTT (thiazolyl blue tetrazolium bromide; 
Sigma) was added to the media (final concentration of MTT = 0.5 mg/mL).  After a 1 
h incubation at 37oC/5% CO2, the media was removed from the cells and the insoluble 
formazan (formed by the reduction of MTT by living mitochondria) was resuspended 
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in DMSO. The absorbance at 550 nm was measured using a Dynex MRXTC II 
microplate reader.   
 Immunoprecipitations- MCF-7 whole cell extracts were incubated for 2 h at 4ºC 
with 40µL of protein A/G conjugated agarose beads (Pierce) to remove nonspecific 
matrix-binding proteins.  The precleared extracts were incubated with 10 µg of either 
sheep IgG (Pierce), affinity purified sheep anti-human cSHMT antibody, or sheep-
anti-human TS antibody (Abcam) overnight at 4ºC.  40µL of the protein A/G agarose 
beads was then added and the reaction was allowed to incubate for 2 h at 4oC.  The 
beads were collected and washed 5 times with lysis buffer (50 mM Tris pH 7.5, 150 
mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 1:100 dilution of Sigma Protease 
Inhibitor Cocktail), and bound proteins were eluted in 2X SDS-PAGE sample buffer 
(160 mM Tris pH 6.8, 20 mM DTT, 4% SDS, 20% glycerol) at 95oC for 10 min.  The 
samples were analyzed by western blotting as described above, except that TrueBlot™ 
(eBioscience, 1:1000 dilution) was used as the secondary antibody to eliminate IgG 
contamination. 
 
Results 
 The expression of cSHMT is induced by UV radiation.  Previously, we have 
shown that cSHMT is rate-limiting for de novo thymidylate biosynthesis during DNA 
replication in MCF-7 cells (28), and that mice lacking cSHMT exhibit elevated levels 
of uracil in their DNA (29).  In this study, the effect of UV radiation on cSHMT 
protein levels was examined to investigate the regulation of nuclear thymidylate 
biosynthesis during DNA repair.  MCF-7 cells were treated with 10,000 µJ/cm2 UVC 
(254 nm).  This dose of UV was not lethal, as 90% of treated cells remained viable 24 
hours after UV exposure compared to 97% of untreated cells (Figure 5.2).  However, 
the dose was sufficient to evoke a stress response.  As anticipated based on previous  
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Figure 5.2.  MCF-7 cells remain viable following 
UV treatment.  The % viability of untreated and 
UV-treated MCF-7 cells was determined by trypan 
blue exclusion 24 h following UV exposure.  The 
data represent the average of three independent 
experiments + standard error. 
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studies (5,20,21,30-32), global protein synthesis was impaired (Figures 5.3A and 
5.3B), p53 protein levels increased (Figure 5.4A), and both p53 and eIF2α became 
phosphorylated in a time-dependent manner following UV exposure (Figure 5.4A), 
indicating that DNA damage had occurred and that cap-dependent protein synthesis 
was suspended.  Western blot analysis of cSHMT protein levels revealed that despite 
the cessation of cap-dependent translation, cSHMT protein levels were increased 12 
and 24 hours following UV treatment (Figure 5.4A).  The increase in cSHMT protein 
levels in response to UV exposure was not specific to MCF-7 cells, as similar results 
were obtained with cervical cancer (HeLa) cells (Figure 5.4B), transformed skin 
fibroblasts (Figure 5.4C) and neuroblastoma (SH-SY5Y) cells (Figure 5.4D).   
 The cSHMT IRES is UV responsive.  CSHMT mRNA levels did not increase 
following UV treatment (Figure 5.5), indicating that the increase in cSHMT protein 
levels may be due to elevated rates of translation.  Consistent with this hypothesis, the 
polysome analysis of untreated (Figure 5.6A) and UV-treated (Figure 5.6B) MCF-7 
cells revealed that cSHMT mRNA continued to be actively translated following UV 
exposure.   Because cellular IRESes are typically responsive to stress stimuli that 
inhibit global cap-dependent translation (25), the effect of UV treatment on cSHMT 
IRES activity was investigated.  Following UV treatment, MCF-7 cells, HeLa cells, 
transformed skin fibroblasts, and SH-SY5Y cells were transfected with bicistronic 
mRNAs containing the cSHMT 5’UTR inserted between the Renilla luciferase (Rluc) 
and Firefly luciferase (Fluc) reporter genes, and the cSHMT 3’UTR located 3’ of the 
Fluc gene (Figure 5.7A).  Whereas expression of the first cistron in this transcript 
(Rluc) is cap-dependent, expression of the second cistron (Fluc) is dependent on IRES 
activity.  The activity of the cSHMT IRES increased significantly in all UV-exposed 
cells compared to unexposed cells as quantified by the Fluc/Rluc ratio (Figure 5.7B).  
Bicistronic mRNAs containing either the reverse (Rev) complement of the cSHMT  
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Figure 5.3.  Nascent protein synthesis decreases following UV treatment.  
(A) MCF-7 cells were treated with 10,000 µJ/cm2 UVC (254 nm).  At the 
indicated times following UV treatment, the cells were pulse-labeled with 
[35S]Met/Cys, and total cell extracts were resolved by SDS-PAGE.  The gel 
was then stained with Coomassie Blue (right panel) to visualize total 
proteins, followed by autoradiography (left panel) to detect newly 
synthesized proteins.  (B) Equal amounts of protein from (A) were 
precipitated with TCA, and 35S incorporation was quantified in a scintillation 
counter.  The counts per minute recorded for the 0 h sample was given a 
value of 1.0.  The data represent the average of three independent TCA 
precipitations + standard error. 
 151
Figure 5.4.  Effect of UVC on protein levels.  (A) MCF-7 cells, (B) HeLa 
cells, (C) transformed skin fibroblasts, and (D) SH-SY5Y cells were 
treated with 10,000 µJ/cm2 UVC (254 nm).  At the indicated times 
following UV treatment, total protein lysates were prepared and resolved 
by SDS-PAGE.  Protein levels were determined by immunoblotting using 
antibodies against phosphorylated p53, p53, phosphorylated eIF2α, eIF2α, 
cSHMT, TS, CUGBP1, H ferritin, and hnRNP H.  GAPDH serves as a 
control for equal protein loading. 
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Figure 5.5.  UV treatment does not increase cSHMT mRNA 
levels.  MCF-7 cells were treated with 10,000 µJ/cm2 UVC (254 
nm).  At the indicated times following UV treatment, total RNA 
was extracted from the cells and reverse transcribed into cDNA.  
Relative cSHMT and GAPDH mRNA levels were determined by 
real time PCR. The data represent the average of three 
independent experiments + standard error. 
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Figure 5.6.  cSHMT mRNA remains associated with polysomes following UV 
exposure.  The polysome profile of (A) untreated and (B) UV-irradiated MCF-7 
cells was recorded 22 h following UV treatment.  The positions of different 
ribosomal species, as determined by the optical density (OD) at 254 nm, are 
indicated.  Total RNA was extracted from each fraction, and cSHMT mRNA was 
detected by reverse-transcription PCR.  CUGBP1 mRNA, which is not known to 
contain an IRES, and ATF4 mRNA, which is known to be translated under 
conditions that induce eIF2α phosphorylation (5,6), are shown for comparison.
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Figure  5.7.  UV treatment results in an increase in cSHMT IRES 
activity.  (A) The bicistronic construct used to quantify cSHMT IRES 
activity.  It consists of (in the 5’ to 3’ direction) a cap analog, the Renilla 
luciferase (Rluc) reporter gene followed by three sequential in-frame stop 
codons, the human cSHMT 5’UTR which contains the IRES element, the 
Firefly luciferase (Fluc) reporter gene, the human cSHMT 3’UTR which was 
shown to stimulate cSHMT IRES activity (1), and a 30 nucleotide poly(A) 
tail. (B)  Untreated (light bars) and UV-treated (dark bars) cells were 
transiently transfected with the bicistronic construct in (A).  22 h following 
treatment, Fluc and Rluc activities were quantified.  The relative ratio of total 
Fluc activity divided by total Rluc activity in untreated cells was given a 
value of 1.0.  The data represent the average of three independent 
experiments + standard error.  (C) Untreated (light bars) and UV-treated 
(dark bars) MCF-7 cells were transiently transfected with either the 
bicistronic construct containing the human cSHMT 5’UTR or bicistronic 
constructs where the human cSHMT 5’UTR was replaced with either the 
reverse (Rev) complement of the human cSHMT 5’UTR or the mouse 
cSHMT 5’UTR.  None of the bicistronic constructs used in this experiment 
contained the cSHMT 3’UTR.  IRES activity is reported as the ratio of total 
Fluc activity divided by total Rluc activity as measured 22 h after UV 
treatment.  The data represent the average of three independent experiments 
+ standard error.  (D) MCF-7 cells were treated with 10,000 µJ/cm2 UVC 
and transiently transfected with the bicistronic mRNA in (A).  22 h following 
UV treatment, total RNA was extracted from the cells and reverse 
transcribed into cDNA.  Rluc and Fluc mRNA levels were determined by 
real time PCR. The data represent the average of three independent 
experiments + standard error.   
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5’UTR or the mouse cSHMT 5’UTR, both of which have been shown previously to 
lack IRES activity (1), were not stimulated by UV exposure (Figure 5.7C).  The results 
from these control bicistronic mRNAs demonstrate that cSHMT IRES activity is 
associated only with the human 5’UTR, and indicate that ribosomal re-initiation 
cannot account for the induction of Fluc translation following UV exposure.  Real 
time PCR analysis of Fluc and Rluc RNA levels following the transfections revealed 
that degradation of the bicistronic construct is likewise not responsible for the 
induction of Fluc translation upon UV treatment (Figure 5.7D).   
 The UV-induced increase in cSHMT IRES activity is mediated by H ferritin, 
hnRNP H2, and CUGBP1. CSHMT IRES activity has previously been shown to be 
mediated by H ferritin (1) the ITAFs hnRNP H2 (Chapter 3) and CUGBP1 (1).  It is 
known that the regulation of many cellular IRESes during stress conditions depends 
on a change in concentration and/or subcellular location of ITAFs.  For example, 
during apoptosis, an increase in polypyrimidine tract binding protein levels correlates 
with the activity of apoptotic IRESes (33); the genotoxic-stress-induced IRES-
mediated translation of BAG-1 results from the relocalization of the BAG-1 ITAFs 
from the nucleus to the cytoplasm (34); and the relocalization of hnRNPA1 from the 
nucleus to the cytoplasm following osmotic shock inhibits XIAP IRES activity (35).  
Thus, given the significant role that H ferritin, hnRNP H2, and CUGBP1 play in the 
stimulation of cSHMT IRES activity, their concentration and/or subcellular 
localization following UV treatment was investigated. 
 Several transcription factors are activated by UV-induced DNA damage.  
Among them is NFκB (36), a known activator of H ferritin expression (37).  In 
agreement with the UV-induced activation of NFκB, western blot analysis of H 
ferritin protein levels in MCF-7 cells, HeLa cells, transformed skin fibroblasts, and 
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SH-SY5Y cells revealed a time-dependent increase following UV treatment (Figure 
5.4A-D).      
 Western blot analysis of hnRNP H1/H2 protein levels in all four cell lines also 
revealed a time-dependent increase following UV treatment (Figure 5.4A-D).  The 
increase in hnRNP H2 protein levels occurred primarily in the cytoplasm (Figure 
5.8A).  This finding is consistent with the previously reported results of siRNA 
knockdown experiments, which showed that hnRNP H2 is essential for IRES 
activation by UV (Chapter 3, Figure 3.6).  
 In contrast to H ferritin and hnRNP H2, CUGBP1 protein levels decreased 
following UV exposure in the majority of the cell types tested (Figure 5.4A-D).  
However, given that CUGBP1 is primarily a nuclear protein under normal cellular 
conditions (38,39), we hypothesized that CUGBP1 cellular localization changes, 
thereby enabling increased cSHMT IRES activity following UV treatment.  To test this 
hypothesis, we determined the nuclear versus cytoplasmic distribution of CUGBP1 in 
MCF-7 cells by western blot analysis (Figure 5.8A) and immunofluorescence (Figure 
5.8B) 22h following UV exposure.  Both methods showed that CUGBP1 protein levels 
increase in the cytoplasm and decrease in the nucleus following UV treatment.  
CUGBP1 was also shown to be essential for IRES activation by UV.  Treatment of 
MCF-7 cells with CUGBP1 siRNA depleted CUGBP1 protein levels by 90% 
compared to cells treated with negative control siRNA (Figure 5.8C), and reduced 
cSHMT protein levels (Figure 5.8C) and IRES activity (Figure 5.8D) in UV-treated 
cells by 50% compared to levels in cells treated with negative control siRNA.  
CUGBP1 depletion had the greatest impact on UV-activated IRES activity when the 
cSHMT 3’UTR was present in the bicistronic construct (Figure 5.8D).  Previously, we 
have shown that the cSHMT 3’UTR is required for CUGBP1 activation of the IRES 
(1).  These data indicate that the increase in H ferritin and hnRNP H2 expression,  
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Figure 5.8.  Exposure to UV radiation results in the cytoplasmic 
accumulation of CUGBP1. (A) Nuclear (NE) and cytoplasmic (CE) extracts 
were isolated from untreated and UV-treated MCF-7 cells 22 h after UV 
exposure.  Whole cells extracts (WCE) were also obtained from the same 
samples.  All extracts were run side-by-side on an SDS gel and subjected to 
immunoblotting using an anti-CUGBP1, anti-H ferritin, or anti-hnRNP H 
antibody.  p53 is shown as a control for UV treatment.  GAPDH is shown as 
a control to demonstrate that the nuclear fractions are free of cytoplasmic 
contamination.  Lamin A is shown as a control to demonstrate that the 
cytoplasmic fractions are free of nuclear contamination.  Both GAPDH and 
Lamin A serve as controls for equal protein loading. (B) 
Immunofluorescence was used to determine CUGBP1 localization in 
untreated and UV-treated MCF-7 cells 22 h after UV exposure.  CUGBP1 
was visualized with Alexa Fluor 488 (green), and the nucleus was visualized 
with DRAQ5 (red).  The right column is a merge of the green and red 
channels.  (C) MCF-7 cells were transfected with negative control siRNA or 
CUGBP1 siRNA and then treated with UV.  22 h after UV treatment, 
CUGBP1, cSHMT, H ferritin, and hnRNP H protein levels were visualized 
by western blotting.  GAPDH serves as a control for equal protein loading.  
(D) The activity of the cSHMT IRES was quantified as the Fluc/Rluc ratio in 
MCF-7 cells treated with negative control siRNA (light bars) or CUGBP1 
siRNA (dark bars).  Cells were transfected with biscistronic mRNA 
containing or lacking the cSHMT 3’UTR in the presence or absence of UVC 
exposure.   For each experimental condition, values obtained from negative 
control siRNA-treated cells were given a relative value of 1.0.  The data 
represent the average of three independent experiments + standard error.  The 
* and ** represent statistical significance (p= 0.04 and p=0.002, respectively) 
as determined by Student’s t-test.
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combined with the relocalization of CUGBP1 to the cytoplasm, are responsible for the 
UV-mediated increase in cSHMT IRES activity. 
 The increase in cSHMT levels is independent of cell cycle.  The increase in 
cSHMT IRES activity could result directly from UV exposure, or result from UV-
induced inhibition of the cell cycle.  Indeed, 24 hours following UV exposure, MCF-7 
cells exhibited cell cycle arrest in the G2/M phase (compare Figures 5.9A and 5.9B).  
Many cellular IRESes are known to be activated during G2/M when cap-dependent 
translation is inhibited (40-42).  To determine if the enhanced levels of cSHMT 
protein resulted directly from UV treatment or resulted from a UV-induced G2/M cell 
cycle block, MCF-7 cells were treated with nocodazole, and changes in cSHMT IRES 
activity, protein expression, and protein localization were monitored.  Like UV, 
nocodazole arrests cells in the G2/M phase of the cell cycle; but whereas UV acts by 
causing DNA damage, nocodazole acts by disrupting microtubules.  Following 
nocodazole treatment, 74% of the cells were arrested in the G2/M phase of the cell 
cycle (Figure 5.9C) compared to 24% following UV treatment (Figure 5.9B).  
However, nocodazole treatment did not affect cSHMT IRES activity (Figure 5.10A), 
or cSHMT, H ferritin, or hnRNP H protein levels (Figure 5.10B).  As in the case with 
UV-treatment, CUGBP1 protein levels decreased in response to nocodazole treatment 
(Figure 5.10B), but there was no relocalization from the nucleus to the cytoplasm 
(Figure 5.10C).  These results demonstrate that the increase in cSHMT protein levels 
following UV treatment was not the result of cell-cycle arrest at G2/M and raised the 
possibility that cSHMT, through its involvement in de novo thymidylate biosynthesis, 
plays a role in the DNA synthesis step of NER. 
 cSHMT enhances genome stability following UV exposure.  To test the 
hypothesis that cSHMT is involved in the repair of UV-induced DNA damage, we 
determined the impact of cSHMT depletion (Figure 5.11A) on genome stability  
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Figure 5.9.  Cell cycle profile of UV and nocodazole-treated cells.  MCF-7 
cells were treated with either 10,000 µJ/cm2 UVC (254 nm) or 60 ng/mL 
nocodazole.  24 h following treatment, cell cycle analysis was carried out by 
fluorescence-activated cell sorting as described in Materials and Methods.  
(A) Untreated cells.  (B) UVC-treated cells.  (C) Nocodazole-treated cells. 
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Figure 5.10.  Nocodazole treatment does not produce the same effects 
as UV radiation.  (A)  MCF-7 cells were treated with either vehicle 
(DMSO) or 60 ng/mL nocodazole for 24 h and then transiently transfected 
with the bicistronic mRNA in Figure 5.7A.  The ratio of Fluc/Rluc in 
DMSO-treated cells was given a value of 1.0.  The data represent the 
average of three independent experiments + standard error. (B) Total 
protein lysates were prepared from untreated and nocodazole-treated cells 
and resolved by SDS-PAGE.  Protein levels were determined by 
immunoblotting using antibodies against cSHMT, TS, CUGBP1, H ferritin, 
and hnRNP H.  GAPDH serves as a control for equal protein loading. (C) 
Nuclear (NE) and cytoplasmic (CE) fractions were also isolated from these 
cells and subjected to immunoblotting using an anti-CUGBP1 antibody.  
GAPDH is shown as a control to demonstrate that the nuclear fractions are 
free of cytoplasmic contamination.  Lamin A is shown as a control to 
demonstrate that the cytoplasmic fractions are free of nuclear 
contamination.  Both GAPDH and Lamin A serve as controls for equal 
protein loading. 
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Figure 5.11.  CSHMT is involved in the repair of UV-induced DNA damage.  
MCF-7 cells were treated with negative control siRNA (light bars) or cSHMT 
siRNA (dark bars) for 55 h and then exposed to UV radiation (245 nm).  At the 
indicated times following UV treatment, the cells were harvested and divided into 
two samples.  One sample was used for immunoblotting to ensure the knockdown 
of cSHMT, and the other sample was used in the comet assay to determine DNA 
damage, or in the MTT assay to determine cell viability.  (A) A representative 
western blot showing cSHMT and TS protein levels in cells treated with either the 
negative control siRNA or the cSHMT siRNA.  GAPDH serves as a control for 
equal protein loading.  (B) For the comet assay, single cells were embedded in 
agarose, lysed, and subjected to electrophoresis.  The DNA content of each cell 
was visualized using SYBR Gold.  The panels are representative images of (from 
left to right) a cell with little DNA damage, a cell with an intermediate amount of 
DNA damage, and a cell with extensive DNA damage.  (C-F)  The DNA content 
of the cells was quantified using Komet 5.5 Software.  The data represent the 
average of three independent experiments + standard error.  Each experiment was 
performed in duplicate, and 75 cells were analyzed per experiment per time point.  
The * represents statistical significance (p<0.05) at a given time point as 
determined by Student’s t-test.  (C) % tail DNA=the proportion of DNA that has 
migrated from the nucleoid core (D) extent tail moment=% tail DNA x tail 
length/100 (E) olive tail moment =(tail center of gravity – head center of gravity) x 
% tail DNA/100 (F) tail length=the distance (microns) of DNA migration from the 
nucleoid core.  (G) For the MTT assay, the production of formazan by living 
mitochondria was measured in negative control siRNA-treated cells (light bars) 
and cSHMT siRNA-treated cells (dark bars) 24 h following UV treatment by 
recording the absorbance at 550 nm.  The absorbance from non-irradiated, 
negative control siRNA-treated cells was given a value of 100%.  The results 
represent the average of four independent experiments + standard error.  The * 
indicates statistical significance (p=0.0002) as determined by Student’s t-test.   
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following UV treatment using the comet assay.  The assay involves the use of 
electrophoresis to separate intact DNA from damaged DNA, which forms a “comet” 
(Figure 5.11B).  The head of the comet represents intact DNA, and DNA containing 
strand breaks comprises the comet tail.  Four different parameters were calculated for 
each comet as defined in Materials and Methods: % tail DNA, extent tail moment, 
olive tail moment, and tail length.  All parameters are directly proportional to the 
number of DNA strand breaks.  Prior to UV treatment, cSHMT depletion did not 
affect any of the comet assay parameters, indicating that cSHMT did not influence 
DNA integrity prior to UV exposure.  Following UV exposure, cSHMT depletion 
resulted in increased levels of DNA damage compared to the control cells for each 
comet assay parameter measured (Figure 5.11C-F).  The increased amount of DNA 
damage in the cSHMT depleted cells correlates with the reduced viability of these 
cells relative to control cells following UV treatment (Figure 5.11G), and supports a 
role for cSHMT in the repair of UV-induced DNA damage.   
 cSHMT and TS localize to the nucleus in response to UV treatment.  De novo 
thymidylate biosynthesis occurs in both the cytoplasm and the nucleus (Figure 5.1).  
Nuclear thymidylate biosynthesis is enabled by the SUMO-dependent nuclear import 
of cSHMT and TS (15,16).  An increase in SUMOylation in response to UV treatment 
has previously been reported for several proteins involved in the cellular stress 
response including TIP60 (43), XPC (44) and DJ-1 (45).  Immunoprecipitation of 
cSHMT and TS from untreated and UV-treated MCF-7 whole cell extract revealed 
that the SUMOylation of these proteins is likewise increased in response to UV 
radiation (Figures 5.12A and 5.12B).  These findings are supported by an increase in 
the amount of cSHMT and TS in the nucleus of UV-treated cells (Figure 5.12C).  In 
the case of TS, increased nuclear concentration occurs despite an overall decrease in 
protein levels (Figure 5.4A and Figure 5.12C).   
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Figure 5.12.  CSHMT and TS SUMOylation and nuclear 
localization increase in response to UV treatment.  (A) cSHMT and 
(B) TS were immunoprecipitated from untreated and UV-treated MCF-
7 whole cell extracts 22 h after UV exposure.  Immunoblotting was 
performed on the immunoprecipitates using antibodies against SUMO-
1, cSHMT, and TS.  The IgG IP (lane 1) serves as control for non-
specific binding.  (C) Whole cell (WCE), nuclear (NE), and 
cytoplasmic (CE) fractions were isolated from untreated and UV-
treated MCF-7 cells 22 h after UV exposure.  All extracts were 
resolved by SDS-PAGE and subjected to immunoblotting using an 
anti-cSHMT or anti-TS antibody.  GAPDH is shown as a control to 
demonstrate that the nuclear fractions are free of cytoplasmic 
contamination.  Lamin A is shown as a control to demonstrate that the 
cytoplasmic fractions are free of nuclear contamination.  Both GAPDH 
and Lamin A serve as controls for equal protein loading. 
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Discussion 
 The results from this study demonstrate a role for cSHMT and nuclear folate-
dependent thymidylate biosynthesis in the repair of UV-induced DNA damage.  
Previous studies have demonstrated that cSHMT activity is rate limiting in 
thymidylate biosynthesis in MCF-7 cells.  Overexpression of cSHMT in MCF-7 cells 
not only favors the partitioning of folate-derived one-carbon units to thymidylate 
biosynthesis, but also enhances the efficiency of de novo thymidylate biosynthesis 
relative to synthesis through the salvage pathway (14).  Unlike the other enzymes 
involved in folate-mediated one-carbon metabolism, cSHMT expression is not 
ubiquitous.  Although it is expressed primarily in the liver and kidney (46), significant 
amounts of the cSHMT transcript are present in exposed tissues of the body such as 
the eyes and skin (UniGene, National Center for Biotechnology Information; Figure 
5.4C), which are highly susceptible to UV-induced DNA damage.   
 The UV-responsive IRES located within the 5’UTR of the cSHMT transcript 
enables cSHMT to escape the control mechanisms that repress cap-dependent 
translation during cellular stress and to function in DNA repair.  CSHMT is not the 
only protein whose expression is activated by a UV-responsive IRES.  It was recently 
shown that lethal doses of UVC result in an increase in both the IRES activity and 
protein levels of the pro-apoptotic factor Apaf-1 (24).  However, this is the first report, 
to our knowledge, of a UV-responsive IRES that regulates the translation of a protein 
involved in DNA repair.  Whereas the mechanism responsible for the UV-induced 
activation of the Apaf-1 IRES has yet to be determined, we have shown that an 
increase in the concentration of H ferritin and hnRNP H2 and a change the localization 
of CUGBP1 enables the UV-induced IRES-mediated translation of cSHMT. 
 H ferritin has previously been proposed to play an important role in protecting 
cells from UV-induced DNA damage.  By sequestering free iron, it prevents the 
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conversion of UV-generated reactive oxygen species to even more damaging hydroxyl 
radicals via the Fenton reaction (47,48).  Based on the results of this study, we can 
now ascribe an additional role to H ferritin in the DNA damage response, as it 
increases cSHMT expression for NER by stimulating the IRES-mediated translation of 
cSHMT.   
 The mechanisms by which hnRNP H2 protein levels increase and CUGBP1 
relocalizes to the cytoplasm following UV treatment remain to be determined.  
Because global protein synthesis decreases upon UV exposure and because hnRNP H2 
mRNA is not known to contain an IRES, changes in transcription or protein stability 
most likely contribute to the accumulation of hnRNP H2.  Several studies have shown 
that changes in the phosphorylation status of a protein can alter its cellular localization 
(49-52).  As it is known that CUGBP1 is phosphorylated in vivo (53), it is interesting 
to speculate that a UV-responsive kinase is responsible for the translocation of 
CUGBP1 from the nucleus to the cytoplasm. 
 The involvement of cSHMT in DNA repair is supported by the increase in 
cSHMT and TS SUMOylation and nuclear compartmentation in response to UV 
radiation.  Nuclear cSHMT and TS form a complex with Proliferating Cell Nuclear 
Antigen (PCNA), the processivity factor for the NER polymerase (54).  Although 
thymidylate generated in the cytoplasm can freely diffuse into the nucleus, production 
of this deoxyribonucleotide directly at the site of DNA repair may allow for more 
rapid DNA synthesis and enhance the fidelity of the repair polymerase by decreasing 
uracil misincorporation.  As uracil misincorporation can ultimately result in DNA 
strand breaks (7), this would account for the decrease in DNA damage observed in 
UV-treated control cells compared to those depleted of cSHMT (Figure 5.11C-F).  
 In mice, such a response to UV-induced DNA damage is not possible as the 
5’UTR of the murine cSHMT transcript, which shares only 42% sequence identity 
 169
with the human cSHMT 5’UTR, lacks IRES activity (1).  The species specificity of 
the UV-inducible cSHMT IRES suggests that it may have evolved as an adaptive 
response to protect the skin from UV damage.  
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REFERENCES 
 
1. Woeller, C. F., Fox, J. T., Perry, C., and Stover, P. J. (2007) J Biol Chem 
282(41), 29927-29935 
2. Ravanat, J. L., Douki, T., and Cadet, J. (2001) J Photochem Photobiol B 63(1-
3), 88-102 
3. Tornaletti, S., and Hanawalt, P. C. (1999) Biochimie 81(1-2), 139-146 
4. de Laat, W. L., Jaspers, N. G., and Hoeijmakers, J. H. (1999) Genes Dev 13(7), 
768-785 
5. Deng, J., Harding, H. P., Raught, B., Gingras, A. C., Berlanga, J. J., Scheuner, 
D., Kaufman, R. J., Ron, D., and Sonenberg, N. (2002) Curr Biol 12(15), 
1279-1286 
6. Vattem, K. M., and Wek, R. C. (2004) Proc Natl Acad Sci U S A 101(31), 
11269-11274 
7. Hori, T., Ayusawa, D., Shimizu, K., Koyama, H., and Seno, T. (1984) Cancer 
Res 44(2), 703-709 
8. Scott, J. M., and Weir, D. G. (1981) Lancet 2(8242), 337-340 
9. Suh, J. R., Herbig, A. K., and Stover, P. J. (2001) Annu Rev Nutr 21, 255-282 
10. Schirch, V., and Strong, W. B. (1989) Arch Biochem Biophys 269(2), 371-380 
11. Strong, W. B., Tendler, S. J., Seither, R. L., Goldman, I. D., and Schirch, V. 
(1990) J Biol Chem 265(21), 12149-12155 
12. Reed, M. C., Nijhout, H. F., Neuhouser, M. L., Gregory, J. F., 3rd, Shane, B., 
James, S. J., Boynton, A., and Ulrich, C. M. (2006) J Nutr 136(10), 2653-2661 
13. Green, J. M., MacKenzie, R. E., and Matthews, R. G. (1988) Biochemistry 
27(21), 8014-8022 
  171
14. Herbig, K., Chiang, E. P., Lee, L. R., Hills, J., Shane, B., and Stover, P. J. 
(2002) J Biol Chem 277(41), 38381-38389 
15. Woeller, C. F., Anderson, D. D., Szebenyi, D. M., and Stover, P. J. (2007) J 
Biol Chem 282(24), 17623-17631 
16. Anderson, D. D., Woeller, C. F., and Stover, P. J. (2007) Clin Chem Lab Med 
45(12), 1760-1763 
17. Laiho, M., and Latonen, L. (2003) Ann Med 35(6), 391-397 
18. Fritz, G., and Kaina, B. (1999) Mol Cell Biol 19(3), 1768-1774 
19. Bender, K., Blattner, C., Knebel, A., Iordanov, M., Herrlich, P., and 
Rahmsdorf, H. J. (1997) J Photochem Photobiol B 37(1-2), 1-17 
20. Jiang, H. Y., and Wek, R. C. (2005) Biochem J 385(Pt 2), 371-380 
21. Wu, S., Hu, Y., Wang, J. L., Chatterjee, M., Shi, Y., and Kaufman, R. J. (2002) 
J Biol Chem 277(20), 18077-18083 
22. Gebauer, F., and Hentze, M. W. (2004) Nat Rev Mol Cell Biol 5(10), 827-835 
23. Mazan-Mamczarz, K., Galban, S., Lopez de Silanes, I., Martindale, J. L., 
Atasoy, U., Keene, J. D., and Gorospe, M. (2003) Proc Natl Acad Sci U S A 
100(14), 8354-8359 
24. Ungureanu, N. H., Cloutier, M., Lewis, S. M., de Silva, N., Blais, J. D., Bell, J. 
C., and Holcik, M. (2006) J Biol Chem 281(22), 15155-15163 
25. Holcik, M., Sonenberg, N., and Korneluk, R. G. (2000) Trends Genet 16(10), 
469-473 
26. Spriggs, K. A., Stoneley, M., Bushell, M., and Willis, A. E. (2008) Biol Cell 
100(1), 27-38 
27. Bensadoun, A., and Weinstein, D. (1976) Anal Biochem 70(1), 241-250 
28. Oppenheim, E. W., Adelman, C., Liu, X., and Stover, P. J. (2001) J Biol Chem 
276(23), 19855-19861 
  172
29. MacFarlane, A. J., Liu, X., Perry, C. A., Flodby, P., Allen, R. H., Stabler, S. P., 
and Stover, P. J. (2008) J Biol Chem 283(38), 25846-25853 
30. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. (1997) Cell 91(3), 325-334 
31. Latonen, L., Taya, Y., and Laiho, M. (2001) Oncogene 20(46), 6784-6793 
32. Maltzman, W., and Czyzyk, L. (1984) Mol Cell Biol 4(9), 1689-1694 
33. Bushell, M., Stoneley, M., Kong, Y. W., Hamilton, T. L., Spriggs, K. A., 
Dobbyn, H. C., Qin, X., Sarnow, P., and Willis, A. E. (2006) Mol Cell 23(3), 
401-412 
34. Dobbyn, H. C., Hill, K., Hamilton, T. L., Spriggs, K. A., Pickering, B. M., 
Coldwell, M. J., de Moor, C. H., Bushell, M., and Willis, A. E. (2007) 
Oncogene  
35. Lewis, S. M., Veyrier, A., Hosszu Ungureanu, N., Bonnal, S., Vagner, S., and 
Holcik, M. (2007) Mol Biol Cell 18(4), 1302-1311 
36. Legrand-Poels, S., Schoonbroodt, S., Matroule, J. Y., and Piette, J. (1998) J 
Photochem Photobiol B 45(1), 1-8 
37. Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., 
Jayawardena, S., De Smaele, E., Cong, R., Beaumont, C., Torti, F. M., Torti, 
S. V., and Franzoso, G. (2004) Cell 119(4), 529-542 
38. Timchenko, L. T., Miller, J. W., Timchenko, N. A., DeVore, D. R., Datar, K. 
V., Lin, L., Roberts, R., Caskey, C. T., and Swanson, M. S. (1996) Nucleic 
Acids Res 24(22), 4407-4414 
39. Michalowski, S., Miller, J. W., Urbinati, C. R., Paliouras, M., Swanson, M. S., 
and Griffith, J. (1999) Nucleic Acids Res 27(17), 3534-3542 
40. Cormier, P., Pyronnet, S., Salaun, P., Mulner-Lorillon, O., and Sonenberg, N. 
(2003) Prog Cell Cycle Res 5, 469-475 
41. Pyronnet, S., and Sonenberg, N. (2001) Curr Opin Genet Dev 11(1), 13-18 
  173
42. Sachs, A. B. (2000) Cell 101(3), 243-245 
43. Cheng, Z., Ke, Y., Ding, X., Wang, F., Wang, H., Ahmed, K., Liu, Z., Xu, Y., 
Aikhionbare, F., Yan, H., Liu, J., Xue, Y., Powell, M., Liang, S., Reddy, S. E., 
Hu, R., Huang, H., Jin, C., and Yao, X. (2007) Oncogene  
44. Wang, Q. E., Zhu, Q., Wani, G., El-Mahdy, M. A., Li, J., and Wani, A. A. 
(2005) Nucleic Acids Res 33(13), 4023-4034 
45. Shinbo, Y., Niki, T., Taira, T., Ooe, H., Takahashi-Niki, K., Maita, C., Seino, 
C., Iguchi-Ariga, S. M., and Ariga, H. (2006) Cell Death Differ 13(1), 96-108 
46. Girgis, S., Nasrallah, I. M., Suh, J. R., Oppenheim, E., Zanetti, K. A., Mastri, 
M. G., and Stover, P. J. (1998) Gene 210(2), 315-324 
47. Balla, G., Jacob, H. S., Balla, J., Rosenberg, M., Nath, K., Apple, F., Eaton, J. 
W., and Vercellotti, G. M. (1992) J Biol Chem 267(25), 18148-18153 
48. Stohs, S. J., and Bagchi, D. (1995) Free Radic Biol Med 18(2), 321-336 
49. Habelhah, H., Shah, K., Huang, L., Ostareck-Lederer, A., Burlingame, A. L., 
Shokat, K. M., Hentze, M. W., and Ronai, Z. (2001) Nat Cell Biol 3(3), 325-
330 
50. Xie, J., Lee, J. A., Kress, T. L., Mowry, K. L., and Black, D. L. (2003) Proc 
Natl Acad Sci U S A 100(15), 8776-8781 
51. Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M. H., and Hung, M. C. (2001) 
Nat Cell Biol 3(3), 245-252 
52. van der Houven van Oordt, W., Diaz-Meco, M. T., Lozano, J., Krainer, A. R., 
Moscat, J., and Caceres, J. F. (2000) J Cell Biol 149(2), 307-316 
53. Timchenko, N. A., Wang, G. L., and Timchenko, L. T. (2005) J Biol Chem 
280(21), 20549-20557 
54. Anderson, D. D., and Stover, P. J. (Unpublished Results)  
174 
CHAPTER 6 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Part I: Abstract 
Cytoplasmic serine hydroxymethyltransferase (cSHMT) is a key regulator of 
folate-mediated one-carbon metabolism.  By preferentially directing one-carbon units 
toward the synthesis of thymidylate and inhibiting methionine synthesis, cSHMT 
decreases uracil content in DNA and impairs cellular methylation reactions.  The 5’ 
untranslated region (UTR) of the cSHMT transcript contains an internal ribosome 
entry site (IRES) that regulates cSHMT expression.  Although it had previously been 
shown that the cSHMT 3’UTR and the proteins CUG-binding protein 1 (CUGBP1) 
and heavy chain ferritin (H ferritin) influence the IRES-mediated translation of 
cSHMT, the mechanism by which they act and the biological function of the cSHMT 
IRES had not yet been determined.  The studies conducted in Chapters 3-5 were 
designed to 1) elucidate the interactions among the 5’UTR, 3’UTR, poly(A) tail, 40S 
ribosomal subunit, and CUGBP1 that contribute to cSHMT IRES activity, 2) 
investigate the role of H ferritin in cSHMT IRES-mediated translation, and 3) 
determine physiological significance of the cSHMT IRES.  The following chapter 
provides a comprehensive summary of the data generated from these studies and 
proposes a model for the UV-induced IRES-mediated translation of cSHMT that is 
consistent with the experimental results.  It also discusses the knowledge gaps that still 
remain in our understanding of the mechanism and physiological function of cSHMT 
IRES activity and suggests experiments that can be conducted to address them.    
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Part II: Summary of Results 
 
CUGBP1 and hnRNP H2 are cSHMT ITAFs   
 The data presented here expand upon the previously reported finding that 
CUGBP1 stimulates IRES activity when the 3’UTR of cSHMT is present in the 
transcript (1) by investigating the interaction between CUGBP1 and the cSHMT 
mRNA.  CUGBP1 is shown to bind directly to the 3’UTR of cSHMT both in vitro and 
in UV-treated cells.  Evidence generated through the use of 3’UTR truncation mutants 
indicates that this binding occurs between nucleotides 157 and 200.  CUGBP1 is also 
shown to interact with the cSHMT 5’UTR both in vitro and in UV-treated cells, 
although in this case, the interaction occurs via an auxiliary factor rather then direct 
mRNA binding.  The results of the binding studies, combined with those from the 
functional experiments (1), enable CUGBP1 to be classified as a novel IRES trans-
acting factor (ITAF). 
 The experiments in this report also identify and characterize a second novel 
ITAF, heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2).  hnRNP H2 interacts 
with CUGBP1 in an RNA-independent manner.  It binds directly to the 5’UTR of 
cSHMT both in vitro and in UV-treated cells, and interacts with the 3’UTR of cSHMT 
in the presence of CUGBP1.  Evidence generated through the use of truncation 
mutants indicates that the binding of hnRNP H2 to the 5’UTR occurs between 
nucleotides 105 and 114.  Like CUGBP1, hnRNP H2 stimulates the IRES-mediated 
translation of cSHMT only when the 3’UTR is included in the transcript.  
 
CUGBP1 and hnRNP H2 Functionally Replace the Poly(A) Tail of the Transcript 
 Translation, both cap-dependent and IRES-mediated, is thought to occur by a 
“closed loop” mechanism whereby interactions between eIF4G, poly(A)-binding 
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protein (PABP), and the poly(A) tail result in circularization of the transcript 
(reviewed in (2)).  However, the studies presented here provide compelling evidence 
that both the poly(A) tail and PABP are dispensable for cSHMT IRES-mediated 
translation when the cSHMT 3’UTR, CUGBP1, and hnRNP H2 are present.  In the 
absence of any one of these factors, PABP-depletion or the removal of the poly(A) tail 
of the mRNA results in an approximately 50% decrease in the IRES-mediated 
translation of cSHMT.   
 
cSHMT IRES-Mediated Translation Proceeds by a “Land and Scan” Mechanism 
 While the mechanism of the IRES-mediated translation of cSHMT is unique in 
that it does not require either PABP or the poly(A) tail for maximal activity, the 
recruitment of the 40S ribosomal subunit to the initiation codon proceeds in a more 
conventional manner.  Consistent with a “land and scan” mechanism whereby the 40S 
ribosomal subunit binds upstream of the initiation codon and then migrates in a 5’-3’ 
direction until AUG recognition occurs, the data presented here show that ribosome 
scanning begins between nucleotides 103 and 118 of the cSHMT 5’UTR and requires 
the helicase eIF4A.  
   
H Ferritin is Not a cSHMT ITAF, but it Regulates IRES Activity 
 It had previously been suggested that there is another cSHMT ITAF in addition 
to CUGBP1 and hnRNP H2– heavy chain ferritin (H ferritin) (1).  However, the 
results from these studies do not support this hypothesis.  H ferritin does not bind to 
either of the cSHMT UTRs in vitro and cannot be detected in polysomal fractions.  
Although H ferritin does not function as an ITAF, it does stimulate the IRES mediated 
translation of cSHMT in an indirect manner.  The indirect effect of H ferritin on IRES 
activity does not involve the poly r(C) binding protein, changes in the labile iron pool, 
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or changes in CUGBP1 or hnRNP H2 protein levels or nuclear localization.  Rather, H 
ferritin interacts with both CUGBP1 (1) and hnRNP H2 (18) and may function in the 
assembly of the initiation complex. 
 
Tbe cSHMT IRES and the Factors that Influence its Activity are UV-Responsive 
 Cellular IRESes allow for the continued expression of a protein during certain 
physiological or stress conditions that inhibit cap-dependent translation (3).  The data 
presented here indicate that for cSHMT, one of these conditions is exposure to UV 
radiation.  UV radiation is shown to increase cSHMT protein levels despite a 
significant reduction in global protein synthesis.  Although this increase could 
potentially be due in part to enhanced protein stability, the finding that cSHMT 
mRNA remains associated with polysomes following UV treatment argues that 
translation also plays a role.  In agreement with this, cSHMT IRES activity is shown 
to increase approximately four-fold upon UV exposure.   
cSHMT is not the only protein whose expression is elevated following 
treatment with UV radiation.  H ferritin protein levels also increase as do the 
cytoplasmic concentrations of the ITAFs hnRNP H2 and CUGBP1, both of which are 
primarily located in the nucleus under normal cellular conditions.  In the case of 
CUGBP1, the increase in the cytoplasmic levels of the protein is concurrent with a 
large reduction in the amount of CUGBP1 in the nucleus, resulting in an overall 
decrease in protein abundance. 
  
UV Increases the SUMOylation and Nuclear Localization of cSHMT and TS 
cSHMT is post-translationally modified by the small ubiquitin-like modifier 
(SUMO) (4).  The SUMOylation of cSHMT results in its import into the nucleus (4) 
where it forms a complex with SUMOylated thymidylate synthase (TS) and 
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proliferating cell nuclear antigen (PCNA) at the site of DNA replication or repair (5).  
The experiments conducted in this report show that cSHMT and TS SUMOylation are 
enhanced following UV exposure, and that there is an increase in the amount of both 
proteins in the nucleus of UV-treated cells. 
  
cSHMT Reduces the Levels of UV-Induced DNA Damage 
 Thymidine nucleotides are required for faithful DNA repair.  Because cSHMT 
had previously been shown to regulate de novo thymidylate synthesis (6,7), and 
because the data presented here show that cSHMT expression is UV-responsive, 
experiments were conducted to determine the contribution of cSHMT to the repair of 
UV-induced DNA damage.  The results show that upon the siRNA-mediated 
knockdown of cSHMT there is an increase in the number of UV-induced DNA strand 
breaks and a parallel decrease in cell viability.  
 
Part III:  Model for the UV-Induced IRES-Mediated Translation of cSHMT 
 Collectively, the results of the studies presented here allow for the formulation 
of a model for the UV-induced IRES-mediated translation of cSHMT (Figure 6.1).  
Under normal cellular conditions, cSHMT translation proceeds primarily by the 
canonical cap-dependent ribosome scanning mechanism.  This is due to the fact that 
CUGBP1 resides almost exclusively in the nucleus and that there is little hnRNP H2 
present in the cytoplasm.  Following UV exposure, which damages DNA and globally 
inhibits cap-dependent translation, the concentrations of H ferritin and hnRNP H2 
increase, and CUGBP1 relocalizes to the cytoplasm.  hnRNP H2 binds directly to the 
5’UTR of the cSHMT transcript, and, with the aid of H ferritin, interacts with 
CUGBP1, which binds directly to the 3’UTR of the transcript.  The interaction 
between the two cSHMT ITAFs results in the formation of a closed loop and thereby  
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Figure 6.1.  Model for the IRES-mediated translation of cSHMT following 
exposure to UV radiation.  Exposure to UV radiation results in the formation of 
DNA lesions, the inhibition of cap-dependent protein synthesis, the cytoplasmic 
accumulation of hnRNP H2 and H ferritin, and the relocalization of CUGBP1 from 
the nucleus to the cytoplasm.  hnRNP H2 binds to the 5’UTR of cSHMT and  
CUGBP1 binds to the 3’UTR of cSHMT.  The interaction of hnRNP H2 with 
CUGBP1, which may be mediated by H ferritin, circularizes the cSHMT transcript 
and in doing so enhances the rate of IRES-mediated translation.  The protein 
produced from the IRES activity of cSHMT is imported into the nucleus in a 
SUMO-dependent manner where it functions to provide the thymidine nucleotides 
necessary for the repair of UV-induced DNA damage. 
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eliminates the need for the eIF4G-PABP-poly(A) tail interaction.  The 40S ribosomal 
subunit is then recruited to the 5’UTR of cSHMT.  It binds between nucleotides 103 
and 118, and then scans through the remainder of the 5’UTR until the initiation codon 
is reached.  The 60S ribosomal subunit then joins the 40S subunit, and the ribosome 
translates the cSHMT open reading frame.  Once the cSHMT protein is synthesized, it 
becomes SUMOylated, as does TS, and both proteins translocate into the nucleus.  In 
the nucleus, cSHMT and TS interact with PCNA, the processivity factor for the 
nucleotide excision repair (NER) polymerase (5).  This allows for thymidylate 
production directly at the site of DNA repair.   
 
Part III: Future Directions 
 
Verifying the Model 
Although the above is an attractive model for the UV-induced IRES-mediated 
translation of cSHMT, there are a few details that still need to be verified.  The first is 
that the interactions among hnRNP H2, CUGBP1, and the cSHMT UTRs do indeed 
form a closed loop.  Reconstitution experiments can be carried out using recombinant 
hnRNP H2 and CUGBP1 and in vitro transcribed cSHMT mRNA, and the resulting 
complex can be visualized by atomic force microscopy.  Such a procedure has been 
used previously to demonstrate the circularization of mRNA by eIF4E, eIF4G, and 
PABP (8).   
The second hypothesis that needs to be addressed is that H ferritin facilitates 
the interaction between hnRNP H2 and CUGBP1.  This can be tested by fluorescence 
resonance energy transfer (FRET).  WT cells, H ferritin-overexpressing cells, and H 
ferritin knockdown cells can be co-transfected with CFP-tagged hnRNP H2 and YFP-
tagged CUGBP1.  Upon CFP excitation, YFP emission will be detected if the two 
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proteins interact.  The amount of YFP emission can then be quantified.  If H ferritin 
does indeed assist in bringing the two cSHMT ITAFs together, the H ferritin 
overexpressing cells will produce the greatest FRET signal while the H ferritin 
knockdown cells will produce the least.   
 
Mechanism of CUGBP1 Relocalization and hnRNP H2 Upregulation Following UV 
Exposure 
 As discussed in Chapter 5, the mechanisms by which hnRNP H2 protein levels 
increase and CUGBP1 relocalizes to the cytoplasm following UV treatment remain to 
be determined.  However, it is hypothesized that changes in transcription or protein 
stability contribute to the accumulation of hnRNP H2, and that changes in 
phosphorylation status alter the cellular location of CUGBP1.  Protein stability and 
hnRNP H2 mRNA levels can be ascertained by carrying out pulse-chase and real-time 
PCR experiments, respectively.  Insight into the contribution of phosphorylation status 
to CUGBP1 relocalization can be gained by immunoprecipitating CUGBP1 from the 
nuclear and cytoplasmic fractions of untreated and UV-treated cells and conducting an 
immunoblot analysis using antibodies specific for phosphorylated serine, threonine, 
and tyrosine residues.  If it is found that transcriptional upregulation and kinase 
activation do indeed play a role, candidate transcription factors and kinases can then 
either be over-expressed in untreated cells or knocked down in UV-treated cells to 
determine which are responsible for the increase in hnRNP H2 protein levels and 
CUGBP1 relocalization.  
 
Canonical Initiation Factor Requirements and Recruitment 
 The canonical initiation factors necessary for IRES-mediated translation vary 
from transcript to transcript.  The IRES-mediated translation of the 
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encephalomyocarditis virus requires all of the canonical initiation factors except eIF4E 
(9,10); the IRES-mediated translation of L-myc involves the entire eIF4F complex 
(composed of eIF4E, eIF4A, and eIF4G) as well as eIF3 and the ternary complex 
(composed of eIF2, GTP, and the initiator Met-tRNA) (11); and the IRES-mediated 
translation of the hepatitis C and cricket paralysis viruses is eIF-independent (12-14).  
Although it has been demonstrated that the IRES-mediated translation of cSHMT can 
function in the absence of eIF4E binding (1) but not upon the inhibition of eIF4A, it is 
not known if eIF4G, eIF3, and eIF2 are necessary for the cap-independent translation 
of this transcript.  The requirement for eIF4G can be tested by reducing eIF4G protein 
levels using an RNAi approach.  Cells in which eIF4G has been knocked down can 
then be transfected with RNAi-resistant eIF4G which harbors a mutation in its eIF3-
binding site to determine the need for eIF3.  A dominant negative mutant of eIF2α 
and/or salubrinal, a selective inhibitor of complexes that dephosphorylate eIF2α, can 
be used to probe the involvement of the ternary complex.  Since the cSHMT IRES has 
been shown to be active under conditions where eIF2α is phosphorylated, it is 
hypothesized that neither the dominant negative mutant nor salubrinal will have an 
effect on IRES-mediated translation. 
 Once it is revealed what canonical initiation factors play a role in the IRES-
mediated translation of cSHMT, the next step will be to determine how these factors 
are recruited to the 5’UTR.  As discussed in Chapter 3, the finding that the ribosome 
scanning start site (between nucleotides 103 and 118) overlaps with the hnRNP H2 
binding site (between nucleotides 105 and 114) suggests that the hnRNP H2-CUGBP1 
complex may serve as a guide to recruit the initiation complex.  It could do so either 
by interacting with one or more of the canonical initiation factors or by acting as a 
chaperone to expose the RNA structure to ribosome binding.  To test the hypothesis 
that the hnRNP H2-CUGBP1 complex is recruiting the ribosome to the cSHMT 
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5’UTR, the hnRNP H2 binding site can be shifted from nucleotides 105-114 to a 
position near one of the upstream engineered AUGs in Figure 3.8C (for example 
between nucleotides 55 and 64).  The experiment used to locate the “landing” spot of 
the ribosome within the cSHMT 5’UTR (Chapter 3) can then be repeated to determine 
if moving the hnRNP H2 binding site also shifts the point of ribosome entry.      
 
The Physiological Significance of Small Changes in cSHMT Protein Levels 
One criticism of the data presented here has been that none of the results show 
large changes in cSHMT expression and thus may have little physiological impact.  
For example, when H ferritin (1), CUGBP1, or hnRNP H2 protein levels are reduced 
by 50%, 90%, and 80%, respectively, cSHMT protein levels and IRES activity only 
decrease by approximately 30%, 50%, and 33%, respectively.  Although this may be 
partially due to the fact that all three factors were never knocked down concurrently, 
UV-treated cells, which have increased concentrations of H ferritin, CUGBP1, and 
hnRNP H2 in the cytoplasm, exhibit, on average, only a four-fold increase in cSHMT 
protein levels.   
In rebuttal to this criticism, recent studies have shown that small changes in the 
expression of cSHMT can have significant physiological consequences.  SHMT1 +/- 
embryos from dams fed a folate- and choline-deficient diet exhibit exencephaly, a fatal 
neural tube defect (NTD) characterized by the absence of the cranial bones and 
protrusion of the brain.  When combined with the splotch mutation, which is known to 
cause the NTD spina bifida, the disruption of a single SHMT1 allele significantly 
exacerbates NTD frequency and severity (15).  The livers of SHMT1 +/- mice also 
show increased levels of uracil misincorporation into their DNA (16).  Although this 
alone does not produce a phenotype, the disruption of a single SHMT1 allele 
significantly increases the occurrence of intestinal and colorectal tumors when 
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combined with either a mutation in the APC gene or exposure to the carcinogen 
azoxymethane (17).  Additional experiments are currently underway to determine the 
physiological impact of small changes in cSHMT expression in response to UV 
radiation.  Hairless WT and SHMT1+/- mice will be exposed to UV and monitored for 
tumor formation.  It is hypothesized that the SHMT1+/- mice will exhibit increased 
cancer incidence compared to their irradiated WT counterparts. 
 
 The Physiological Significance of Small Changes in cSHMT Nuclear Localization 
In addition to the reported changes in cSHMT protein levels, concerns have 
also been raised about the impact of the small (approximately 2-fold) increase in the 
SUMOylation and nuclear localization of cSHMT that was observed following UV 
treatment.  To address these concerns, work is currently underway to produce a mouse 
which harbors K38R and K39R mutations in the cSHMT enzyme.  These mutations 
have previously been shown to inhibit cSHMT SUMOylation and decrease the nuclear 
localization of the protein in vitro and in cell culture models (4,5).  Hairless WT and 
SHMT1+/K38R, K39R mice can then be exposed to UV radiation and monitored for the 
development of skin cancer. 
 
The Physiological Significance of Small Changes in cSHMT IRES Activity 
Although transgenic mice are useful in determining the physiological relevance 
of small changes in cSHMT protein levels and nuclear localization in response to UV-
induced DNA damage, they cannot directly address the biological significance of 
changes in IRES-mediated translation because murine cSHMT lacks IRES activity (1).  
In the human population, there are two single nucleotide polymorphisms (SNPs), one 
at nucleotide 47 (rs3783) and one at nucleotide 412 (rs9902011), that exist in linkage 
disequilibrium within the 3’UTR of cSHMT.  cSHMT transcripts that contain a C at 
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nucleotide 46 and a G at nucleotide 412 exhibit a 60% reduction in UV-induced IRES-
mediated translation compared to transcripts that contain a G at nucleotide 47 and an 
A at nucleotide 412 (18).  Although the mechanism by which these SNPs affect IRES 
activity is not known, the SNPs can be exploited to investigate the contribution of 
cSHMT cap-independent translation to protection against skin cancer.  A case-control 
study can be conducted using healthy individuals and those that have been diagnosed 
with skin cancer.  The 3’UTRs of all participants in the study can be genotyped and 
the odds ratio calculated to assess the correlation between the SNPs and UV-induced 
malignancies.  
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